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ABSTRACT 
We tested the hypothesis that the interaction of Cx36 with the cytoskeleton is necessary to achieve 
synaptic plasticity in neurons. In living cells, BioID and FRAP technology was used to 
demonstrate binding of Cx36 to actin and tubulin. Wild-type and mutant proteins, together with 
pharmacological blockers or TAT peptides were used to characterize the interaction. Major results 
of this study are that rCx36 interacts primarily with the neuronal βIII-tubulin isoform to regulate 
the trafficking and aggregation of connexons at the GJP. Amino acid Lys279 in the CTB domain 
is critical for this interaction. A potential actin-binding site in the CLB domain of rCx36 was 
identified, with actin mainly serving as an anchor to stabilize connexons. During a simulation of 
plasticity in vitro, GJPs became more stable; we attribute this to interactions with the cytoskeleton 
and associating proteins. We conclude that cytoskeletal-dependent interaction is required to 
modulate the strength of Cx36 synapses.  
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1 INTRODUCTION 
 
Communication between neurons and glia is vital for the optimization and regulation of brain 
function in higher organisms. Synapses, the dynamic regions that allow for this cross-talk between 
neurons, are recognized as protein-dense areas that operate under two main modalities of synaptic 
transmission referred to as chemical and/or electrical synapses. At the chemical synapse, the 
release of a neurotransmitter from the presynaptic neuron is detected by receptors of the 
postsynaptic membrane, allowing for the unidirectional transfer of information and appropriate 
cellular response. Alternatively, under the electrical transmission model, signaling molecules may 
be transmitted bi-directionally between directly adjacent neurons through channels known as gap 
junctions. Although both models of synaptic transmission are often targets for debate, chemical 
and electrical synapses are now known to co-exist (Pereda, 2014). Evidence to support properties 
and distributions of these two modalities at mixed synapses is still emerging, yet, allows for the 
opportunity to identify commonalities in machinery and operation between the two.  
 
Synaptic plasticity, the ability of neuronal synapses to strengthen or weaken over time, serves as 
the fundamental basis underlying learning, memory and behavior. As such, delineating the 
mechanism(s) governing synaptic plasticity will drive our fundamental understanding of the 
regulatory means by which these processes operate. Although research aimed at defining the 
cellular signaling cascade(s) involved in learning, memory and behavior have largely focused on 
chemical synapses, emerging evidence supports a significant role of electrical synapses to the 
contribution of neuronal plasticity. 
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1.1 THE GAP JUNCTION FAMILY OF PROTEINS 
Electrical synapses, the gap junctions of the nervous system, are specialized channels that allow 
for bidirectional intercellular communication between neurons. Permeability of gap junctions has 
been attributed to the channel size as the large hydrophobic pore has an estimated diameter of 1.2 
nm (M. V. L. Bennett & Zukin, 2004). As such, these structures provide an efficient means of 
signaling between directly adjacent neurons, allowing for the passage of small molecules (up to 1 
kDa) including, but not limited to, second messengers, glucose, ATP, cations and anions (Jabeen 
& Thirumalai, 2013; Söhl, Maxeiner, & Willecke, 2005). In addition to its involvement in signal 
transduction pathways and maintenance of cellular homeostasis, gap junctions have also been 
shown to be involved in the synchronous activity of cardiomyocytes and neuronal networks in 
electrically excitable cells; consequently, the term “electrical synapse” was derived accordingly 
(M. V. L. Bennett & Zukin, 2004; Paul, 1995; Revel & Karnovsky, 1967; Weidmann, 1952). Gap 
junctions differ from most membrane channels in that they exist between two opposing cells rather 
than function as single membrane units. As determined by electron microscopy, a narrow gap (2-
4 nm) exists between the adjoining cells, which in turn lead its designated title as a “gap junction” 
(Revel & Karnovsky, 1967). Typically, gap junctions are localized in the plasma membrane as 
aggregates referred to as gap junction plaques, consisting of up to thousands of intercellular 
channels (Simon & Goodenough, 1998). Although the opening of gap junction channels typically 
requires a sizeable amount of aggregates (in the order of hundreds) as a prerequisite, in established 
gap junction plaques meeting this requirement, approximately 1 in 10 remain open at a time 
(Bukauskas et al., 2000).  
 
From their initial discovery in the crayfish giant motor synapse, gap junctions were later 
demonstrated to exist in most vertebrate and invertebrate tissues with the exception of spermatozoa, 
erythrocytes, thrombocytes and adult skeletal muscle cells (Dermietzel & Spray, 1993; Söhl, 
Odermatt, Maxeiner, Degen, & Willecke, 2004). However, evolutionary divergence of gap 
junctions lead to the identification of protein families which have similar morphological and 
physiological properties; in chordates, gap junctions are formed by the family of proteins termed 
connexins (Cx), whereas the innexin (Inx) protein family is found exclusively in invertebrates. A 
third family of proteins, termed pannexins (Panx), are found in both invertebrates and chordates, 
however classification of pannexins as belonging to the gap junction family of proteins is currently 
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debated (Baranova et al., 2004; Bruzzone, White, & Paul, 1996; Kumar & Gilula, 1996; Pauline 
Phelan, Bacon, Davies, Stebbings, & Todman, 1998). Although innexins and pannexins will not 
be described here in detail, it is important to note that all serve to allow for cellular permeability 
through the formation of hemichannels (Scemes, Spray, & Meda, 2009). 
 
1.1.1 Connexins 
The first gap junction proteins were discovered in mouse hepatocytes in 1974 and were classified 
as belonging to the connexin family. Initially, the names connexin A and B were proposed to 
coincide with the two identified components of differing molecular weight generated by bulk 
preparation (Goodenough, 1974). Since then, a number of connexin isoforms have been found. To 
date, there are 20 known connexin genes in murines, 21 in the human genome and 37 genes in 
zebrafish; of the 37 genes expressed in zebrafish, 23 are related to 16 mammalian connexins and 
14 connexins are completely unique (Eastman, Chen, Falk, Mendelson, & Iovine, 2006; Cruciani 
and Mikalsen, 2007). Likewise, between the mouse and human genome, 19 genes are orthologs 
(Söhl & Willecke, 2003). Connexins are identified as the gap junctions of chordates, a phylum 
consisting of organisms characterized by the presence of a notochord, dorsal neural tube, 
pharyngeal slits, post-anal tail and an endostyle at some stage throughout development (Holland, 
2005). 
 
In vertebrates, each gap junction channel is composed of two docking connexin hemichannels (also 
referred to as connexons), both formed by six connexin proteins (Figure 1A) (M. Bennett, 1977; 
Kumar & Gilula, 1996). Connexins are tetraspan membrane proteins with two extracellular loops 
sharing three conserved cysteine residues crucial for docking; both the N-terminal and C-terminal 
domains are located intracellularly (Figure 1B). Connexons can arrange either homotypically or 
heterotypically, whereby the composition of the gap junction channel will affect both its 
localization and conductance properties (voltage dependence, open probability, permeability and 
gating kinetics), allowing for regulatory variety; mediation of connexon-connexon interaction is 
achieved through both extracellular loops (M. V. L. Bennett & Zukin, 2004; Cao et al., 1998; 
Weber, Chang, Spaeth, Nitsche, & Nicholson, 2004). Alternatively, functional hemichannels have 
been described both in vivo and in vitro allowing for the passage of molecules between the 
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intracellular and extracellular space (Kamermans et al., 2001; Paul, Ebihara, Takemoto, Swenson, 
& Goodenough, 1991). As connexins are named according to their molecular weight (in kDa), 
variation between connexin isoforms are mainly due to residual differences in the cytoplasmic 
loop and carboxyl-terminal (Söhl et al., 2005). Additionally, connexins are classified into the alpha 
(α-), beta (β-), gamma (γ-), delta (δ) or epsilon (ε-) subclasses depending on gene sequence 
similarity (Söhl & Willecke, 2003). 
 
Properly folded connexin proteins are transferred from the endoplasmic reticulum to the Golgi 
apparatus prior to transport to the plasma membrane; in the case of Cx26, trafficking to the plasma 
membrane occurs in a Golgi-independent manner. Connexon assembly may occur in an isoform-
specific manner (Sarma, Wang, & Koval, 2002) with evidence supporting assembly at the ER 
(Ahmad, Diez, George, & Evans, 1999; Falk, Buehler, Kumar, & Gilula, 1997), trans-Golgi 
network (Musil & Goodenough, 1993) or ER-Golgi intermediate (Diez, Ahmad, & Evans, 1999). 
Upon exiting the trans-Golgi network, connexin hemichannels are packaged into vesicles for 
delivery to the cell surface. Fusion of the vesicles with the phospholipid bilayer allows 
hemichannels to diffuse laterally and dock with the connexons of the adjacent cell, with the aid of 
N- and E-cadherins, to form gap junctions (Jongen et al., 1991; Lauf et al., 2002a; Meyer, Laird, 
Revel, & Johnson, 1992; Thomas et al., 2005; Wei, Francis, Xu, & Lo, 2005). Although upon 
docking a delay in functional activity typically occurs until coalescence into gap junction plaques, 
recent studies have confirmed that gap junction channels could acquire an active state in the 
absence of microscopically identifiable plaques (Essenfelder et al., 2004). Clustering of gap 
junctions is a continual dynamic event as the turnover rate of connexin-forming gap junctions is 
typically 1-5 h although longer turnover rates have been recorded (JC Hervé, Derangeon, Bahbouhi, 
Mesnil, & Sarrouilhe, 2007).  
 
Among the connexin genes identified in mammalian cells, more than half are expressed in the 
nervous system. As such, several connexins have been identified as significant contributors to 
neuronal activity such as Cx29 (GJE1), Cx30 (GJB6), Cx30.2 (GJC3), Cx31.1 (GJB5), Cx32 
(GJB1), Cx36 (GJD2), Cx43 (GJA1), Cx45 (GJC1), Cx47 (GJC2), and Cx50 (GJA8) (Pereda et 
al., 2013; Shimizu & Stopfer, 2013; Söhl et al., 2005). Of the known neuronal gap junction proteins, 
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connexin 36 (Cx36), the focus of this study, was the first isoform to be described as expressed in 
mammalian neurons (Condorelli et al., 1998). 
 
1.1.2 Innexins 
In 1998, analysis of Drosophila melanogaster and Caenorhabditis elegans lead to the 
identification of the connexin homologues termed invertebrate connexin analogs, abbreviated as 
innexins or Inx (P Phelan et al., 1998). In similar topology to connexins, innexins are tetraspan 
membrane proteins with two extracellular loops sharing two conserved cysteine residues, except 
in the case of Inx4 containing 3 conserved cysteine residues; both the amino- and carboxy- termini 
are located intracellularly. Despite being morphologically and physiologically similar to connexins, 
they lack sequence homology; instead, innexins share sequence identity with another family of 
proteins named pannexins. However, it is worth noting that the conservation of the cysteine 
residues of the extracellular loops and surrounding amino acids in innexins may reflect an 
evolutionary functional significance related to the docking of the hemichannels in a similar fashion 
to connexins (Bauer et al., 2005). 
 
1.1.3 Pannexins 
Pannexins, first discovered in 2000 by Panchina et al., were originally described in the human 
genome as a second family of gap junction proteins (Panchina et al., 2000). Since their discovery, 
much debate has been focused on the characterization of pannexins where some reports support 
its classification as a gap junction protein (Sahu, Sukumaran, & Bera, 2014) and others reject it 
(Sosinsky et al., 2011). Structurally, pannexins are similar to connexins with four transmembrane 
domains, two extracellular loops sharing two conserved cysteine residues, and both the N- and C- 
terminal located intracellularly; however, no sequence homology exists between connexins and 
pannexins. A unique feature of the pannexin family of proteins, not seen in connexins, is the 
asparagine glycosylation sites located on the extracellular loops responsible for the regulation of 
localization and intermixing of isoforms (Penuela, Bhalla, Nag, & Laird, 2009), which some argue 
would prevent formation of gap junctions between cells (Boassa et al., 2007; Boassa, Qiu, Dahl, 
& Sosinsky, 2008; Penuela et al., 2007). As it is understood to date, pannexins predominantly exist 
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as single membrane units, allowing for the passage of molecules in and out of cells. As such, these 
channels are particularly sensitive to changes in the extracellular environment.  
 
 
 
 
Figure 1| Topology of gap junctions and connexin subunits.  
(A) Two docking hemichannels of adjacent cells form a gap junction channel that is either homotypic (1-2) or 
heterotypic (2-3). Each hemichannel is comprised of 6 connexin proteins to form a channel that allows for the passage 
of small molecules 1 kDa. (B) Connexins are tetraspanning membrane proteins that share three conserved cysteine 
residues on both extracellular loops crucial for docking. Variations between connexins are mainly due to alterations 
in the carboxyl terminal and/or cytoplasmic loop. Modified from Sohl et al., 2005 
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1.2 CONNEXIN36, THE MAJOR NEURONAL CONNEXIN OF THE CNS 
1.2.1 The Cx36 Gene and Protein 
Connexin 36 (Cx36), encoded by the GJD2 gene, is a 321 amino acid protein identified as a major 
component of neural gap junctions in the CNS. The connexin gene is highly conserved, displaying 
98% sequence identity between the rat, mouse and human genomes and 80% identity to its fish 
ortholog connexin 35 (Belousov & Fontes, 2013). Based on the gene structure, Cx36 is classified 
as belonging to the gamma (γ) sub-family, determined by the presence of an intron located within 
its coding region (Abascal & Zardoya, 2012; Condorelli et al., 1998; O’Brien, Al-Ubaidi, & Ripps, 
1996; Söhl, Degen, Teubner, & Willecke, 1998). Typically, Cx36 is found between dendro-
dendritic and dendro-somatic contacts but has also been described at axon terminals (Hamzei-
sichani et al., 2007). In reference to the domains of Cx36, notations were derived from Alev et al. 
(2008) based on the findings that both the cytoplasmic loop (CL) and cytoplasmic terminal (CT) 
housed CaMKII binding and phosphorylation sites (Alev et al., 2008). As such, the 
phosphorylation sites (CLP and CTP) and more specifically the binding domains (CLB and CTB) 
are referenced in the abbreviated form throughout this thesis. 
 
 
 
Figure 2| Relevant Connexin36 domains and corresponding nomenclature. 
An outline of the Cx36 binding domain nomenclature and corresponding amino acids referenced throughout this thesis. 
Nomenclature was derived from Alev et al. (2008) based on the binding and phosphorylation sites of CaMKII. Taken 
from Alev et al., 2008 
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1.2.2 Electrophysiological Properties of Cx36 
Relative to other connexin isoforms, Cx36 is described as having one of the lowest voltage 
sensitivities (half-inactivation voltage ±75 mV) and single channel conductance (10-15 pS). With 
a low unitary conductance, it is inferred that Cx36 allows for in-depth precision of electrical 
coupling through the regulation of the number of channels present in the gap junction plaque. 
Further, during neuronal activity and development, low voltage sensitivity prevents uncoupling in 
cells that have acquired a high resting potential (Srinivas et al., 1999). Regulation of Cx36 channel 
gating open probability has been attributed to intracellular [Mg2+] in an ATP-dependent manner 
(Palacios-Prado et al., 2012) and pH (González-Nieto et al., 2008). Experimental efforts aimed at 
defining the molecular mechanism of connexin gating have proposed a dual mechanism of “slow 
Vj-gating” inferring the involvement of the N-terminal domain and “fast Vj-gating” involving the 
cytoplasmic domain in a connexin-specific manner (Anumonwo et al., 2001; Beyer, Lipkind, Kyle, 
& Berthoud, 2012; González, Gómez-Hernández, & Barrio, 2007; Moreno et al., 2002; Verselis, 
Ginter, & Bargiello, 1994). Studies on Cx36 channel gating properties have supported this two-
tier mechanism for opening and closing probabilities in a pH-dependent manner (González-Nieto 
et al., 2008). Additionally, coupling of Cx36 gap junction channels has been shown to be mediated 
by calcium where high intracellular [Ca2+] results in the uncoupling of junctions (Baux, Simonneau, 
Tauc, & Segundo, 1978; Rao, Barnes, & McNaughton, 1987). 
 
1.2.3 Implications of Cx36 in Learning, Memory, Behavior and Vision 
In the mammalian brain, Cx36 is expressed in a variety of regions including the cerebral cortex 
and hippocampus (Condorelli et al., 1998). Both the hippocampus and neocortical regions are 
dictated by the highly regulated synchronous oscillations of neuronal networks and in turn 
correlate to cognitive and sensory function, attention and memory formation (Buzsaki, Horvath, 
Urioste, Hetke, & Wise, 1992; Cape, Manns, Alonso, Beaudet, & Jones, 2000; Csicsvari, Hirase, 
Czurko, Mamiya, & Buzsaki, 1999). The hippocampus, a member of the limbic system, is most 
notably known for its role in the integration of short-term and long-term memory in addition to 
spatial navigation. In Cx36 deficient (Cx36 -/-) mice, dendro-dendritic coupling in the 
hippocampus was nearly abolished. At the behavioral level, Cx36 -/- mice showed impairments in 
object recognition, displaying an inability to distinguish between new and old objects after short 
 9 
 
delays of 15 and 45 minutes. Additionally, the lack of Cx36 expression in mice also resulted in an 
impairment in short-term spatial memory as determined by their poor performance on a rewarded 
alternation T-maze task in comparison to wild-type mice (Allen, Fuchs, Jaschonek, Bannerman, 
& Monyer, 2011; Frisch et al., 2005). Again, the significance of Cx36 at the hippocampus must be 
elaborated as this demonstrates that Cx36 -/- mice display impairments in learning and memory 
formation. Furthermore, Cx36 knockout (KO) significantly disrupted synchrony of interneurons 
in both the cortex and hippocampus, without any signs of a compensatory mechanism (Deans, 
Gibson, Sellitto, Connors, & Paul, 2001; Hormuzdi et al., 2001; Hormuzdi, Filippov, Mitropoulou, 
Monyer, & Bruzzone, 2004). 
 
The retina, a light-sensitive tissue, is organized into distinct layers of neuronal cells, interconnected 
by synapses and responsible for receiving and transmitting visual input through the optic nerve to 
the brain for visual processing. In the mouse retina, Cx36 is expressed between AII amacrine cells, 
OFF cone bipolar cells, as well as light sensitive photoreceptors located at the base of the retina. 
Photoreceptors are divided into two classes known as cones and rods and are responsible for 
photopic and scoptic vision, respectively. Although Cx36 -/- mice show the normal cellular 
organization of the retina, coupling between AII amacrine cells and bipolar cells was disrupted. 
Further, rod-mediated transmission to ganglion cells was impaired in Cx36 KO mice indicating 
that Cx36 is critical for rod signal propagation and essential for night vision (Deans, Volgyi, 
Goodenough, Bloomfield, & Paul, 2002; Feigenspan et al., 2004; Güldenagel et al., 2001).  
 
Knockout of Cx36 typically displays a broad range of consequences. In addition to the 
aforementioned, KO studies have also revealed deficits in the circadian activity, regulated by the 
suprachiasmatic nucleus (SCN), and behavior as KO mice showed an increase in locomotion and 
running speed, a reduction in object exploration and displayed more anxiety-like behavior (Long, 
Jutras, Connors, & Burwell, 2005; Zlomuzica et al., 2012). It is also interesting to acknowledge 
that in the rat hippocampus and cortex, Cx36 KO resulted in the impairment of long-term 
potentiation (LTP) of chemical synapses suggesting a close relationship between electrical and 
chemical synapses (Postma et al., 2011; Wang & Belousov, 2011).  
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1.3 SYNAPTIC PLASTICITY 
As just demonstrated, communication between neurons is critical for optimization and regulation 
of brain function and synapses allow for this cross-talk between cells. Although the focus of this 
thesis is on electrical synapses, chemical synapses will be addressed briefly given its developing 
relationship with electrical synapses and significance in neuronal plasticity. As previously 
mentioned, synaptic plasticity can involve either the strengthening or weakening of synapses, and 
in the case of chemical synapses, this is referred to as long-term potentiation (LTP) or long-term 
depression (LTD) respectively.  
 
1.3.1 LTP of Chemical Synapses 
In the chemical synapse model, a release of neurotransmitters from the presynaptic terminal into 
the synaptic cleft takes place upon a depolarization event. Embedded in the post-synaptic 
membrane is a combination of both metabotropic and ionotropic receptors capable of binding to 
neurotransmitters and evoking a response through a defined series of signaling cascades (Figure 
3) (Sheng, Sabatini, & Sudhof, 2012). Two ionotropic receptors of importance in long-term 
potentiation (LTP), the underlying basis of the learning, memory and behavior cascades, are N-
methyl-D-aspartate receptor (NMDAR) and α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid receptor (AMPAR).  
 
Previous studies have shown that upon release of glutamate from the vesicles of the presynaptic 
neuron, the post-synaptic membrane responds by depolarizing. In combination with the binding of 
glutamate to NMDAR, this depolarization event in turn activates NMDARs, relieving the Mg2+ 
blockade. Activated NMDARs allow for the influx of Ca2+, triggering a number of signaling 
cascades critical for LTP to occur (Collingridge, Isaac, & Wang, 2004; Traynelis et al., 2010). 
Most notably, the rapid rise in intracellular calcium levels activates Ca2+/calmodulin-dependent 
kinase II (CaMKII), a protein kinase responsible for phosphorylating a number of targets, upon 
the initial binding of CaM (Fukunaga, Stoppini, Miyamoto, & Muller, 1993). AMPA receptors, a 
target of CaMKII, increases in activity levels, trafficking and insertion into the postsynaptic 
membrane in response to phosphorylation. This is of significance since an abundance of receptors 
is a crucial regulator in synaptic strength (Sheng & Hoogenraad, 2007). Phosphorylation of 
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NMDAR by CaMKII increases calcium conductance, thus providing an additional means for 
controlling synaptic strength (Figure 4) (Derkach, Oh, Guire, & Soderling, 2007; Sanhueza et al., 
2011; Zhou et al., 2007). These two events are critical for the LTP of chemical synapses and has 
been widely accepted as a cellular mechanism contributing to learning and memory formation. 
 
 
 
 
 
Figure 3| Chemical and electrical models of synaptic transmission.  
(A) Upon a depolarizing event, such as an action potential, voltage-gated calcium channels open and allow for an 
influx of Ca2+ ions, mobilizing synaptic vesicles to release neurotransmitters into the synaptic cleft. Neurotransmitters 
bind to ionotropic receptors on the post-synaptic membrane and in turn influence various signaling cascades. (B) 
Electrically coupled cells allow for the bi-directional transmission of small molecules and ions. Taken from Pereda, 
2014 
 
 
 
 
 
 
 12 
 
 
Figure 4| NMDAR-dependent long-term potentiation of chemical synapses.  
NMDARs are activated by the binding of glutamate and depolarization of the post-synaptic membrane. Upon 
activation, calcium levels increase transiently, activating CaM which in turn activates CaMKII. Phosphorylation of 
AMPAR and NMDAR strengthens synapses by increasing activity, trafficking and insertion of AMPAR in addition 
to enhancing the calcium conductance of NMDAR. 
 
 
1.3.2 Role of Gap Junctions in Synaptic Plasticity 
Although addressed briefly here, synaptic plasticity (both LTP and LTD) is a well-described 
phenomenon at chemical synapses in various regions of the brain. However, since there is an 
emerging role for the contribution of electrical synapses to plasticity, Cx36, the fore-runner of 
neuronal gap junctions in the CNS, has been of particular interest. The LTP-like "run-up" 
phenomenon, in which gap junctional conductance increases 10-fold, has been exclusively 
described at the Cx36 nexus and was found to be CaMKII dependent (Alev et al., 2008; Del Corsso, 
Iglesias, Zoidl, Dermietzel, & Spray, 2012). This phenomenon resembles phosphorylation of 
NMDAR by CaMKII to further evoke an influx of Ca2+, a critical mediating step in LTP-based 
plasticity at chemical synapses, as previously outlined. This demonstrates that electrical and 
chemical synapses share a common molecular mechanism in modulating synaptic strength. 
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However, additional critical mediators involved in Cx36-specific plasticity of neurons still remains 
unclear. Since the transport of Cx36 to the plasma membrane is a prerequisite, we hypothesized 
that the dynamic delivery, insertion and removal of Cx36 from the Nexus could be a critical 
mediating step in run-up plasticity. As such, our investigations were directed towards interactions 
of Cx36 with cytoskeletal proteins.  
 
1.4 THE DYNAMIC CYTOSKELETON 
In eukaryotes, the neuronal cytoskeleton is a dynamic network comprised of microtubules, actin 
microfilaments, and neurofilaments/intermediate filaments (Figure 5). The primary roles of the 
cytoskeleton include the maintenance of cell structure as well as intracellular trafficking of 
organelles and cargo-carrying vesicles. As the focus of this thesis is on the interaction of Cx36 
with tubulin and actin, the basic unit of microtubules and microfilaments respectively, 
neurofilaments will not be described.  
 
1.4.1 Actin 
Actin in its free monomeric form is a 42 kDa globular protein (G-actin) with 375 amino acids 
which can polymerizes to form microfilaments (F-actin), a major contributor to the cytoskeleton, 
particularly at synapses (Figure 5A). Of the three classes of actin that have been described: α, β 
and γ, the latter two are involved in F-actin polymerization. Both G-actin and F-actin are essential 
for maintaining cell morphology, motility, cell signaling as well as the trafficking of organelles 
and vesicles in a highly dynamic manner. Typically, actin localizes beneath the plasma membrane 
where, in addition to structural support, interacts with membrane proteins to facilitate receptor 
mobility and anchoring with the aid of scaffolding proteins (Dillon & Goda, 2005). Interestingly, 
it was recently determined that the actin cytoskeleton and associating proteins, being functionally 
linked to synaptic receptors, are also necessary entities in memory formation (Bi et al., 2010; 
Fischer, Sananbenesi, Schrick, Spiess, & Radulovic, 2004; Hou et al., 2009; Nelson, Witty, 
Williamson, & Daniel, 2012; Young et al., 2014).  
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1.4.2 Microtubules 
Microtubules (MTs) are hollow tubes approximately 25 nm in diameter formed by protofilaments 
of α-, β-tubulin heterodimers running lengthwise (Figure 5B). During assembly, tubulin 
heterodimers are typically added to the plus (+) end, giving MTs a characteristic structural polarity, 
while the minus (-) end grows at a slower rate. Microtubule assembly is a GTP-dependent process 
with GTP being hydrolyzed to GDP forming a stable GDP-tubulin cap at the plus end. A number 
of proteins have been shown to interact with MTs including microtubule-associated proteins 
(MAPs), responsible for stabilizing MTs, and motor proteins dynein and kinesin, essential for 
microtubule-dependent trafficking (Wade, 2009).  
 
The α- and β-tubulin monomers responsible for the configuration of microtubules are 
approximately 55kDa in size with 450 amino acids residues. Throughout evolution, the tubulin 
monomers have remained highly conserved, showing approximately 60% sequence identity across 
species; between the tubulin monomers themselves, there is approximately 40% conservation 
(Wade, 2009). Multiple copies of the tubulin gene exist in both human and murine genomes, 
leading to the identification of 19 isoforms in humans (10 of which belong to the alpha isotype and 
9 to the beta) and 16 in murines (8 alpha and 8 beta) (Saillour et al., 2014).  
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Figure 5| Cytoskeletal components and structure.  
(A) Actin microfilaments, about 7 nm in diameter, is formed by the polymerization of G-actin at the plus (+) end to 
form F-actin. (B) Microtubules are hollow tubes, approximately 25 nm in diameter formed by α and β tubulin 
heterodimers. Polymerization of microtubules occurs typically at the plus (+) end in a GTP-dependent manner. (C) 
Intermediate filaments, the third component of the cytoskeleton. Adapted from Mostowy & Cossart, 2012. 
 
 
1.4.3 The Role of the Cytoskeleton in Gap Junction Trafficking  
All three filaments of the cytoskeleton differ in a variety of ways including assembly dynamics, 
polarity and associating motor proteins (Fletcher & Mullins, 2010). However, most notably is the 
organization within neuronal cells. Actin, for example, can be found within the dendritic and axon 
terminal ends, highly concentrated at protein-rich areas known as post-synaptic densities (PSD) 
beneath the synapse (Hotulainen & Hoogenraad, 2010; Sheng & Hoogenraad, 2007). In contrast, 
microtubules are excluded from end terminals and are considered to be restricted to the dendritic 
spine (Gu, Firestein, & Zheng, 2008). As such, transport of proteins destined for the synapse often 
requires a combination of tubulin- and actin-dependent transport.  
 
Interactions between gap junctions and actin have only recently been described in the past few 
years. Although Cx30 has been shown to interact directly with actin, more often gap junctions 
require adaptor proteins to facilitate indirect contact, such in the case of Cx43 (Bhalla-Gehi, 
Penuela, Churko, Shao, & Laird, 2010; Butkevich et al., 2004; Qu, Gardner, & Schrijver, 2009). 
Early reports have indicated that actin is involved in turnover and endocytosis of gap junctions, 
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typically in cells expressing connexins known to interact indirectly with actin, through an 
invagination event into the cytoplasm prior to degradation (Watanabe, Washioka, & Tonosaki, 
1988). However, a more recent study on connexin 30 (Cx30) proposed that actin is likely involved 
in the anchoring of connexons and short distance transport rather than in the facilitation of 
internalization (Qu et al., 2009).  
 
As previously mentioned, evidence suggests that upon leaving the Golgi apparatus, connexon are 
assembled and transported in vesicles to the plasma membrane. In support to this, it was found that 
Cx43 binds to both α- and β-tubulin with equal affinity and trafficking to the membrane was indeed 
dependent on microtubules (Giepmans, Verlaan, & Moolenaar, 2001; Giepmans, Verlaan, 
Hengeveld, et al., 2001). Although microtubules facilitate transport of connexons to the membrane 
thus improving efficiency, it is thought that under some circumstances, MTs may not be essential 
(Laird, 2010); however, in the case of Cx43, MT-dependent trafficking is indeed necessary 
(Giepmans, Verlaan, Hengeveld, et al., 2001; Lauf et al., 2002a). Recent reports have indicated 
that upon binding of tubulin, the tubulin binding site and surrounding region (encompassing amino 
acids K243-D259) adopts a helical structure to promote interaction. Furthermore, mediation of 
interaction between tubulin and Cx43 is achieved by phosphorylation where phosphorylation of 
Tyr247 by v-Src prevents association with tubulin. The microtubule binding region, located within 
the C-terminal (CT) domain of Cx43, is enriched in the basic amino acids lysine (K), glycine (G), 
proline (P), valine (V) and arginine (R), and our group was the first to identify that this region is 
conserved in the Cx36 CT domain (Figure 6). Furthermore, our research group has successfully 
confirmed the interaction between rCx36 and tubulin in vitro and has provided evidence indicating 
that tubulin inhibition abolishes the run-up phenomenon previously described. As such, 
interactions with tubulin were of particular interest in this thesis. 
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             235        243 
Cx43 Rat         ---GVKDRVKGR---------------------------------- 
Cx36 Human       GWRKIKLAVRGAQAKRKSIYEIRNKDLPRVSVPNFGRTQSSDSAYV  
Cx36 Rat         GWRKIKLAVRGAQAKRKSVYEIRNKDLPRVSVPNFGRTQSSDSAYV  
Cx36 Chicken     GWRKIKMAVRGVQAKRKSIYEIRNKDLPRMSMPNFGRTQSSDSAYV  
Cx35 Zebrafish   GWRKIKTAVRGVQARRKSIYEIRNKDLPRMSMPNFGRTQSSDSAYV 
               276   :*  *:*                                                                                 321    
 
Figure 6| Sequence alignment of the rCx43 tubulin binding region to Cx36 and respective fish ortholog. 
Protein sequence alignment of the rCx43 binding domain against Cx36 across specifies including the fish ortholog 
Cx35. Sequence alignment revealed that the tubulin binding domain is conserved in Cx36, encompassing amino acid 
residues spanning from 279-287. 
 
 
1.5 RESEARCH DESIGN 
Since synaptic plasticity is critically dependent on the trafficking of the protein in/out of the Nexus, 
determining possible binding partners influencing trafficking of Cx36 is an area of significant 
interest. As such, the objective of this research study was to confirm the interaction of tubulin and 
actin with rCx36 in living cells. We hypothesized that both tubulin and actin, the basic unit of 
microtubules and microfilaments respectively interact with Cx36 to facilitate its transport to the 
plasma membrane. To approach this research question, the in vivo techniques BioID and 
fluorescence recovery after photobleaching (FRAP) were employed in combination with 
recombinant DNA technology like Site-Directed Mutagenesis, and pharmacological blocking in a 
cell culture model. 
 
1.5.1 BioID 
Bio-ID is a newly developed technique used for proximity-dependent identification of interacting 
proteins in eukaryotic cells. Originally, this technique was employed to study the interacting 
candidates of human lamin A (LaA), an intermediate filament protein associated with the inner 
nuclear membrane, a component of the nuclear envelope. In this technique, the promiscuous E. 
coli protein ligase BirA is utilized for its ability to attach biotin to close proximity proteins. Since 
biotinylation is a rare modification, the BirA used in this methodology, denoted as BirA*, has been 
mutated to achieve is promiscuous characteristic and to prevent self-association. By this technique, 
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the authors were able to successfully identify a novel interacting partner of LaA (Roux, Kim, Raida, 
& Burke, 2012). 
 
For the purpose of this thesis, we utilized rCx36-BirA* wild-type and mutant variant (directed 
against the CLB and CTB) fusion proteins to achieve biotinylation of proximal proteins. The 
biotin-labeled protein fraction was then enriched using a highly selective purification procedure 
by Dynabeads MyOne Streptavidin. Upon protein denaturation, biotin affinity capture is achieved 
using magnetic streptavidin-conjugated beads to which biotin has high affinity. By this technique, 
interacting proteins can be segregated, screened and identified via mass spectrometry and/or 
western blot. 
 
1.5.2 Fluorescence Recovery After Photobleaching 
Fluorescence recovery after photobleaching (FRAP) is a microscopy based tool that allows for the 
in vivo measurement of molecular dynamics such as diffusion, active transport and protein binding. 
In this technique, a fluorescently labeled region of interest (ROI) can be selected and bleached 
with a high power laser. The recovery rate of the ROI is dependent on diffusion and potential 
interacting partners. Two parameters of particular interest for this thesis were: firstly, the mobile 
fraction (%), the amount of bleached molecules that are replaced by unbleached molecules and 
secondly, the half-time of recovery (t½), which measures the time taken for fluorescence intensity 
to recover to half of its initial value (Carisey, Stroud, Tsang, & Ballestrem, 2011). 
 
Previous studies on connexin 43 (Cx43) have successfully confirmed the in vivo dynamics of 
Cx43-YFP gap junction plaques in HeLa cells using FRAP, concluding that Cx43 delivery at the 
lateral ends of the gap junction plaque occurs in a rapid manner (Shaw et al., 2007). For the purpose 
of this study, we have selected several ROIs for analysis: (1) intracellular space (2) first lateral end 
of Cx36 gap junction plaque (3) center of the Cx36 gap junction plaque (4) second lateral end of 
the Cx36 gap junction plaque (5) plasma membrane and (6) extracellular space (Figure 7). Since 
it has been reported that connexons are delivered to the plasma membrane singly or in small groups 
moving laterally to replenish the gap junction plaques from the outer margins, with older channels 
removed from the center of the plaque (Lauf et al., 2002a), we were interested in determining if 
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the dynamics of the rCx36 gap junction plaque were consistent with literature and if cytoskeletal 
dependency existed. 
 
 
Figure 7| Regions of Interest (ROIs) for FRAP Experiments. 
Several ROIs were selected for analysis: (1) intracellular space (2) first lateral end of Cx36 gap junction plaque (3) 
center of the Cx36 gap junction plaque (4) second lateral end of the Cx36 gap junction plaque (5) plasma membrane 
and (6) extracellular space. Analyzing the GJP in sub-sections allowed for transport dynamics to be determined under 
wild-type, mutant or pharmacologically altered conditions. The intracellular space and the plasma membrane were 
used as comparative references; results were normalized against the extracellular space to improve the signal-to-noise 
ratio. 
 
 
1.5.3 Pharmacological Blocking and Site-Directed Mutagenesis 
In addition to our wild-type analyzes, we selected a number of reagents directed against tubulin. 
In particular, both colchicine, which inhibits the polymerization of microtubules, and paclitaxel, 
which prevents the disassembly of MTs were utilized. Cytochalasin D was selected for is ability 
to prevent the polymerization of actin filaments. Peptide blocking the tubulin binding site of wild-
type rCx36 was achieved with a TAT peptide. The TAT peptide, utilized for its cell-penetrating 
ability, is derived from the transactivator of transcription (TAT) of human immunodeficiency virus. 
Cell penetrating peptides (CPPs) have been used to overcome the lipophilic barrier of the cellular 
membranes to deliver molecules variable in size inside the cell for their specified biological actions. 
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Here, this property is used to carry the C-terminal binding (CTB) sequence and respective controls 
into Neuro2a cells as a competitor for tubulin binding. Both, pharmacological and peptide 
approaches provide a means to test the hypothesis that Cx36 transport to the plasma membrane is 
tubulin- and/or actin-dependent. 
 
Additionally, mutants carrying deletions in regions of the Cx36 protein considered critical for 
transport and plasticity were used in this analysis. Site-directed mutagenesis allowed for the 
generation of point mutations in both the CT binding (CTB) regions and CL binding (CLB) region 
to determine critical residues in the tubulin- and actin-mediated transport respectively (Figure 8).  
 
 
 
 
Figure 8| Illustration of Mutants Generated by Site-Directed Mutagenesis.  
Highlight of the site-directed mutagenesis targeted residues generated in the CLB (in yellow) and CTB (in orange) 
region of rCx36. These were specifically directed against the hypothesized actin and tubulin binding domain 
respectively. All original amino acids, as highlighted, were mutated to alanine (A) to determine effects on rCx36 
transport.  
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2 AIM OF THESIS 
 
The central hypothesis of this thesis is that plasticity of gap junctions formed by Cx36 depends on 
interaction with the cytoskeleton. In previous studies, the Zoidl group demonstrated interaction of 
rCx36 with the microtubule protein tubulin in vitro (unpublished). The aim of this thesis is to 
investigate rCx36 interactions with the cytoskeleton in vivo and to explore the potential 
involvement of this interaction in the run-up plasticity mechanism. 
To confirm the interaction between cytoskeletal elements and rCx36 in living cells, neuroblastoma 
cells (N2a) were selected since previous work has been performed in this cell model. At the 
beginning of this thesis work, investigations were primarily focused on tubulin-specific 
interactions with rCx36, and BioID was chosen as the methodology to study such interaction. 
BioID is a newly developed technique for studying proximity dependent protein-protein 
interactions in vivo using a highly selective enrichment and purification procedure developed for 
eukaryotic systems (Roux, Kim, Raida, & Burke, 2012b). The first aim of this thesis was to 
confirm the interaction between rCx36 and tubulin in vivo while simultaneously assessing the 
efficiency of the methodology.  
The second objective of this thesis was to specifically characterize the involvement of the 
cytoskeleton in rCx36 trafficking, focusing on transport and insertion into the gap junction plaque. 
For the purpose of this study, the in vivo technique termed fluorescence recovery after 
photobleaching (FRAP) was utilized for its ability to measure molecular dynamics specific to 
diffusion and protein-protein interaction as it relates to trafficking. A series of experiments using 
rCx36 wild-type and deletion mutant constructs in addition to pharmacological blocking of 
cytoskeletal dynamics was utilized to characterize wild-type conditions and determine the specific 
contributions of actin and tubulin interaction. 
Using the same technique, the third aim of this thesis was carried out to determine the critical 
binding sites involved in rCx36-cytoskeletal interaction. Specifically, this thesis addresses critical 
amino acid residues pertaining to the rCx36-tubulin interaction. 
The final aim of this thesis was to assess the involvement of the cytoskeleton in the run-up 
phenomenon, first described by Zoidl et al. (2002). In this phenomenon, rCx36 is described to 
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undergo an LTP-like behavior in which gap junctional conductance increases 10-fold in a CaMKII 
dependent manner (Del Corsso et al., 2012; Zoidl et al., 2002). However, the mechanism by which 
this occurs is unknown. As such, in the finals parts of this thesis, cytoskeletal-dependent trafficking 
is assessed as a potential contender in the mediation of the run-up phenomenon. 
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3 MATERIALS 
3.1 ORGANISMS 
All handling, manipulation and storage of bacterial and eukaryotic cell lines were performed in a 
licensed CL2 laboratory located in the Department of Biology, Life Science Building, York 
University in compliance with federal, provincial and institutional bylaws.  
 
3.1.1 Bacterial Strains 
Escherichia coli (E.coli) DH5α (Invitrogen, Burlington, Canada) 
 Genotype: F- Φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 hsdR17 (rk–, mk+) 
    phoA supE44 thi-1 gyrA96 relA1 λ– 
 
 
E.coli NEB 5-alpha competent  (New England Biolabs, Whitby, Canada) 
 Genotype:  fhuA2 Δ(argF-lacZ) U169 phoA glnV44 Φ80 Δ(lacZ)M15 gyrA96 recA1  
   relA1 endA1 thi-1 hsdR17 
 
3.1.2 Eukaryotic Cell Lines 
Neuroblastoma 2a cells (Neuro 2a or N2a cells) were derived from Mus musculus from a 
spontaneous tumor in a strain A albino mouse (Klebe & Ruddle, 1969). N2a cells were purchased 
from ATCC®.  
 
3.2 MEDIA AND SOLUTIONS 
 
3.2.1 Solutions and Media for Cell Culture 
Phosphate buffered saline (PBS -/-)  130 mM NaCl, 2.8 mM KCl, 10 mM Na2HPO4,  
      1.8 mM KH2PO4, pH 7.4 
 
Trypsin-EDTA solution   0.05% trypsin, 0.02% EDTA (1x) in D-PBS (PAA) 
 
Dulbecco's Modified Eagle Medium  + 10% Fetal Bovine Serum (FBS) 
(DMEM)     + 1% non-essential amino acids (NEA) 
      +1% penicillin/streptomycin  
      (10,000 U/ml/10mg/ml) 
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3.2.2 Solutions and Media for Microscopic Analyses 
Clear DMEM     +1% L-glutamine 
      - phenol red 
 
PBS +/+     + 0.0133% calcium chloride dihydrate 
      + 0.01% magnesium chloride hexahydrate 
 
3.2.3 Solutions and Media for Bacterial Cultivation 
LB media     1% bacto tryptone, 0.5% yeast extract, 0.5% NaCl 
      50µg/ml kanamycin or 100µg/ml ampicillin 
 
LB agar plates    LB medium containing 1% agar 
      50µg/ml kanamycin or 100µg/ml ampicillin 
 
SOC medium     2% bacto tryptone, 0.5% bacto yeast extract, 
      10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 
      10 mM MgSO4, 20 mM glucose 
 
3.2.4 Solutions for Molecular Biology 
Tris-acetate-EDTA (TAE)   1 mM EDTA, 40 mM Tris-acetate 
 
6x DNA Loading Dye (Fermentas)  10 mM Tris-HCl (pH 7.6),  
      0.03% bromophenol  blue,  
      0.03% xylene cyanol FF, 
      60% glycerol 
      60 mM EDTA 
            
3.2.5 Solutions for Protein Biochemistry 
Laemmli sample buffer   2% SDS, 10% glycerol, 5% β-meraptoethanol,  
      0.1% Orange G, 50 mM Tris-HCl, pH 6.8 
 
Laemmli running buffer   192 mM glycine, 0.1% SDS, 25 mM Tris-HCl,  
      pH 8.3 
 
Transfer buffer    20% methanol, 48 mM Tris. 39 mM glycine,  
      0.037% SDS, storage at 4°C 
 
Blocking solution    Odyssey Blocking Buffer (LI-COR) 
 
iBind™ Solution    1% iBind 100X Additive 
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      20% iBind 5X buffer 
3.2.6 Solutions for BioID Protein Purification 
NP40 Lysis buffer* 1% Nonidet P40 
50 mM Tris-HCl, pH 7.4 
 250 mM NaCl 
5 mM EDTA 
50 mM NaF 
1 mM Na3VO4 
0.02% NaN3 
*used with 1% Protease Inhibitor Cocktail (Thermo Scientific) 
 
Wash buffer 1     2% SDS 
 
Wash buffer 2     0.1% deoxycholate, 1% Triton X-100,  
      500 mM NaCl, 1mM EDTA, 50 mM Hepes, 
      pH 7.5   
   
Wash buffer 3     250 mM LiCl, 0.5% NP-40, 0.5% deoxycholate, 
      1 mM EDTA, 10 mM Tris, pH 8.1 
 
Wash buffer 4     50 mM Tris, pH 7.4, 50 mM NaCl 
 
 
3.3 ANTIBODIES 
 
Table 1: List of primary antibodies. 
Name Species 
(Type) 
Origin Specification Used Dilution* 
anti-β-actin Mouse 
IgG 
 
Sigma-Aldrich β-actin 1:10000 
anti-GFP Rabbit 
IgG 
 
Santa Cruz EGFP, EYFP 1:1000 
anti-HA Mouse 
IgG 
 
Sigma-Aldrich HA-tag 1:10000 
anti-β-tubulin Mouse 
IgG 
 
Sigma-Aldrich β-tubulin 1:1000 
*for the use of the iBind protocol, antibodies were concentrated to 5X of the listed dilutions 
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Table 2: List of secondary antibodies. 
Name Species 
(Type) 
Origin Specification Used Dilution* 
anti-mouse 
IRDye800 
Goat Li-Cor 
Biosciences 
Against mouse IgG 
with IRDye800 tag 
 
1:10000 
Anti-rabbit 
IRDye680 
Donkey Li-Cor 
Bioscience 
Against mouse IgG 
with IRDye680 tag 
1:15000 
*for the use of the iBind protocol, antibodies were concentrated to 5X of the listed dilutions 
 
Table 3: List of enzyme conjugates. 
Name Origin Specification Used Dilution* 
Streptavidin-HRP Invitrogen Biotin 1:2500 
 
3.4 CHEMICALS, ENZYMES, AND KITS 
3.4.1 Chemicals 
Acetic Acid Glacial (Bioshop), Acrylamide (Bioshop), agar (Bioshop), agarose (Fisher), 
ammonium persulphate (Bioshop), bacto tryptone (Fisher), bacto yeast extract (Fisher), 
bromphenol blue (Bioshop), CaCl2 (Bioshop), colchicine (Sigma), cytochalasin D (Sigma), D-
Biotin (Bioshop), EDTA (Bioshop), ethanol (Commercial ALC.), ethidium bromide (Bioshop), 
ethylenediaminetetraacetic acid (EDTA) (Bioshop), fetal bovine serum (FBS) (Life Technologies), 
formaldehyde solution (formalin) (Sigma), Glucose (Fisher), L—glutamine (100x) (Life 
technologies), glycerol (Bioshop), glycine (Bioshop), Hepes (Sigma), immersion oil (Zeiss), HCl 
(Fisher),  ionomycin calcium salt (Sigma), Isopropyl alcohol (Bioshop), KCl (Fisher), KH2PO4 
(Sigma), LiCl (Bioshop), 2-Mercaptoethanol (Bioshop), methanol (Bioshop), MgCl2 (Fisher), 
MgSO4 (Fisher), NaCl (Bioshop), Na-deoxycholate (Sigma), Na2HPO4 (Sigma), non-essential 
amino acids (100x) (Sigma), odyssey blocking buffer, Orange G (Sigma), paclitaxel (Sigma), 
protease inhibitor cocktail (Thermo Scientific), SDS (Bioshop), TAT peptides (United 
Biosystems), tetramethylethylenediamine (TEMED) (Bioshop), tris(hydroxymethyl) 
aminomethane (Tris) (Bioshop), Triton X-100 (Sigma), Trypsin-EDTA (Sigma), Tween 20 
(Sigma), water (ultrapure Distilled Water DNAse RNAse free) (CellGrow), Xylene Cyanol FF 
(Bioshop) 
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3.4.2 Enzymes 
Calf intestine alkaline phosphatase (CIAP) (Invitrogen), FastDigest restriction endonucleases 
(Fermentas), T4 DNA ligase (Thermo Scientific), Phusion High-Fidelity DNA Polymerase 
(NEB) 
 
3.4.3 Kits 
Polymerase Chain Reaction (PCR)   Phusion High Fidelity PCR Kit 
(Thermo Scientific) 
Purification of PCR and DNA fragments  NucleoSpin® Gel and PCR Cleanup Kit 
(Clontech) 
DNA gel elution     QIAquick Gel Extraction Kit (Qiagen) 
Cloning of DNA fragments    CloneJET PCR Cloning Kit  
(Thermo Scientific) 
Rapid DNA Ligation Kit (Thermo Scientific) 
Plasmid Purification     QIAPrep Spin Miniprep Kit (Qiagen) 
Subcloning of DNA fragments   Rapid DNA Ligation Kit  
       (Thermo Scientific) 
DNA Restriction Digest    Fast Digestion Top Fermentas Kit 
       (Thermo Scientific) 
DNA Transfection     Effectene Transfection Reagent (Qiagen) 
Site-Directed Mutagenesis    Q5® Site-Directed Mutagenesis Kit  
       (New England Biolabs) 
iBind Western Blot     iBind™ Solution Kit (Life technologies) 
 
Protease Inhibition     Protease Inhibitor Cocktail Kit  
       (Thermo Scientific) 
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3.5 ANTIBIOTICS 
Ampicillin (Bioshop), kanamycin (Bioshop), penicillin/streptomycin (Life Technologies) 
 
3.6 PLASMIDS AND OLIGONUCLEOTIDES 
3.6.1 Plasmids 
 
Table 4: List of commercially available plasmids used. 
Name Description Sources 
pcDNA 3.1 MCS-
BirA(R118G)-HA 
Eukaryotic expression vector used for the generation of 
BirA-tagged C-terminal fusion proteins, ampicillin 
resistance 
 
Addgene 
pEGFP-N1 Eukaryotic expression vector used for the generation of 
EGFP-tagged C-terminal fusion proteins, kanamycin 
resistance 
 
Clontech 
pEYFP-N1 Eukaryotic expression vector used for the generation of 
EYFP-tagged C-terminal fusion proteins, kanamycin 
resistance 
 
Clontech 
pJET 1.2 Blunt end cloning vector, ampicillin resistance Thermo-
Fisher 
 
Table 5: List of plasmid constructs generated by in vitro recombination.* 
Vector Insert Description of usage 
pcDNA 3.1 MCS-
BirA(R118G)-HA 
rCx36 
 
For the in vivo detection of tubulin interaction via 
BioID 
 rCx36 Δ279-292 
 
                                    “     ˮ 
 rCx36 Δ175-196 
 
                                    “     ˮ  
pEYFP-N1 rCx36 
 
For the in vivo determination of cytoskeletal 
interaction and respective dynamics at the Cx36 
nexus using confocal microscopy imaging and 
FRAP 
 rCx36 Δ175-196 
 
                                    “     ˮ 
 rCx36 Δ182-198 
 
                                    “     ˮ 
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 rCx36 Δ279-292 
 
                                    “     ˮ 
 rCx36 Δ182-198, 
279-292 
 
                                    “     ˮ 
pEGFP-N1 rCx36 
 
                                    “     ˮ 
 rCx36 Δ279-292      
 
                                    “     ˮ 
 rCx36 Δ182-198, 
279-292 
                                    “     ˮ 
   
pDsRed-
monomer 
CaM For the in vivo assessment of cytoskeletal 
involvement in the run-up using FRAP 
*All plasmids were made readily available by Dr. Georg Zoidl, Dept. of Biology. See Appendix 
A. 
 
Table 6: List of plasmid constructs generated by site-directed mutagenesis. 
Vector Insert Description of usage 
pEGFP-N1 rCx36 V171A For the determination of critical binding residues 
in the Cx36-actin interaction 
 rCx36 H177A                                   “     ˮ 
 rCx36 S179A                                   “     ˮ 
 rCx36 L181A                                   “     ˮ 
 rCx36 R182A                                   “     ˮ 
 rCx36 K279A For the determination of critical binding residues 
in the Cx36-tubulin interaction 
 rCx36 I280A                                   “     ˮ 
 rCx36 K281A                                   “     ˮ 
 rCx36 L282A                                   “     ˮ 
 rCx36 V284A                                   “     ˮ 
 rCx36 R285A                                   “     ˮ 
 rCx36 G286A                                   “     ˮ 
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3.6.2 Oligonucleotides 
 
Table 7: List of oligonucleotides used for cloning.* 
Name Sequence 5’→3’ 
(Description) 
rCx36 s 
rCx36 as 
 
GAATTCATGGGGGAATGGACCATCTTGGAGAG 
GAATTCCACATAGGCGGAGTCACTGGACTGA 
 
Introduces EcoRI restriction site at the 5’ end used for the cloning of 
rCx36 into pcDNA 3.1 BirA expression vector 
 
*Restriction enzyme site bolded and underlined. 
 
Table 8: List of oligonucleotides used for site-directed mutagenesis and sequencing.*  
Name Sequence 5’→3’ 
rCx36 V171A  
F1: 
R1: 
 
CTTAGAGGTTCATGAGCTGGCTC 
CAATCTGGTTCTGTCTCC 
rCx36 H177A 
F1: 
R1:  
 
GCTGGCTCCAGCTCCATCTGGGC 
TCTTTAACCTCTAAGCAATC 
rCx36 S179A 
F1: 
R1: 
 
TCCACATCCAGCTGGGCTGCGCA 
GCCAGCTCTTTAACCTCTAAGCAATCTGG 
rCx36 L181A 
F1: 
R1: 
 
TCCATCTGGGGCGCGCACAGCAG 
TGTGGAGCCAGCTCTTTAAC 
rCx36 R182A 
F1: 
R1:  
 
ATCTGGGCTGGCCACAGCAGCAAGGTC 
GGATGTGGAGCCAGCTCT 
rCx36 K279A 
F1: 
R1: 
 
GGGATGGCGGGCGATCAAACTGG  
AGATGGTTAAGTTCAGCC 
rCx36 I280A 
F1: 
R1:  
 
ATGGCGGAAGGCCAAACTGGCTG  
CCCAGATGGTTAAGTTCAG 
rCx36 K281A 
F1: 
R1: 
 
GCGGAAGATCGCACTGGCTGTCC  
CATCCCAGATGGTTAAGTTC 
rCx36 L282A 
F1: 
R1: 
 
GAAGATCAAAGCGGCTGTCCGGGG  
CGCCATCCCAGATGGTTA 
 31 
 
rCx36 V284A 
F1: 
R1: 
 
CAAACTGGCTGCGCGGGGAGCCC  
ATCTTCCGCCATCCCAGATG 
rCx36 R285A 
F1: 
R1: 
 
ACTGGCTGTCGCGGGAGCCCAGG  
TTGATCTTCCGCCATCCC 
rCx36 G286A 
F1: 
R1: 
pEGFP-N1 
R1: 
 
GGCTGTCCGGGCGGCCCAGGCCA  
AGTTTGATCTTCCGCCATCCCAG 
 
GTCCAGCTCGACCAGGATG 
Sequencing of EGFP-N1 constructs 
* Mutated sites underlines and bolded 
 
3.7 PEPTIDES 
 
Table 9: List of peptides used for rCx36 specific tubulin interference. 
Name Sequence 
(Description) 
TAT CT-ON GRKKRRQRRRPQGWRKIKLAVRGAQAKRK 
(Used for competitive binding of the tubulin binding site of Cx36. Targets 
residues:276-292) 
 
 
 
TAT CT-OFF GRKKRRQRRRPQKDLPRVSVPNFGRTQSSDSAYV 
(Used as a control for competitive binding of the CT domain, outside of 
the tubulin region. Targets residues: 300-321) 
 
TAT CT-ON 
(Scrambled) 
 
GRKKRRQRRRPQQARWKLKVRRGGIKKAA 
(Control sequence of CT-ON in a scrambled orientation) 
 
TAT CT-OFF 
(Scrambled) 
GRKKRRQRRRPQDRVVSSSVLSPNGYKARDFTQP 
(Control sequence of CT-OFF in a scrambled orientation) 
  
  
*TAT sequence denoted in red 
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3.8 SIZE STANDARDS 
3.8.1 DNA Size Standard 
GeneRuler 1kb Plus DNA Ladder    Fermentas 
 
3.8.2 Protein Size Standard 
Spectra™ Multicolor Broad Range Protein Ladder  Thermo Scientific 
 
3.9 CONSUMABLES   
Serological pipettes (5ml, 10ml, 25ml)   Fisher Scientific 
Culture dishes (6cm, 10cm)     Falcon, Thermo Scientific 
24-well plates       Falcon 
MatTek plate       MatTek Corp 
Petri dish       Fisher Scientific 
Plastic consumables (pipette tips, eppendorf tubes, etc.) Fisher Scientific, Sarstedt, Qiagen, 
Neptune 
Syringe filters (0.20µm²)     HSW 
 
3.10 EQUIPMENT 
3.10.1 Cell Culture Equipment 
Incubator       Formula Steri-Cycle CO2 Incubator;  
        Thermo-Scientific 
Laminar flow unit      1300 Series A2; Thermo Scientific 
Lab centrifuge and rotor     CL10 Centrifuge (Thermo Scientific) 
Water bath       VWR 
Hemocytometer      La fontaine 
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3.10.2 Molecular Biology Equipment 
Bacterial shaker      (Innova40) 
        MaxQ4450 (Thermo Scientific)  
Rocking Platform      Model 100 (VWR) 
Water bath       Isotemp 205 (Fisher Scientific) 
Scale        Navigator XT (OHAUS) 
        AB104-S/FACT (Mettler Toledo) 
Magnetic Stirrer and Hot Plate    Isotemp® (Fisher Scientific) 
Electrophoresis Chamber System    (Bio-Rad) 
Incubator       HERA THERM (Thermo Scientific) 
Nucleic Acid Purification Systerm    Qiacube (Qiagen) 
Centrifuge       Sorval Legend Micro 21R  
(Thermo Scientific) 
PCR machine       Mastercycler Nexus 
        (Eppendorf) 
Vortex Mixer       (Fisher) 
UV Transilluminator High Performance UV 
Transilluminator (UVP) 
UV Gel Documentation System    Alpha Imager HP System 
        (Fisher Scientific) 
Nanodrop 2000 Photospectrometer    (Thermo Scientific) 
Agarose gel electrophoresis     Mini-sub cell GT (Biorad) 
pH Meter       Five Easy FE20 (Mettler Toledo) 
Programmable rotator-mixer     Multi Bio RS-24 (Peqlab) 
 
3.10.3 Protein Biochemistry Equipment 
Sodium dodecyl sulphate polyacrylamide gel   Mini-PROTEAN tetra  
electrophoresis (SDS-PAGE)    System (BioRad) 
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Blotting chamber      Trans-Blot® Turbo transfer system 
        (BioRad) 
Infrared western blot scanning system   Odyssey Infrared Imaging System; 
        (Licor) 
Nitrocellulose membrane Tran-blot Turbo Transfer Pack; 
(BioRad) 
Thermomixer       (Eppendorf) 
 
3.10.4 Microscopic Analysis Equipment 
Light Microscope      CKX41 (Olympus) 
Confocal Microscope      LSM 700 (Zeiss) 
Coverslips       (Fisher Scientific) 
Mounting slides      (Fisher Scientific) 
 
3.11 SOFTWARE 
DNA Concentration      Nanodrop 2000 
Gel Documentation      AlphaImager 
Image processing      Image J, Photoshop and   
         Illustrator CC 2015 (Adobe) 
Primer design       NEBaseChanger  
(New England Biolabs)  
Analysis of DNA sequences     SnapGene Viewer 
Protein Sequence alignments     ClustalW2 
Image acquisition and processing    ZEN 2010 software (Zeiss) 
Spreadsheet analyses      Excel 2010 (Microsoft) 
Text processing      Word 2013 (Microsoft) 
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4 METHODS 
4.1 MOLECULAR BIOLOGICAL METHODS 
4.1.1 Cloning of DNA Fragments 
4.1.1.1 Cultivation of bacteria 
Recombinant bacteria was cultured on LB-agar plates supplemented with the appropriate selection 
antibiotic, as determined by the expression vector, and incubated at 37ºC overnight. Single 
colonies were obtained and grown in 5mL of antibiotic supplemented LB medium for overnight 
incubation at 37ºC. To achieve optimal growth conditions, bacterial cells were placed on a tilted 
rack in a horizontal shaker at 200 rpm for the duration of incubation.  
4.1.1.2 Determination of nucleic acid concentration 
DNA concentration was measured using the NanoDrop 2000 and Nanodrop2000 software under 
the nucleic acid program, at an absorbance of 280 nm (A280). Simultaneously, samples were 
assessed for purity as indicated by the quotient A260/A280. As pure DNA typically reads as a value 
of 1.8, residual chemical contamination was recognized as a significant deviation from this value; 
an increase ≥2.0 or decrease ≤1.6 is indicative of RNA or protein contamination respectively. EB 
buffer (Qiagen), the final DNA elution buffer, was used as a blank prior to concentration 
measurements.  
4.1.1.3 Plasmid DNA preparation 
To obtain highly purified DNA for further applications, such in the case of DNA sequencing or 
transient transfection, small-scale plasmid purification from DH5α E.coli was performed. Plasmid 
purification was carried out using the Qiacube and with respective QIAPrep Spin Miniprep Kit as 
per the manufacturer’s guidelines. From a 5mL overnight culture, approximately 9-12µg of 
plasmid DNA was purified by this method. The DNA concentration was subsequently determined 
by measurement of the A280 (see section 4.1.1.2). 
4.1.1.4 Agarose Gel electrophoresis and DNA gel elution. 
Agarose gel electrophoresis was performed for the confirmation of inserts through test restriction 
digests with type II restriction endonucleases or as prerequisite for DNA purification. In 
preparation of either PCR or general purification, DNA samples were mixed 5:1 with the 6x DNA 
loading dye as loading buffer (see 4.1.1.6 for DNA preparation for restriction digest). 1% agarose 
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gels were supplemented with 0.1g/mL ethidium bromide for DNA staining. A horizontal Mini-
Sub® Cell GT electrophoresis chamber (BioRad) was used in operation with PowerPac™ Basic 
power supply. Gel electrophoresis was achieved using consistent voltages ranging from 90-100 V 
and operated in 1x TAE buffer solution. DNA was visualized and digitally documented with the 
Alpha Imager HP system (Fisher Scientific). The GeneRuler 1kb Plus DNA Ladder was used as 
the size standard. The DNA of interest was excised rapidly from the agarose gels under UV light 
supplied by the UV Transilluminator TFM-20V (UVP) using a sharp scalpel. Elution and 
purification was performed using the NucleoSpin®gel and PCR Clean-up kit in the case of PCR 
(for details see section 4.1.1.5) or Qiaquick gel extraction kit for general purification as per the 
manufacturer’s protocols.  
4.1.1.5  Amplification of DNA fragments by PCR 
For the amplification of specific DNA fragments, the polymerase chain reaction (PCR) was carried 
out using the Mastercycler® Nexus. The assembly of the PCR reaction and program listed in Table 
9. Amplicons were fractionated on a 1% agarose gel and purified using the NucleoSpin®gel and 
PCR Clean-up kit. Modifications to the manufacturer’s protocols were as follows: (i) washing of 
the silica membrane with NT3 buffer was repeated twice and (ii) for DNA elution, 15µl of NE 
buffer was added to the amplicons and incubated at room temperature (RT) for 1 minute and 
repeated twice for a total elution flow-through of 30µl. For DNA concentration measurements, NE 
buffer was used as a blank.  
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Table 10: Assembly of PCR reaction and PCR program. 
 PCR Reaction 
Primer (s/as) (10µM) 1.0 µl 
dNTPs 1.0 µl 
10x buffer 10.0 µl 
(Phusion High-Fidelity) DNA polymerase  0.5 µl 
template DNA (10 ng/µl) 1.0 µl 
A. dest. 35 µl 
PCR program  
   initial denaturation 1. 94ºC, 3 min 
   denaturation 2. 94ºC, 30 s 
   hybridization 3. 52ºC or 63ºC, 30s 
   elongation 4. 72ºC, 1 min 
5. 25 cycles of steps 2-4 
   elongation 6. 72ºC, 10 min 
7. 4ºC ∞ 
 
4.1.1.6 DNA restriction digest 
Restriction digests of DNA were performed with type II restriction endonucleases with the Fast 
Digestion Top Fermentas Kit (Thermo Scientific) as per the manufacturer’s guidelines. For 
analysis of recombinant plasmids, digest reactions were set up with 0.2-0.4µg DNA and incubated 
for 5 min at 37ºC. Prior to the ligation, vector DNA was dephosphorylated with calf intestine 
alkaline phosphatase (CIAP), preventing the vector from re-ligating on itself and producing false-
positive clones. Under the dephosphorylation protocol, 1 µl of CIAP was added to the digest 
reaction and incubated at 37ºC for 30 min. Upon completion, CIAP was inactivated by an 
incubation step carried out at 65ºC for 10 min. Restriction digests to be used further in cloning 
were electrophoresed, excised and eluted from the gel with the QiaCube in combination with the 
QiaQuick gel extraction kit as per the manufacturer’s guidelines. Test restriction digests, such in 
the case of positive clone confirmation, were imaged upon completion of gel electrophoresis. 
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4.1.1.7 Ligation of DNA fragments 
Initial ligation of DNA to pJET1.2, chosen for its high efficiency cloning of PCR products, was 
performed using the CloneJET PCR Cloning Kit as per manufacturer’s guidelines for the blunt 
end cloning protocol. Ligation reactions were incubated at RT for 30 minutes prior to 
transformation. Listed below is the corresponding reactants of the ligation mixture. 
T4 DNA Ligase 
2X Reaction Buffer 
pJET1.2/blunt Cloning Vector 
(50ng/µl) 
purified PCR product 
Water, nuclease-free 
 
1.0 µl 
10.0 µl 
1.0 µl 
 
50 ng (3:1 molar ratio to pJET1.2/blunt) 
up to 19 µl for a total reaction volume of 
20µl 
For sub-cloning, such in the case of obtaining pcDNA 3.1 MCS-BirA(R118G)-HA-rCx36 
(abbreviated as pcDNA 3.1 BirA*-rCx36) wild-type and mutant constructs, ligation was achieved 
using the Rapid DNA Ligation Kit as per the manufacturers guidelines. A base pair ratio of 1:6.4 
(insert:vector) was used. Ligation reactions were incubated at RT for 5 minutes prior to 
transformation. Listed below is the corresponding reactants of the ligation mixture: 
T4 DNA Ligase (5u/µl) 
5X Rapid Ligation Buffer 
Linearized Vector DNA 
purified PCR product 
Water, nuclease-free 
 
1.0 µl 
4.0 µl 
80-90 ng 
40-50 ng 
up to 19 µl for a total reaction volume of 
20µl 
 
4.1.1.8  Transformation of plasmid DNA into competent bacteria via heat-shock 
For the preparative production of recombinant plasmid DNA, 100µl of competent DH5α E. coli 
bacteria was added to 2-5 µl of previously prepared ligation mixture (see section 4.1.1.7 for details) 
and incubated on ice for 30 minutes. Following incubation, the bacterial/ligation mixture was 
briefly heat shocked at 42ºC for 30 s and recovered in 800 µl of pre-warmed SOC medium. Post-
heat-shock, bacteria was incubated at 37ºC in a bacterial shaker for 1h at 200 rpm. Upon 
completion, 200 µl of the bacterial suspension was plated on LB-agar plates containing the 
appropriate selection antibiotic and incubated overnight at 37ºC for the production of single 
isolated colonies.  
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4.1.2 Site-Directed Mutagenesis 
Prior to start, primers were designed to introduce alanine point mutations at selected residues of 
rCx36 cytoplasmic loop and carboxyl terminal domain. Primers were generated using the 
NEBaseChanger™ online program and were ordered from Integrated DNA Technologies, Iowa. 
Mutant pEGFP-rCx36 plasmids were generated using Q5® Site-Directed Mutagenesis Kit (New 
England Biolabs, Canada) as per manufacturer's protocol with pEGFP-rCx36 as the template. 
Transformed NEB 5-alpha competent E. coli cells were plated onto LB-KAN plates to isolate 
single bacterial colonies which were subsequently grown in LB-KAN media overnight. Small-
scale plasmid purification (starting from 5ml bacterial cultures) was carried out via the QiaCube 
and respective QIAPrep Spin Miniprep Kit as per manufacturer's protocols. A list of the used 
mutagenic primers is provided in Table 8.  
 
4.1.3 Sequencing of Plasmid DNA 
Purified pEGFP-rCx36 mutant plasmid DNA generated from the Q5® Site-Directed Mutagenesis 
Kit was sent to Eurofins Genomics, USA, for sequencing. 
 
4.1.4 Bioinformatics 
Protein and DNA sequences were obtained from the National Center for Biotechnology 
Information (NCBI; http://www.ncbi.nlm.nih.gov) under the protein and nucleotide database 
engine respectively. DNA sequences were analyzed using ClustalW2, for the generation of 
sequence alignments with the multiple sequence alignment tool and SnapGene Viewer to confirm 
mutated constructs and generate DNA restriction maps. ImageJ software was used to generated 
image montages and to measure gap junction plaque area and fluorescence (CTFcell and CTFGJP) 
with the free-hand trace tool. Predicted models of the rCx36 structure were generated using the 
online I-TASSER tool. 
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4.2 CELL CULTURE 
4.2.1 Culture of N2a 
Mouse neuroblastoma 2a (N2a) cells were grown in Dulbecco's Modified Eagle Medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS), 1% non-essential amino acids (NEA) and 1% 
penicillin/streptomycin. Cells were maintained in a Forma Steri-cycle CO2 Incubator at 37ºC and 
5% CO2 in a humidified atmosphere. Cells were passaged routinely twice a week, allowing cells 
to grow to confluence over a three to four day time period. For passaging purposes, cells were 
initially washed with pre-warmed PBS (- calcium chloride/- magnesium chloride; -/-) and 
subsequently treated with pre-warmed trypsin-EDTA for 30-60 seconds to relieve cell adherence. 
Upon addition of 10ml pre-warmed DMEM, trypsin-EDTA was rendered inactive. Cells were 
collected and resuspended in solution to produce a homogenous mixture. Finally, 1 ml of the cell 
suspension was added to 9 mL of fresh DMEM in a 10 cm dish. 
 
4.2.2 Transient Transfection 
Transient transfection of N2a cells was achieved using the Effectene Transfection Reagent Kit 
(Qiagen) as per the manufacturer’s protocols. For localization studies of fixed cells, 10000 cells 
were seeded onto coverslips in a 24-well plate. For a small scale production of whole cell protein 
lysates to be used in western blot and/or SDS-PAGE gel staining analyses, 30000 cells were seeded 
into a 24-well plate. For utilization in the biotinylation assay (BioID), 900000 cells were plated on 
a 6 cm dish. For live cell imaging and fluorescence recovery after photobleaching (FRAP) studies, 
10000 cells were seeded onto a 14 mm microwell of a 35 mm MatTek dish. Transient transfected 
was performed 24h after seeding using 0.2-2.0 µg of DNA depending on the appropriate protocol. 
Cells were used 48 h post-transfection in the analyses as outlined.  
 
4.2.3 Preparation for BioID Pull-Down 
For use in the biotinylation assay, media was exchanged 24h post-transfection and supplemented 
with 50 µM of biotin.  
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4.2.4 Preparation for Confocal Analyses 
For use in live cell imaging analyses, N2a cells were washed with pre-warmed PBS (+/+) and 
cultured in 2mL of DMEM (without phenol red) 48 h post-transfection. N2a cells were incubated 
under normal conditions for a minimum of 10 minutes prior to live cell studies. In the case of drug 
treatment, cytochalasin D (3µM), colchicine (0.1µg/ml) or paclitaxel (2.5µg/ml) was added 
additionally and cells were incubated at 37°C for 10 min prior to use. For the purpose of this study, 
cytochalasin D was used to inhibit the polymerization of microfilaments (Sigma-Aldrich, USA). 
Paclitaxel (Sigma-Aldrich, USA) and Colchicine (Sigma-Aldrich, USA) were used for tubulin-
specific interference (See Appendix B).  
Cells destined for fixation were washed with RT PBS (+/+) and subsequently treated with 500 µl 
of 10% formalin for 15 min at RT. Upon completion of the incubation period, cells were washed 
with RT PBS (+/+), distilled water and subsequently mounted onto a microscope slide 
(Fisherbrand) using 10 µl of Fluoroshield™ with DAPI (Sigma). Slides were stored at 4ºC until 
ready for use. 
 
4.3 PROTEIN BIOCHEMICAL METHODS 
4.3.1 Determination of Protein Concentration 
Refer to section 4.1.1.2 with the following exceptions: (i) the nanodrop 2000 software was used 
under the Protein A280 program (ii) purified protein was indicated by the A260/A280 value of 
approximately 1.6. 
 
4.3.2 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Whole cell lysates for SDS-PAGE and western blots were prepared by aspirating the culturing 
media and scraping the cells into 1x Laemmli sample buffer. Preparation of cell lysates used in the 
biotinylation assay (BioID) is detailed in section 4.3.4. Protein samples were denatured at 95ºC for 
5 min prior to electrophoresis using a vertical Mini-PROTEAN® Tetra System used in operation 
with PowerPac™ Basic power supply. Spectra™ Multicolour Broad Range Protein Ladder was 
used as the size standard. Typically, 10-20 µg of protein was loaded per lane, equally across 
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experiments. Gel electrophoresis was achieved using consistent voltages ranging from 100-150 V 
until complete protein separation was achieved; the operation was in 1x Laemmeli running buffer 
solution. Denaturing SDS-polyacrylamide gels were prepared with the following compositions: 
Separation gel: 10% acrylamide 
380 mM Tris-HCl, pH 8.8 
0.1% SDS 
0.08% tetramethylethylenediamine TEMED 
0.8% ammonium persulphate (APS) 
Comb gel: 5% acrylamide 
125 mM Tris-HCl, pH 8.8 
0.1% SDS 
0.08% tetramethylethylenediamine TEMED 
0.8% ammonium persulphate (APS) 
 
Gels were stained with PageBlue Protein Staining solution (post-transfer if destined for western 
blot) for 30 min before overnight destaining commenced. Protein stained gels were visualized and 
digitally documented with the Alpha Imager HP system (Fisher Scientific). 
 
4.3.3 Western Blot 
Post-SDS-PAGE, proteins were transferred onto a nitrocellulose membrane in accordance with the 
semi-dry blot system. The Trans-Blot® Turbo™ Transfer Pack used contained equilibrated 
nitrocellulose membranes prepackaged with filter paper and buffer. Proteins were transferred using 
the Trans-Blot® Turbo™ Transfer System (Bio-Rad) at 5A, 25V, for 10 min under the high 
molecular weight protocol. 
 
4.3.3.1 Traditional 
Nitrocellulose-bound immobilized proteins were washed with PBS and blocked with Odyssey 
Blocking Buffer for 1 h at RT to minimize nonspecific interactions thus enhancing detection 
sensitivity. Primary antibodies directed against the protein(s) of interest were applied in blocking 
buffer overnight at 4ºC (see Table 1 for primary antibodies and dilutions). To remove unbound 
primary antibodies and further reduce unspecific binding, membranes were washed with PBS 
supplemented with 0.1% Tween 20 (PBS-T). Membranes were incubated with IRDye coupled 
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secondary antibodies in blocking buffer for 1h at RT in the dark (see Table 2 for secondary 
antibodies and dilutions). Upon completion, membranes were washed 4 times in PBS-T and once 
in PBS for removal of Tween 20. Membranes were kept in the dark until imaged; fluorescent 
signals were detected using the Odyssey Infrared Imaging System.  
 
4.3.3.2 iBind 
As an alternative to the traditional method, nitrocellulose-bound immobilized proteins were 
immersed in 5 ml 1x iBind™ solution. Membrane blocking and antibody application was achieved 
using the iBind™ Western System in combination with the iBind™ Solution Kit and iBind™ 
Cards as per manufacturer’s guidelines. Upon completion, membranes were stored in distilled 
water kept in the dark. Fluorescent signals were detected using the Odyssey Infrared Imaging 
System.  
 
4.3.4 Biotinylation Pull-Down (BioID) 
For preparation of cell lysates used in the biotinylation pull-down (BioID), N2a cells were washed 
with cold PBS (-/-) upon removal of the culturing media. Cells were collected into 2 ml of PBS (-
/-) and centrifuged at 400 rpm for 5 min at RT. Supernatant was discarded, and the pellet was 
washed by resuspension in PBS (-/-) following by centrifugation under the same conditions; 
washing step was repeated twice. Cells were lysed with 200 µl of NP40 Cell Lysis Buffer 
supplemented with 1% protease inhibitor cocktail and transferred into a Protein LoBinding Tube 
(Eppendorf). Lysate(s) was incubated on ice for 30 minutes with periodic vortexing every 10 
minutes. For protein separation, lysates were centrifuged at 13,000 rpm for 10 min at 4ºC. The 
supernatant was transferred into a new Protein LoBinding Tube and subjected to further 
experiments; a small aliquot was retained for western blot analysis as pre-incubation lysate (pre-
lysate).  
 
Dynabeads®MyOne™ Streptavidin C1 were prepared by vortexing to re-suspend the beads. 90 µl 
of the resuspension was transferred into a Protein LoBinding Tube and washed 3 times with 1 ml 
of PBS; bead capture was achieved using a magnetic rack. Pre-lysate was incubated with the beads 
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overnight at 4ºC on a rotating platform. Upon completion of incubation, beads were collected on 
the magnetic rod, and supernatant was stored as the lysate post-incubation (post-lysate). Collected 
beads were washed twice for 8 min at RT with 1 mL of wash buffer 1 (2% SDS in dH2O), once 
with wash buffer 2 (0.1% deoxycholate, 1% Triton X-100, 500 mM NaCl, 1 mM EDTA and 50 
mM Hepes, pH 7.5), once with wash buffer 3 (250 mM LiCl, 0.5% NP-40, 0.5% deoxycholate, 1 
mM EDTA and 10 mM Tris, pH 8.1) and twice with wash buffer 4 (50 mM Tris, pH 7.4, and 50 
mM NaCl); a small aliquot of the last wash fraction was reserved for western blot analysis as the 
“wash.” Bound proteins were eluted from the bead in 50 µl of 1x Laemmeli sample buffer at 95ºC 
for 5 minutes; a total of two elutions were performed. 
 
4.3.5 Protein Identification by Mass Spectrometry 
Proteins eluted from the streptavidin beads were fractionated by SDS-PAGE and stained with 
PageBlue Protein Staining solution. After destaining, whole gel lanes were cut into 6 equal-sized 
gel bands, and mass spectrometry was performed at the in house facility of the Dept. of Chemistry, 
York University.  
 
4.4 MICROSCOPIC METHODS 
4.4.1 Confocal Laser Scanning Microscopy 
Confocal imaging was performed using the Zeiss LSM 700 confocal microscope in operation with 
the ZEN 2010 software program for data analysis. The microscope was equipped with the 405, 
445, 488, 555 and 639 nm laser lines of which the 405 and 555 lasers were used in conjunction 
with this thesis for the detection of EGFP, EYFP, DAPI and DsRed fluorescence. Images were 
taken with a resolution of 512 x 512 pixels and exported as TIFF files to be used for documentation 
in Image J, Adobe Photoshop and/or Illustrator. Tables generated from FRAP studies were 
exported as .txt files and transferred into Microsoft Excel 2013 for data analysis and preparation 
of graphs.  
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4.4.2 Localization Studies of N2a Cells 
Confocal laser scanning microscopy was used to analyze the cellular localization of EYFP- or 
EGFP-tagged rCx36 variants in transfected N2a cells. Images were taken with either living or fixed 
cells using the Plan-Apochromat 63x/1.4 Oil DIC M27 objective at a resolution of 512 x 512 pixels. 
Scanning repetitions were set to an averaging of 4 in the single or double track mode depending 
on fluorophores used for detection. A combination of single plane and z-stacked images were taken 
for the compilation of localization studies. In the case of time-lapse observations, averaging was 
set to 1, and single track mode was utilized for observations made in the single plane. 
 
4.4.3 Fluorescence Recovery After Photobleaching (FRAP) 
To analyze the dynamics of rCx36 and variant gap junction plaques, fluorescence recovery after 
photobleaching (FRAP) was utilized. Specifically, rCx36 GJ plaques (center and lateral ends), 
plasma membrane, intracellular space and extracellular space were photobleached using Zeiss 
LSM 700 confocal microscope system under Zeiss 63X (Plan-Apochromat, DIC M27 1.4) oil 
immersion lens, with the 405 nm laser, 48h post-transfection. Samples were placed in an 
incubating chamber and maintained at a temperature of 37ºC. Acquisition mode was set at a speed 
of 10 and 8 bit depth. Mobile fraction (%) and half-time of recovery (t½) in seconds, was recorded 
for each ROI of the GJP and respective controls; ROIs were manually drawn using the rectangle 
tool. Bleaching was achieved with a single event of 40 iterations at a laser intensity of 70% after 
10 cycles of 1.0-sec; total recording event was observed over 200 cycles. Observations were 
recorded with a pinhole of 1.0 airy units (AU) with a scan area of 31.1µm x 31.1µm and resolution 
of 512x512 pixels. Consistent parameters were used in all experiments. Experiments with 
considerable fluctuations in fluorescence intensity or frame-shifts were not included in the 
analyses. Results were normalized against the extracellular space to improve the signal-to-noise 
ratio and averaged amongst the population, represented as the mean ± the standard error of the 
mean (SEM). Sample sizes ranged based on the efficiency of plaque formation, however, typically 
a minimum of n=5 was used for analysis (see Appendix C). The data was exported from Zen 2010 
for statistical analysis and graphing (see section 4.5). 
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4.5 ANALYSIS OF DATA 
 
For the analysis of corrected total fluorescence (CTF) and gap junction plaque area, select regions 
were traced with the ImageJ free-hand tool. Fluorescence measurements were subtracted from 
background fluorescence to obtain the corrected value; the mean fluorescence of the background 
was averaged across a sample size of three. In the case of gap junction plaque area, tracings were 
made along the axis that yielded the largest surface area (see Appendix C for sample size). Values 
obtained for CTFcell (Relative fluorescence units or RFU), CTFGJP (RFU), gap junction plaque area 
(µm²), mobile fraction (%) and half-time of recovery (s) were averaged across samples and 
represented as the mean± the standard error of the mean (SEM). To determine statistical 
significance, the student t-test was performed; significance was arbitrarily determined at a 99% 
confidence interval where significance (or lack thereof) was denoted as: 
ns p ˃ 0.01 
** p ≤ 0.01 
*** p ≤ 0.001 
**** p ≤ 0.0001 
 
where ‘ns’ represents no statistical significance. Data analysis and generation of respective figures 
were completed in Microsoft Excel 2013. 
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5 RESULTS 
5.1 INVESTIGATION OF CX36-TUBULIN INTERACTION VIA BIOID 
The first aim of this thesis was to confirm the interaction between rCx36 and tubulin in Neuro2a 
cells while simultaneously testing a new method for identifying protein interacting partners termed 
BioID. In this technique, we utilized a C-terminal fusion protein with rCx36 and the promiscuous 
bacterial ligase BirA* capable of covalently attaching biotin to proteins in close proximity. The 
biotin labeled protein fraction was then enriched using a highly selective enrichment and 
purification procedure to identify potential interacting partners (Figure 9). Results generated were 
to serve as the in vivo complement to pre-existing in vitro data demonstrating rCx36-tubulin 
interaction with the CTB region. 
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Figure 9: Schematic diagram of the BioID method. 
(A) The promiscuous bacterial ligase BirA* is fused to the bait protein of interest and is responsible for the selective 
biotinylation of proximal proteins once expressed in eukaryotic cell lines. Upon cell lysis and protein denaturation, 
biotinylated proteins are isolated via biotin affinity capture and identified by mass spectrometry and/or western blot 
analysis. (B) For use in this thesis, N2a cells were transfected with rCx36-BirA* and treated with 50 µM biotin 24 h 
post-transfection. Biotinylation was carried out over a time span of 24 h. Upon cell lysis, the biotin-labelled fraction 
was recovered on streptavidin-conjugated Dynabeads in accordance to the Dynabead MyOne Streptavidin purification 
procedure. Protein(s) of interest were identified via mass spectrometry and/or western blot analysis. Modified from 
Roux, Kim, Raida, & Burke, 2012   
 
 49 
 
5.1.1 Cloning and Confirmation of rCx36-BirA Wild-type and Mutant Constructs 
For the generation of the C-terminal fusion protein(s) used in the BioID methodology, PCR was 
performed for the amplification of the full-length rCx36 gene (Rattus norvegicus, 321 amino acids). 
Previously, full-length rCx36 was cloned into the pEGFP-N1 expression vector to generate 
pEGFP-rCx36, which served as the template DNA for amplification; all constructs were made 
readily available by the Dr. Georg Zoidl lab, Department of Biology, York University. PCR was 
carried out at an annealing temperature of either 52°C or 63°C. The rCx36 amplicons generated 
from PCR were confirmed via fractionation on a 1% agarose gel and identified by the presence of 
a band 975bp in length (Figure 10). Since the annealing temperature of 52°C yielded unspecific 
bands, amplicons of rCx36 annealed at 63°C was chosen for subsequent purification. 
  
PCR purified amplicons of rCx36 were ligated into the pJET 1.2 vector, chosen for its ability to 
clone quickly with high efficiency. The ligated products were transformed into E.coli DH5α 
competent cells and plated onto LB-AMP plates overnight for selection. Four single bacterial 
colonies were isolated and grown in LB-AMP media overnight and subjected to small-scale 
plasmid purification. To confirm positive clones as well as to excise rCx36 DNA from pJET 1.2, 
a restriction digest with EcoRI was performed. For re-ligation purposes, the vector plasmid pcDNA 
3.1 MCS-BirA(R118G)-HA (abbreviated as pcDNA 3.1 BirA*) was also digested with EcoRI and 
treated with calf intestine alkaline phosphatase (CIAP) to prevent re-ligation of the vector; digest 
was confirmed by the presence of a band 6382bp in length (Figure 11A). Upon the identification 
of positive clones, rCx36 was re-ligated to pcDNA 3.1 BirA* and subsequently transformed into 
DH5α E.coli for plating. Similarly, four single colonies were selected and grown overnight in LB-
AMP followed by plasmid purification. Three pcDNA 3.1 BirA*-rCx36 positive clones were 
identified via restriction digest with EcoRI by the presence of a band 969 bp (Figure 11B). A 
second restriction digest with BamHI confirmed one clone in the correct orientation by the 
presence of a band 899bp in length (Figure 11C). 
 
Using this method we were able to successfully generate pcDNA 3.1 BirA*- rCx36 Δ175-196 and 
Δ279-292 and fusion constructs, which contained deletions in the CLB and CTB domains 
respectively, to be used for further studies. The pEGFP-N1 expression vector with the rCx36 Δ279-
292- and rCx36 Δ175-196 genes were used as template DNA for PCR amplification; constructs 
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were made readily available by the Dr. Georg Zoidl lab. Amplification of the mutant rCx36 by 
PCR was carried out at an annealing temperature of 52°C to account for the reduction in DNA 
base pair length. Upon confirmation of mutant amplicons, the DNA was purified and cloned into 
pcDNA 3.1 BirA* as previously described. Restriction digest with BamHI revealed one positive 
clone in the correct orientation for pcDNA 3.1 BirA*-rCx36 Δ175-196 (Figure 12A) and three 
clones for pcDNA 3.1 BirA*-rCx36 Δ279-292 as indicated by a band 833bp and 857bp 
respectively (Figure 12B). 
 
 
 
 
 
 
 
Figure 10| Amplification of the rCx36 gene from pEGFP-rCx36 template DNA.  
Amplicons of the rCx36 gene generated from pEGFP-N1-rCx36 template DNA via PCR with annealing temperatures 
of either 63°C or 52°C. "+" indicates the presence of the template whereas "-" indicates the absence of the template 
DNA; in the latter case nuclease-free water served as the negative control. Full length rCx36 protein coding region 
was identified by the presence of a band 975bp. 1% agarose gel with ethidium bromide (EtBr); M: marker, bp: base 
pairs.  
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Figure 11| Confirmation of pcDNA 3.1 BirA*-rCx36 fusion constructs.  
(A) Restriction digest of the pcDNA 3.1 BirA* plasmid vector and four clones post pJET1.2-rCx36 ligation and 
transformation with E. coli; restriction digest was achieved with EcoRI. Two positive clones for rCx36 were identified 
(#1 and #2) by the presence of a band 969bp; similarly pcDNA 3.1 BirA* was confirmed by a band 6382bp. (B) 
Positive clones previously identified were excised, purified and re-ligated to the pcDNA 3.1 BirA* vector plasmid. 
Four clones were selected for DNA extraction and subsequently digested with EcoRI. Clones #1, 3 and #4 were 
identified as positive for the insertion of full length rCx36 gene by the presence of a band 969bp in length as indicated. 
(C) Restriction digest of pcDNA 3.1 BirA*-rCx36 DNA purified from the three previously identified positive clones 
was achieved with BamHI to confirm orientation. Correct orientation of rCx36 is denoted by a band approximately 
899bp whereas the incorrect orientation is denoted by a band approximately 100bp. One clone (#2) was identified as 
possessing the full length rCx36 gene in the correct orientation, housed within the pcDNA 3.1 BirA* vector. 1% 
agarose gel with ethidium bromide (EtBr); M: marker, bp: base pairs. “+” indicated presence of respective restriction 
enzyme; "-" indicates absence of restriction enzyme where water served as the control.  
 
 
 
 
 
 52 
 
 
 
Figure 12| Confirmation of the pcDNA BirA*-rCx36 Δ279-292 and -Δ175-196 fusion constructs.  
(A) Following ligation of rCx36 Δ175-196 to pJET 1.2 and re-ligation to the pcDNA 3.1 BirA* vector, two clones 
were identified as positive for the insertion of the rCx36 Δ175-196 gene. Clones were digested with HindIII to confirm 
orientation; correct orientation of pcDNA 3.1 BirA-rCx36 Δ175-196 is denoted by a band 833bp whereas the incorrect 
orientation is denoted by a band approximately 100bp. Clone #1 was identified as possessing the rCx36 Δ175-196 
gene in the correct orientation. (B) Similarly, post-ligation to the pcDNA 3.1 BirA* vector, clones for rCx36 Δ279-
292 were digested with BamHI to confirm orientation. By this, three positive clones were identified by the presence 
of an 857bp band. 1% agarose gel with ethidium bromide (EtBr); M: marker, bp: base pairs. “+” indicated presence 
of respective restriction enzyme; "-" indicates absence of restriction enzyme where distilled water served as the control. 
 
 
 
 
 
 
 
 53 
 
5.1.2 Confirmation of BirA* Fusion Protein Expression 
To confirm the expression of our target protein(s), N2a cells were transfected with pcDNA 3.1 
BirA* -rCx36 WT, -Δ175-196, or -Δ279-292. Since three clones were generated for the pcDNA 
3.1 BirA*-rCx36 Δ279-292 construct, all were tested to determine if differences in expression 
quality existed. Small scale whole cell protein lysates were prepared and subsequently fractionated 
on a 10% SDS-PAGE gel. Proteins were transferred onto a nitrocellulose membrane for western 
blotting and the anti-HA primary antibody was applied for validation of protein expression. 
Expression of BirA* was confirmed by the presence of a 30kDa band whereas all rCx36-BirA* 
fusion proteins (abbreviated as WT, Δ175-196 and Δ279-292) were confirmed by the presence of 
a band approximately 60kDa (Figure 13). Although detection of rCx36 Δ279-292-BirA* was 
observed, fluorescence intensity in all three samples was lesser than that of the wild-type indicating 
that this mutant was poorly expressed in our cell model; therefore suggesting that this may be a 
region of interest in mediating expression. As such, this result was taken into consideration for the 
BioID pull-down experiments to follow. Furthermore, since the first sample of rCx36 Δ279-292-
BirA* had the least amount of protein expression, it was not used for further studies.  
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Figure 13| Western blot analysis of rCx36 -WT, -Δ279-292- and -Δ175-196-BirA* fusion proteins. 
N2a cells transfected with pcDNA 3.1 BirA*-rCx36 WT, -Δ175-196 or -Δ279-292 were lysed 48h post-transfection. 
Lysates were fractionated on a 10% SDS-PAGE gel and subsequently used for western blot analysis with the anti-HA 
and anti-mouse IRDye800 primary and secondary antibodies respectively. BirA* was confirmed by the presence of a 
band 30kDa and showed strong protein expression. Similarly, strong protein expression was shown for wild-type 
rCx36-BirA* and rCx36 Δ175-196-BirA* as confirmed by a band approximately 60kDa. Poor protein expression was 
noted for all three samples of rCx36 Δ279-292-BirA*; the first sample in particular displayed minimal expression and 
was not used in future analysis. 
 
 
5.1.3 Confirmation of Eluted Wild-type rCx36-BirA* Fusion Protein Expression  
To confirm the expression of the BirA* fusion protein throughout the biotinylation assay, the 
neuroblastoma cell line Neuro2a (N2a) was transfected with wild-type rCx36 (pcDNA 3.1 BirA*-
rCx36). Approximately 900,000 N2a cells were seeded and cultured in supplemented DMEM 
overnight. Cells were transfected with 2.0 µg of DNA and 50µM biotin was applied 24h post-
transfection. Cells were lysed 24h post-biotin application and samples were collected throughout 
the biotinylation assay for western blot assessment (see 4.3.4 for details). Protein lysates were 
fractionated on a 10% SDS/PAGE gel and transferred to a nitrocellulose membrane for western 
blotting. The primary antibody anti-HA was applied for the detection of the wild-type rCx36-
BirA* fusion protein. Additionally, for the detection of biotinylated proteins, the conjugate enzyme 
streptavidin-HRP was also applied. The following sample fractions were collected for analysis: 
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N2a pellet, lysate prior to Dynabead incubation (pre-lysate), lysate post-incubation (post-lysate), 
last wash fraction (wash) and two elution fractions.  
 
Western blot analysis revealed modest levels of biotinylated protein in N2a cells expressing wild-
type rCx36-BirA* in the pellet and pre-lysate fractions. Absence of biotinylated proteins in the 
post-lysate fraction indicated that streptavidin-conjugated beads were able to successfully capture 
and isolate biotin-labeled proteins. Elution from the beads resulted in a highly enriched fraction of 
biotinylated proteins, most of which were successfully eluted in the initial fraction. Furthermore, 
biotinylated proteins were not detected in the last wash fraction confirming that elutions were 
strictly comprised of biotinylated proteins that had bound to the streptavidin-conjugated beads 
(Figure 14A). As predicted, rCx36-BirA* detection was most notable in the first elution fraction 
and negligible in the pellet fraction. Additionally, due to low protein:solvent ratio, detection of 
rCx36-BirA* was minimal in the pre-lysate fraction (Figure 14B). Taken together, these results 
served as an indication that BirA* was capable of biotinylating proximal proteins including wild-
type rCx36 to which it is fused. By this it was concluded that rCx36-BirA* was successfully 
expressed and eluted during the affinity capture of biotinylated proteins. 
 
To identify potential interacting partners of rCx36, the first elution sample was again fractionated 
on a 10% SDS/PAGE gel in parallel with the first elution fraction of a control biotinylation pull-
down performed with BirA* and subsequently stained with PageBlue™ Protein Staining Solution. 
Mass spectrometry was performed to identify interacting partners that were unique to rCx36 in 
comparison to the BirA* control. Among the candidates yielded, the tubulin beta-3 chain (βIII-
tubulin) was identified as being unique to rCx36, confirming in vivo that tubulin is an interaction 
candidate of rCx36 either directly or indirectly (See Appendix D). Furthermore interaction 
between rCx36 may occur at a region of βIII-tubulin that is not conserved across tubulin 
heterodimer monomers and isotypes. 
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Figure 14| Western blot analysis of biotinylated proteins captured via BioID confirms the presence of  
                     rCx36-BirA*. 
(A) Western blot analysis of protein fractions collected throughout the BioID methodology. Samples were prepared 
post-transfection of N2a cells with wild-type rCx36-BirA* and fractionated on a 10% SDS-PAGE for western blotting 
with the anti-HA primary antibody and anti-mouse IRDye800 secondary antibody; conjugate enzyme Streptavidin-
HRP was also applied for the detection of biotinylated proteins. Biotinylated proteins, as shown in red, were detected 
modestly in the pellet and pre-lysate and second elution fractions and highly concentrated in the first elution. Absence 
of biotinylated protein in the post-lysate and wash fractions indicates that the biotin affinity capture was successful. 
(B) Wild-type rCx36-BirA* was shown to be detected modestly in the pellet and pre-lysate fractions and heavily 
concentrated in the first elution fraction. Presence of a band approximately 60kDa indicated that wild-type rCx36-
BirA was amongst proteins tagged with biotin. (C) Overlay of biotinylated proteins and rCx36-BirA* detection.  
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5.1.4 Detection of Tubulin via Biotin Affinity Capture 
For the detection of tubulin via BioID, sample preparation remained as previously mentioned (also 
see 4.3.4) and the anti-β-tubulin primary antibody was utilized for the detection of tubulin across 
the various fractions. We hypothesized that if rCx36 and tubulin were interacting partners in vivo, 
tubulin would follow a similar detection pattern as previously observed with wild-type rCx36-
BirA*. Western blot analysis revealed that tubulin was modestly detected in the pellet fraction and 
prominent in the pre-lysate and post-lysate fractions, likely due to the naturally high abundance of 
protein. However, it was noted that the fluorescence signal in the post-lysate was lesser than that 
of the pre-lysate which served as a preliminary indication that a small subset of the total cell tubulin 
protein had interacted with wild-type rCx36-BirA*, and was successfully isolated during the biotin 
affinity capture procedure. In support of this, a reduced amount of tubulin was detected in the first 
elution fraction in comparison to the pre- and post-lysates. Absence of tubulin detection in the 
wash fraction further confirmed that eluted protein was representative of only that which had been 
biotinylated by wild-type rCx36-BirA* (Figure 15). These results indicated that rCx36 was 
capable of interacting with tubulin; however, whether the interactions was direct or indirect in vivo 
had yet to be established.  
 
 
 
Figure 15| Biotin affinity capture of tubulin with wild-type rCx36-BirA*. 
Western blot analysis of protein fractions collected throughout the BioID methodology. Samples were prepared post-
transfection of N2a cells with wild-type rCx36-BirA* and fractionated on a 10% SDS-PAGE for western blotting with 
anti-β-tubulin and anti-mouse IRDye800 primary and secondary antibodies respectively. Tubulin (approx. 50kDa seen 
in green) was detected in all fractions with the exception of the wash and second elution. The low intensity band in 
the 1st elution is representative of the small fraction of tubulin that interacted with the rCx36-BirA fusion in 
comparison to total tubulin available in the N2a cells. 
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5.1.5 BirA* Interaction with Tubulin Indicates Non-Mutuality 
To assess whether the BioID methodology was subject to false-positive results, a control 
experiment was designed to determine if BirA* was capable of interacting with tubulin in the 
absence of rCx36. We hypothesized that if the relationship between rCx36 and tubulin was 
mutually exclusive, tubulin would not be detected in the eluted fractions of the control sample. 
N2a cells were transfected with either pcDNA 3.1 BirA*-rCx36 or pcDNA 3.1 BirA* for the 
production of rCx36-BirA* and BirA* respectively; samples were prepared as previously 
described (see section 4.3.3 for details). For analysis purposes, the pre-lysate, wash and first elution 
fractions were used in the confirmation of BirA* and rCx36-BirA* expression and detection of 
tubulin. As predicted, biotinylated proteins in N2a cells expressing BirA* alone were present in 
the same fractions as with rCx36-BirA*. However, less biotinylated protein was eluted in the 
elution fraction of BirA* in comparison to rCx36-BirA* suggesting that BirA* alone interacts with 
a minimal amount of proteins; fusion to rCx36 allowed for a broader range of interactions. 
Additionally, rCx36-BirA* was exclusively detected in the pre-lysate and elution fraction 
indicating that it had been biotinylated by BirA*; BirA* was not present in the respective elution 
fraction indicating the inability to self-associate (Figure 16A). 
 
In addition to the pre-lysate fractions, tubulin was also detected in the elution fractions of both 
rCx36-BirA* and BirA* expressing cells (Figure 16B). This result indicated that BirA* alone was 
sufficient to facilitate interaction with tubulin. As determined by the fluorescence intensity, BirA* 
interaction with tubulin (0.103±0.002 relative fluorescence units, RFU) was 29% greater than that 
of the wild-type (0.073±0.001 RFU), exposing a quantitative limit to the amount of tubulin rCx36 
is capable of interacting with (Figure 16C). Since the BioID methodology was not able to 
discriminate between tubulin interaction with the BirA* control, we could not conclude that the 
rCx36-tubulin relationship was mutually exclusive and therefore rejected our hypothesis.  
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Figure 16| Western blot and fluorescence analysis of the biotin affinity capture of tubulin with rCx36-BirA*  
                   and BirA*. 
(A) Western blot analysis of the pre-lysate, wash and first elution protein fractions collected throughout the BioID 
methodology. N2a cells were transfected to express either wild-type rCx36-BirA* (WT) or the control BirA* (Ctrl) 
and fractionated on a 10% SDS-PAGE for western blotting with anti-HA and Streptavidin-HRP primary antibodies 
and anti-mouse IRDye800 secondary antibody. Biotinylated proteins, shown in red, were detected in the pre-lysate 
and first elution fractions. BirA*, confirmed by the detection of a band 30kDa (shown in green), was shown not to 
self-associate since it was not detected in the respective elution fraction. Wild-type rCx36-BirA was confirmed by a 
band approximately 60kDa (shown in yellow). (B) Samples, prepared as previously described, were tested for the 
detection of tubulin with the anti-β-tubulin and anti-mouse IRDye800 primary and secondary antibodies respectively. 
Tubulin was detected in the pre-lysate and first elution fraction of both the WT and Ctrl as confirmed by the presence 
of a band approximately 50kDa (shown in green). (C) Corrected Total Fluorescence of the WT and CTRL elution 
bands were averaged across three measurements. The BirA* control displayed a significantly higher fluorescence 
intensity (RFU) in comparison to wild-type rCx36-BirA indicating that BirA* interaction with tubulin was more 
accessible. 
 
 
 
5.1.6 Deletion of the rCx36 Tubulin Binding Region 
Since it was previously determined that BirA* was capable of interacting with tubulin, a second 
control experiment was performed in parallel, designed to find rCx36-specific interactions. In 
addition to wild-type rCx36-BirA*, two mutants were utilized; rCx36 Δ175-196-BirA*, which 
housed a deletion in the cytoplasmic loop, served as a positive control and rCx36 Δ279-292-BirA*, 
which lacked the predicted tubulin binding region in the cytoplasmic terminal domain, as the 
negative control. We hypothesized that if the rCx36 interaction with tubulin was abolished with 
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the expression of the C-terminal mutant rCx36 Δ279-292-BirA*, a significantly reduced 
fluorescence signal would be detected in the respective elution fraction in comparison to wild-type 
rCx36-BirA*. As such, the signal detected in the rCx36 Δ279-292-BirA* elution would account 
specifically for the interaction between tubulin and BirA*. Similarly, by this notion we predicted 
that tubulin would be detected in the eluted fraction of the positive control rCx36 Δ175-196-BirA* 
and this would be comparable to its wild-type counterpart. For comparative purposes, each control 
experiment was done in parallel with wild-type rCx36-BirA* with the pre-lysate, post-lysate, wash 
and first elution fractions chosen for detection against tubulin, and confirmation of BirA* fusion 
variants and biotinylated proteins. 
 
The pattern of detection for biotinylated proteins were consistent between wild-type and positive 
and/or negative controls; biotinylated proteins were present in the pre-lysate and elution fractions 
and absent in the post-lysate and wash fractions indicating successful affinity capture of 
biotinylated proteins. Additionally, the amount of biotinylated proteins detected in these fractions 
were comparable between wild-type and respective controls suggesting that the rCx36 mutant 
proteins were still sufficient to allow for protein-protein interactions despite the partial deletion of 
the cytoplasmic loop region (Δ175-196) and the cytoplasmic-terminal domain (Δ279-292). As 
expected, the fusion proteins were highly concentrated in the elution fractions; wild-type rCx36-
BirA* was confirmed by the presence of a band approximately 60kDa where as both rCx36 Δ175-
196-BirA* and rCx36 Δ279-292-BirA* displayed a slight shift in molecular weight, indicative of 
the smaller protein size due to the partial deletions (Figure 17A-B). 
 
Due to its high abundance, tubulin was detected in the pre-lysate and post-lysate fractions of the 
wild-type rCx36-BirA*, positive control rCx36 Δ175-196-BirA* and negative control rCx36 
Δ279-292-BirA*. Again, absence of tubulin detection in the wash fractions indicated that eluted 
the tubulin were interacting partners of the respective fusion protein. However, a significant 
reduction in the detection of tubulin was observed for both the positive control and negative control 
elution fractions in comparison to the respective wild-type (Figure 17C-D). Corrected total 
fluorescence of rCx36 Δ175-196-BirA* (0.0155±0.0003 RFU) displayed a 36% reduction with 
respect to the wild-type (0.0242±0.0003 RFU). Similarly, corrected total fluorescence of rCx36 
Δ279-292-BirA* (0.0038±0.0002 RFU) was reduced by 74% in comparison to the respective wild-
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type (0.0148±0.00006 RFU) (Figure 17E-F). These results suggested that tubulin was still capable 
of close proximity interaction with rCx36 without the requirement of the hypothesized protein 
binding domain, likely attributed to interactions with BirA*. However, a significant reduction in 
tubulin detection signal was observed with the rCx36 Δ279-292 mutant variant suggests that 
tubulin interaction is at least in part rCx36-specific. Since the positive control rCx36 Δ175-196-
BirA* also showed a reduction in fluorescence intensity, we concluded that the BioID method was 
not suitable to determine the tubulin binding region by in vivo affinity capture.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 62 
 
 
 
  
 
Figure 17| Biotin affinity capture and tubulin detection achieved with rCx36 Δ175-196-BirA* and  
                  -Δ279-292-BirA* fusion proteins. 
(A-B) Western blot analysis of the pre-lysate, post-lysate, wash and first elution protein fractions collected throughout 
the BioID methodology. Samples were prepared post-transfection of N2a cells with wild-type rCx36-BirA* (WT) in 
parallel with either (A) rCx36 Δ175-196-BirA* as a positive control or (B) rCx36 Δ279-292-BirA*. Samples were 
fractionated on a 10% SDS-PAGE for western blotting with anti-HA and Streptavidin-HRP primary antibodies and 
anti-mouse IRDye800 secondary antibody. Biotinylated proteins, shown in red, were detected in the pre-lysate and 
first elution fractions. Wild-type rCx36-BirA* (A and B) was confirmed by the presence of a band approximately 
60kDa in the first elution fraction. Similarly, (A) Cx36 Δ175-196-BirA* and (B) rCx36 Δ279-292-BirA* was also 
confirmed, displaying a small shift in molecular weight respective to the reduction in protein size. (C-D) Samples, 
were tested for the detection of tubulin with the anti-β-tubulin and anti-mouse IRDye800 primary and secondary 
antibodies respectively. Tubulin was detected in the pre-lysate, post-lysate and first elution fractions of both the WT 
(C and D),  (C) positive and (D) negative controls as confirmed by the presence of a band approximately 50kDa 
(shown in green). (E-F) Corrected total fluorescence of the WT (E and F), positive control (E) and negative control 
(F) elution bands were averaged across three measurements. Cells expressing rCx36 Δ175-196-BirA* displayed a 
36% reduction in fluorescence intensity of tubulin in comparison to wild-type rCx36-BirA* indicating a decrease in 
interaction with tubulin. Similarly, a 74% reduction in fluorescence intensity of rCx36 Δ279-292-BirA* was found in 
comparison to the control indicating that tubulin interaction was severely impacted.  
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5.2 DETECTION OF CYTOSKELETAL INTERACTION AT THE CX36 NEXUS USING 
FRAP 
 
Since it was concluded that the BioID methodology was not selective enough to confirm amino 
acids Lys279-Ala287 as the rCx36 tubulin binding region in vivo, we continued our investigations 
using an alternative in vivo technique termed fluorescence recovery after photobleaching (FRAP) 
to complement existing in vitro data. Since this technique utilizes fluorescent signals, EYFP- 
and/or EGFP-tagged fusion proteins were selected for use in the following studies. 
 
5.2.1 Confirmation of Fluorescently-tagged rCx36 WT and CLB/CTB Deletion Mutant 
Expression 
Previously, full-length rCx36 WT (Rattus norvegicus, 321 amino acids) and mutants, Δ182-198, 
279-292, Δ182-198, Δ279-292 and Δ175-196, were cloned into the pEYFP-N1 expression vectors 
to generate EYFP C-terminally tagged fusion proteins; all constructs were made readily available 
by the Dr. Georg Zoidl lab, Department of Biology, York University. These four mutants: (1) 
rCx36 Δ182-198, 279-292, (2) rCx36 Δ182-198, (3) rCx36 Δ279-292 and (4) rCx36 Δ175-196, 
carry deletions in the regions of the rCx36 protein considered critical for transport and plasticity 
(Alev et al., 2008).  
 
To verify the expression of the fusion proteins, N2a cells were transfected with 200ng of the 
respective DNA and subsequently lysed with 1x laemmeli sample buffer, 48h post-transfection. 
Whole cell protein lysates were fractionated on a 10% SDS/PAGE gel and transferred to a 
nitrocellulose membrane for western blotting; anti-GFP primary antibody was utilized for the 
detection and validation of the rCx36-EYFP wild-type and mutant expression. (Figure 18). As 
determined by the results of the western blot, we were successfully able to detect wild-type rCx36-
EYFP (approx. 62kDa) and mutant variants with the anti-GFP antibody; β-actin served as a loading 
control. A reduction in molecular weight was observed in all mutants in comparison to the wild-
type due to the partial deletion of protein sequence(s). Both wild-type and mutant rCx36 variants 
showed similar levels of expression and were used for further studies. 
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Figure 18| Expression confirmation of EYFP-tagged rCx36 wild-type and deletion mutant variants in N2a cells. 
N2a cells transfected with pEYFP-rCx36 WT, -Δ182-198, 279-292, -Δ182-198, -Δ279-292 or -Δ175-196 were lysed 
48h post-transfection. Lysates were fractionated on a 10% SDS-PAGE gel and subsequently used for western blot 
analysis with the anti-GFP (denoted in red) and anti-β-tubulin primary antibodies; anti-mouse IRDye800 and anti-
rabbit IRDye 680 were the secondary antibodies applied. Expression of rCx36-EYFP was confirmed by the presence 
of a band approximately 62kDa. Additionally, rCx36 mutant expression was confirmed, displaying a shift in molecular 
weight respective to the reduction in protein size due to the partial deletion of protein sequence(s). 
 
5.2.2 Localization and Quantitative Analysis of Wild-type rCx36-EYFP and Mutants 
To start, localization studies were performed to confirm typical gap junction plaque formation with 
the rCx36 wild-type and deletion variants previously mentioned. N2a cells were transfected with 
the respective pEYFP-rCx36 DNA (WT, -Δ182-198, 279-292, -Δ182-198, -Δ279-292 or -Δ175-
196) and imaged using Zeiss LSM 700 confocal microscope system, 48h post-transfection. Cells 
were assessed qualitatively for the ability of GJP formation and presence of intracellular deposits. 
Qualitative assessments were complimented quantitatively with measurements of mean corrected 
total fluorescence of the gap junction plaque (CTFGJP), corrected total cell fluorescence (CTFcell) 
and mean gap junction plaque area (µm2). Wild-type rCx36-EYFP was used as a comparative 
reference throughout these analyses to identify deviances in the aforementioned parameters.  
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Through these studies we have confirmed that rCx36 wild-type and mutant variants were capable 
of localizing into gap junction plaques at the plasma membrane of two adjoining cells (Figure 
19A-E). Interestingly, rCx36 Δ175-196 (1.25±0.21 µm2) showed a significant reduction in gap 
junction plaque area in comparison to the wild-type (2.22± 0.19µm2, p=0.002). However, the 
mean gap junction plaque areas of cells expressing rCx36 Δ182-198, 279-292 (2.33±0.37 µm2), - 
Δ182-198 (1.38±0.23 µm2), and -Δ175-196 (1.75±0.19 µm2) were indistinguishable from the wild-
type (Figure 19F). Localization studies also revealed that the presence of intracellular aggregates 
was variable across rCx36 mutant variants in comparison to the wild-type. This effect was most 
pronounced in rCx36 Δ175-196 expressing cells, which showed an increase in intracellular 
deposits and decrease in observable puncta. To quantify the amount of rCx36 protein at the plaque, 
the corrected total GJP fluorescence (CTFGJP) was measured and averaged across the population 
of wild-type and mutant transfected cells. In doing so, the averaged CTFGJP of N2a cells expressing 
rCx36 mutant variants were shown to be significantly reduced in comparison to the wild-type 
expressing cells (58335.13±8949.49 RFU) (Table 10).  
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Figure 19| Localization and GJP area of rCx36-EYFP WT and mutant variants in N2a cells. 
N2a cells were transfected with pEYFP-rCx36 WT, -Δ182-198, 279-292, -Δ182-198, -Δ279-292 or -Δ175-196 vector 
constructs to determine localization. Confocal images were obtained 48h post transfection. rCx36-EYFP (A) -WT, 
(B) -Δ182-198, 279-292, (C) -Δ182-198, (D) -Δ279-292 or (E) -Δ175-196 displayed gap junction formation at the 
plasma membrane of two adjoining cells as indicated by the arrows. An increase in intracellular deposits was observed 
with rCx36 Δ175-196. Scale bar 5µm. (F) Gap junction plaque area (µm²) was averaged across pEYFP-rCx36 wild-
type and mutant variant transfected cells. N2a cells expressing rCx36 Δ182-198, 279-292, -Δ182-198 and -Δ279-292 
were indistinguishable from the wild-type. A significant reduction in GJP area was observed for rC36-Δ175-196 
expressing cells. 
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To ensure that the reduction in CTFGJP was not a direct reflection of a reduction in whole cell 
protein production, corrected total cell fluorescence (CTFcell) was measured, and averaged across 
the population of adjoining cells. In this way, the effect of cell stage or cell age on whole cell 
protein production could be normalized across the trials in which the measurements were taken. 
The CTFcell of N2a cells expressing rCx36 mutant variants was determined to be indistinguishable 
in comparison to the wild-type (Table 11). Therefore, it was concluded that the reduction in 
CTFGJP of rCx36 mutant variants was not directly correlated to the total cell protein production 
and likely representing a reduction in hemichannel accumulation. As such, we speculated that 
amino acid residues spanning from 175-196 and 279-297 is involved in rCx36 trafficking, and 
insertion/removal of rCx36 at the gap junction plaque was compromised in its absence.  
 
In addition to rCx36 Δ279-297, the mutant variant specific to tubulin, rCx36 Δ175-196 was of 
particular interest since this mutant displayed a significant reduction in observable puncta, GJP 
size and CTFGJP in addition to increased intracellular deposits. We speculated that this region might 
be involved in a compensatory trafficking mechanism that afforded rCx36 Δ182-198, 279-292,  
-Δ182-198 and -Δ279-292 mutant variants gap junction plaque areas comparable to the wild-type. 
 
 
Table 11: Corrected total fluorescence in GJP-coupled N2a cells.* 
  
WT 
 
 
Δ182-198, 
279-292 
 
Δ 182-198 
 
Δ175-196 
 
Δ 279-297 
CTFGJP 58335.13±8949.49 434.28±42.37 263.30±59.86 384.73±52.52 239.77±40.71 
 p-value - 1.41-3 4.00-4 7.31-6 6.76-5 
CTFcell 9376.16±2019.27 3362.71±418.57 9297.53±2915.06 3944.72±1286.13 4283.12±1731.38 
 p-value - 1.19-1 9.82-1 6.38-2 9.56-2 
*values determined to be significant from the wild-type are bolded. 
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5.2.3 Identification of a Potential Actin Binding Region 
Since localization studies revealed atypical distribution in cells expressing the rCx36 Δ175-196 
mutant variant, we suspected that this region may be critical for the stabilization and/or trafficking 
of rCx36. As such, a Eukaryotic Linear Motif (ELM) was performed to investigate short linear 
motifs of the rCx36 protein in all cell compartments with the motif probability cut-off set to 100. 
Output generated identified a potential actin binding domain (DCLEVKELAPHPSGLRTA) 
spanning amino acid residues Asp167-Ala184 (See Appendix E). Since this region was largely 
deleted in the rCx36 Δ175-196 mutant, we hypothesized that actin may be an interacting partner 
of rCx36, and partial deletion of the binding motif modulating transport and/or stabilization of the 
protein post-insertion. Additionally, we speculated that amino acid residues between Ala175-
Ala184 may be most critical in mediating the interaction since the deletion of aa: 175-196 alone 
was sufficient in altering the distribution and characteristics of the GJP.   
 
Next, a sequence alignment was performed across species using the hypothesized rCx36 (rattus 
norvegicus) actin binding domain generated from ELM; in the case of zebrafish, the ortholog 
zfCx35 was used (Figure 20A). Protein sequences were obtained from the NCBI Protein database 
and the alignment was achieved using ClustalW2 for the multiple sequence alignment tool. The 
selected species, human (homo sapien), chicken (gallus gallus) and zebrafish (danio rerio), all 
displayed a high degree of amino acid conservation of the hypothesized actin binding region 
inferring structural preservation and biological significance despite speciation. Similarly, sequence 
alignment of the hypothesized rCx36 actin binding domain was compared to full length rCx43 
(382 amino acids) and full length rCx30 (261 amino acids) (Figure 20B). Since it has been 
previously shown that actin interaction with rCx43 occurs indirectly, we hypothesized that the 
proposed actin binding domain of rCx36 would be minimally conserved. Additionally, alignment 
with rCx30, which has been shown to interact with actin directly, would expose the uniqueness of 
the hypothesized actin binding domain to rCx36. Results generated from ClustalW2 revealed 
minimal conservation of a potential actin binding domain when comparing neuronal rCx36 to 
rCx30 and rCx43 expressed in astrocytes, suggesting that this potential actin binding domain is 
restricted to rCx36 and respective orthologs.  
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A 
 
Actin          ---------------DCLEVKELAPHPSGLRTA----------------  
Rat        152 GVLQNTETTSKETEPDCLEVKELAPHPSGLRTAARSKLRRQEGISRFY- 199  
Human      152 GVLQNTENTSKETEPDCLEVKELTPHPSGLRTASKSKLRRQEGISRFY- 199  
Chicken    138 GVLQNTENSTKEAEPDCLEVKEIP--NPAIRTT-KSKMRRQEGISRFYI 183 
Zebrafish  138 GVLQNTENSTKESEPDCLEVKEIP--NSAMRTT-KSKMRRQEGISRFYI 183 
                              *******:.   ..:**:                 
 
B 
 
Actin        ----------D-C-LEVKELAPHPSG--------LRTA--------  
rCx43    180 SLSAVYTCKRDPCPHQVDCFLSRPTEKTIFIIFMLVVSLVSLALNI 225 
rCx30    162 HLPWVLKCGIDPCPNLVDCFISRPTEKTVFTVFMISASVICMLLNV 207 
                       * *   *. : .:*:         : .:                       
 
Figure 20| Cross-species sequence alignment of the actin binding domain identified in rCx36. 
(A) Sequence alignment of the potential actin binding domain identified in rCx36 (rattus norvegicus) was performed 
against the human (homo sapiens), chicken (gallus gallus), and zebrafish (danio rerio) species. Sequence alignment 
identified the potential actin binding region as being highly conservation across species. (B) Sequence alignment of 
the proposed rCx36 actin binding domain showed minimal conservation across rCx43 and rCx30 proteins. 
 
 
 
5.2.4 The rCx36 Connexons are Dynamically Transported to the Laterals of the GJP and  
Removed from the Center 
It was previously reported that Cx43 hemichannels are delivered singly or in small groups to the 
lateral ends of the gap junction plaque and removal of older channels occurs from the center of the 
GJP (Lauf et al., 2002b). Additionally, a similar report has supported this trafficking mechanism 
for Cx35, the fish ortholog of Cx36, at mixed synapses of the goldfish Mauthner cells (Flores et 
al., 2012). Therefore, time lapsed imaging of rCx36-EGFP was performed to confirm if rCx36 
hemichannels behaved similarly to these reports. N2a cells were transfected with wild-type 
pEGFP-rCx36 and analyzed 48h post-transfection. A time series experiment was achieved using 
LSM 700 confocal microscope system under Zeiss 63X oil immersion lens. The selected gap 
junction plaque was briefly observed to confirm activity prior to recording, and subsequently 
monitored over a period of 26 minutes; images were generated in 20 second intervals.  
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Delivery of wild-type rCx36-EYFP hemichannels to the gap junction plaque were successfully 
identified to occur at the lateral ends of the plaque. Initiation of hemichannel contact with the 
‘plaque lateral’ ends was observed at t=20s (Figure 20A) and t=420s (Figure 20B) of the timed 
series experiment.  
 
Additionally, removal of rCx36 hemichannels was also successfully documented over a time span 
of approximately 280 seconds, with the initiation of removal beginning at t=1020s. Interestingly, 
prior to hemichannel removal, the rCx36 GJP was observed to invaginate at the center of the plaque 
(t=1040s). Invagination of the GJP lead to total plaque separation (t=1080s), thus allowing for the 
removal of hemichannels at the center of the plaque (t=1100s and t=1200s). Upon completion, the 
separated GJP rejoined as a functional unit (t=1280s) (Figure 21). Taken together, dynamics of 
the rCx36 GJP, with respect to lateral replenishment and center removal, was found to be 
consistent to the reports of Lauf et al. (2002) on Cx43 and Flores et al. (2012) on Cx35. This result 
was novel, as trafficking dynamics of Cx36 in N2a cells has not been previously studied. 
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Figure 21| Delivery of wild-type rCx36-EGFP hemichannels to the gap junction plaque lateral ends. 
N2a cells were transfected with wild-type pEGFP-rCx36 and observed for delivery and removal dynamics 48h post-transfection. (A) 
First recorded occurrence of rCx36-EGFP hemichannel delivery to the lateral end of the gap junction plaque. Connexons are seen in 
close proximity to the gap junction plaque at t=0s-20s and merges at t=20s-60s as indicated by the circle. (B) Second recorded occurrence 
of rCx36-EGFP hemichannel delivery to the lateral end of the gap junction plaque. Connexons are seen in close proximity to the GJP 
at t=380s-400s and merges at t=420s-440s, as indicated by the circles. Scale bar = 5µm 
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Figure 22| Removal of wild-type rCx36-EGFP hemichannels from the center of the gap junction plaque. 
Recorded occurrence of wild-type rCx36-EGFP hemichannel removal from the center of the gap junction plaque. N2a cells were transfected with wild-type 
pEGFP-rCx36 and observed for removal dynamics 48h post-transfection. An invagination event was initiated at t=1040s and complete separation was 
achieved at t=1080s. Removal of wild-type rCx36-EGFP connexons was observed between t=1100s-1200s. Rejoining of the separated gap junction plaque 
was initiated at t=1220s and completed at t=1280s. Invagination, removal, and rejoining is indicated by the blue, red, and yellow circles respectively. Scale 
bar = 5µm 
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5.2.5 Wild-Type rCx36 Gap Junction Plaques are Stable 
Since we were interested in determining whether dynamics of connexin hemichannel insertion into 
the rCx36 gap junction plaque were comparable to existing literature reports about other connexins, 
a quantitative study using FRAP was performed. The mobile fraction (%) and half-time of recovery 
(t½) in seconds were the chosen parameters for analysis. The following ROIs were selected: (1) 
intracellular space (2) left lateral end of Cx36 gap junction plaque (3) center of the Cx36 gap 
junction plaque (4) right lateral end of the Cx36 gap junction plaque (5) plasma membrane and (6) 
extracellular space for background subtraction. The left/right assignments for the ‘plaque lateral’ 
ends were arbitrarily chosen and did not reflect any functional polarity of the gap junction plaque. 
For this reason, values obtained for both ‘plaque lateral’ ends were combined and referenced as 
the 'plaque lateral' end ROI. It was hypothesized that given the relative stability of the GJP, 
mobility would be reduced in comparison to the intracellular space and plasma membrane. We 
predicted that the half-time of recovery at the plaque would be quicker in comparison to the 
intracellular space. However, we expected half-time of recovery of the GJP would be comparable 
to the plasma membrane since trafficking to this region is a prerequisite to hemichannel insertion. 
In this way, the intracellular space and the plasma membrane served as comparative references. 
N2a cells were transfected with wild-type pEYFP-rCx36 and was analyzed 48h post-transfection 
(see section 4.4.3 for details).  
 
The mobile fraction (%) was plotted as an average across wild-type rCx36-EYFP recovering 
plaques (n=8) and respective regions of interest (Figure 23A). It was determined that all regions 
of the rCx36 GJP were significantly less mobile than the plasma membrane (plaque center 
10.46±1.32%, p=0.009; ‘plaque lateral’ 11.01±1.25%, p=0.000418). Similarly, the intracellular 
space showed a significantly greater mobile fraction in comparison to the GJP lateral end 
(p=0.001685); no significant difference was found between the intracellular space and the center 
of the GJP (p=0.022). The mobile fraction of the plasma membrane (33.77± 7.5%) was 
indistinguishable from the intracellular space (37.02±10.2%; p=0.801). As expected, variation 
between the gap junction plaque ROIs appeared to be negligible as no statistical significance was 
found.  
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Half-time of recovery (t½) was graphed as an alternative to recovery time (Figure 23B). Although 
the plasma membrane (20.33±9.69s) and the intracellular space (11.85±6.01s) appeared to display 
long recovery times, no statistical significance was found between the ROIs analyzed.  
 
As expected, all regions of the plaque showed little mobility indicating that wild-type rCx36-EYFP 
GJPs were stable in nature, more so than the intracellular space and plasma membrane. We 
hypothesized that all regions of the GJP would recovery more quickly than the intracellular space 
since the protein would be dynamically traffic in/out of the latter region for delivery to the plasma 
membrane. However, our results have shown that the half-time of recovery time was unaffected 
across the analyzed regions thus rejecting this hypothesis.  
 
 
Figure 23| Mobile fraction and half-time of recovery of selected ROIs for wild-type rCx36-EYFP  
N2a cells were transfected with wild-type pEYFP-rCx36 to determine the dynamics of the gap junction plaque. ROIs 
were bleached briefly at 70% laser power and recorded over 200 cycles at 1.0-second intervals. Results were 
normalized against the extracellular space. (A) Mobile fraction (%) was averaged across recovering gap junction 
plaques and represented as the mean±SEM. No significant difference was found between the regions of the plaque or 
between the intracellular space and the plasma membrane. All regions of the gap junction plaque showed a significant 
reduction in the mobile fraction in comparison to the plasma membrane indicating that the gap junction plaque was 
stable in nature; however, no significant difference between the intracellular space and plaque center was found. (B) 
Half-time of recovery was averaged across recovering gap junction plaques and represented as the mean±SEM. No 
significant difference was found between the ROIs analyzed.  
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5.2.6 Alteration of the CL or CT rCx36 Domains Reduces Stability 
To assess the functional consequences of the aforementioned rCx36 deletion mutants, N2a cells 
were transfected with the respective pEFYP-rCx36 DNA (Δ182-198, 279-292, Δ182-198, Δ279-
292 and Δ175-196) to be used in FRAP studies. Since literature has reported insertion of connexin 
hemi-channels at the lateral ends, a phenomenon which was consistent with our previous 
observations, the lateral ends were taken for comparison against the membrane region across the 
various mutants. The pre-determined wild-type values for both mobile fraction (%) and half-time 
of recovery (s) were maintained as a comparative reference. 
 
Analysis of the mobile fraction across ROIs revealed that the membrane region and the respective 
‘plaque lateral’ ends of all rCx36 mutant variants were indistinguishable. This was in contrast to 
the previous observations with wild-type rCx36 where it was found that the mobile fraction of the 
‘plaque lateral’ ends was significantly lower than that of the plasma membrane (see section 5.2.5). 
Since stability of the GJP was impaired in cells expressing rCx36 mutant constructs, this further 
supported the hypothesis that amino acid residues spanning 175-196 and 279-297 are involved in 
transport and/or stability. To support this, cross comparison of the ‘plaque lateral’ end ROIs to the 
wild-type revealed that cells expressing rCx36 Δ182-198 (35.47±4.98%, p=5.34-6), rCx36 Δ279-
292 (24.80±2.31%, p=7.40-5) or rCx36 Δ175-196 (25.68±3.26%, p=7.50-4) were all significantly 
greater in mobility. Interestingly, no significant difference in the mobile fraction was found 
between the lateral ends of rCx36 Δ-182-198,279-292 (18.42±3.60%) and the WT (11.02±1.25%). 
When the plasma membrane ROIs of the rCx36 mutants were crossed compared to the wild-type, 
it was determined that no significant difference existed (Figure 24A). Therefore we concluded 
that the fluidity of the protein in the membrane region was not affected by the existing mutations. 
As such it was inferred that the activity of rCx36 at the GJP (or lack thereof) was independent of 
the plasma membrane dynamics and specific interaction candidates affected by the deletions.  
  
From the half-time of recovery it was determined that no significant difference between the 
membrane region and the respective ‘plaque lateral’ ends existed in rCx36 Δ182-198, 279-292, -
Δ182-198, -Δ279-292 or -Δ175-196. Each mutant was subsequently cross compared to the wild-
type, which revealed no significant difference at the either the plasma membrane ROIs or ‘plaque 
lateral’ ends ROIs (Figure 24B).  
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Figure 24| Mobile fraction and half-time of recovery of selected ROIs for EYFP-tagged rCx36 WT and deletion 
                  mutant variants. 
N2a cells were transfected with pEYFP-Cx36 WT, Δ182-198, 279-292, Δ182-198, Δ279-292 or Δ175-196 to 
determine functional consequences of region-specific deletions. ROIs were bleached briefly at 70% laser power and 
recorded over 200 cycles at 1.0-second intervals. Results were normalized against the extracellular space and averaged 
across each ROI, represented as the mean±SEM. (A) Mobile fraction (%) of the ‘plaque lateral’ end showed no 
significant difference to the respective membrane region of cells transfected with mutant constructs. Cells expressing 
rCx36 Δ182-198, -Δ279-292 and -Δ175-196 showed a significant increase in the mobile fraction of the ‘plaque lateral’ 
end in comparison to the respective wild-type indicating a reduction in stability. (B) No significant difference in the 
half-time of recovery (s) was found between the ROIs analyzed.  
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5.3 CHEMICAL DISRUPTION AND ALTERATION OF CYTOSKELETAL 
INTERACTION 
 
5.3.1 Competitive Binding of the Tubulin Binding Region with TAT 
To determine the functional consequences of competitive binding at the proposed tubulin binding 
region, peptide blocking was achieved with the TAT peptide. The TAT peptide, utilized for its 
cell-penetrating ability, is derived from the transactivator of transcription (TAT) of human 
immunodeficiency virus. Cell penetrating peptides (CPPs) are typically used to overcome the 
lipophilic barrier of the cellular membranes to deliver molecules inside the cell for their specified 
biological actions. Here, this property was used to carry the C-terminal binding (CTB) sequence, 
and respective controls, into N2a cells as a competitor for tubulin binding. The TAT peptide used 
to target the tubulin binding region was denoted as TAT CT-ON, meaning that it was "on target" 
to the CT binding domain. Additionally, we made use of a TAT peptide outside of the tubulin 
binding region referred to as TAT CT-OFF, meaning that was "off target" to the CT binding 
domain. Instead, TAT CT-OFF targeted the CTP region and served as the first of three controls. 
Scrambled sequences of both TAT CT-ON/OFF were generated and were denoted as '(scrambled)'; 
these peptides generated served as the remaining two (positive) controls (see Table 9). We 
anticipated that blocking of the tubulin binding region could only be achieved with the TAT CT-
ON peptide. As such, we expected that treatment with TAT CT-ON would significantly increase 
the recovery time and mobile fraction, reflecting a reduction in trafficking and stability, in 
comparison to the untreated wild-type. Additionally, we hypothesized that the control peptides 
would yield similar results to untreated wild-type, with any observed differences being statistically 
negligible. 
 
Previously it was determined that the mobile fraction of wild-type rCx36-EYFP expressing cells 
at the lateral ends of the GJP was significantly reduced in comparison to the respective membrane 
region. Similar to this observation, the mobile fraction at the ‘plaque lateral’ ends was considerably 
lower than the respective plasma membrane region in cells treated with TAT CT-OFF (p=2.00-5), 
TAT-CT-OFF (scrambled) (p=0.002), and TAT CT-ON (scrambled) (p=0.0002). Comparison to 
the untreated wild-type revealed no significant difference in the mobile fraction at either the plasma 
membrane ROIs or the ‘plaque lateral’ end ROIs, regardless of treatment with the control TAT 
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peptides. Our observations confirmed that the treatment of wild-type rCx36 expressing cells with 
TAT CT-OFF, TAT CT-OFF (scrambled) and TAT CT-ON (scrambled) showed similar behavior 
to the untreated wild-type. Therefore, we concluded that these peptides were not targeting a region 
that compromised the stability of the GJP. 
 
In contrast, cells treated with TAT CT-ON showed no significant difference in the mobile fraction 
between the ‘plaque lateral’ ends (32.81±3.31%) and the respective membrane region 
(37.53±5.25). Comparison to the untreated wild-type cells revealed a significant increase in the 
mobile fraction (p=4.00-6) at the ‘plaque lateral’ ends. However, the plasma membrane ROI of 
cells treated with TAT CT-ON was indistinguishable from the untreated wild-type expressing cells 
(Figure 25A). As expected, treatment with TAT CT-ON diminished the stability of the GJP at the 
lateral ends suggesting that the CTB domain was successfully targeted and is involved in the 
stabilization of rCx36 at the GJP post-insertion. Therefore, it is inferred that tubulin may be a 
necessary interaction candidate for stabilization. Furthermore, since the mobility of rCx36 at the 
plasma membrane was unaffected across treatments, it was successfully confirmed that the 
addition of the TAT peptides did not affect the integrity of the plasma membrane post-penetration. 
 
We previously reported that the half-time of recovery at the ‘plaque lateral’ ends of wild-type 
rCx36-EYFP expressing cells was indistinguishable from the plasma membrane. Similarly, no 
significant difference was found between the plasma membrane and respective ‘plaque lateral’ 
ends of wild-type rCx36 expressing cells treated with either of the control TAT peptides. 
Comparison of the control TAT peptides to the untreated wild-type expressing cells revealed no 
significant difference in recovery at either the plasma membrane ROIs or the ‘plaque lateral’ end 
ROIs. However, with TAT CT-ON treatment, half-time of recovery significantly increased at the 
‘plaque lateral’ ends (26.17±4.63s) in comparison to the respective membrane region (4.92±1.23s,  
p=3.21-3). Comparison of the TAT CT-ON treatment to the untreated wild-type revealed no 
significant difference in recovery time at the membrane region. However, a considerable increase 
in recovery time at the ‘plaque lateral’ ends was observed (Figure 25B). By this, we were 
successfully able to achieve inhibition of recovery exclusively at the ‘plaque lateral’ ends with the 
use of TAT CT-ON. This result suggested that the CTB domain, and more specifically tubulin, is 
involved in the delivery of rCx36 to the lateral ends of the GJP.  
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Interestingly, the gap junction plaque area of wild-type rCx36 expressing cells treated with TAT 
CT-OFF and TAT CT-OFF (scrambled) was found to be 1.43±0.21µm² and 2.34±0.51µm² 
respectively. However, only the former of which was significantly reduced in comparison to the 
untreated wild-type (2.22±0.19µm²). Therefore, it is probable that TAT CT-OFF targets a region 
of the rCx36 protein implicated in tubulin-independent trafficking and/or stabilization. Wild-type 
rCx36-expressing cells treated with TAT CT-ON (1.71±0.14µm²) or TAT CT-ON (scrambled) 
(1.50±0.18µm²), however, were both found to be indistinguishable from the untreated wild-type 
(Figure 25C). This result further supports the hypothesis of a compensatory trafficking mechanism, 
likely attributable to actin, which may operate in a temporal and/or spatial manner.  
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Figure 25| Effects of TAT-driven competitive binding of the rCx36 tubulin binding region in N2a cells. 
N2a cells were transfected with wild-type pEYFP-rCx36 and subsequently treated with various TAT peptides to 
determine the function consequence of inhibiting tubulin interaction. ROIs were bleached briefly at 70% laser power 
and recorded over 200 cycles at 1.0-second intervals. Results were normalized against the extracellular space and 
averaged across each ROI, represented as the mean±SEM. (A) Mobile fraction (%) of the ‘plaque lateral’ end of cells 
treated with TAT CT-ON showed a significant increase to the respective region of untreated wild-type cells suggesting 
that tubulin interaction was successfully inhibited. Control treatments were indistinguishable from the untreated wild-
type. (B) A significant increase in half-time of recovery was observed at the ‘plaque lateral’ ends of wild-type rCx36 
expressing cells treated with TAT CT-ON in comparison to the untreated wild-type. This result indicated that 
inhibition of the tubulin binding region produces trafficking impairments. No significant difference in half-time of 
recovery was recorded for cells treated with the control TAT peptides. (C) GJP area was similar in N2a cells treated 
with TAT CT-ON, ON (scrambled) and OFF. A significant reduction in gap junction plaque size was observed in cells 
treated with TAT CT-OFF (scrambled).  
 
 
 
 
   
84 
   
5.3.2 Pharmacological Alteration of Tubulin Dynamics  
We aimed to further determine the interaction of rCx36 with tubulin, and confirm its role in 
delivery and stabilization in vivo, by analyzing the effects of the tubulin-specific pharmacological 
agents: colchicine and paclitaxel. Colchicine, responsible for binding to the tubulin heterodimer, 
prevents microtubule (MT) polymerization, promoting disassembly. Paclitaxel, also known by its 
common name taxol, displays the opposite effect and stabilizes MTs. Therefore, we hypothesized 
that colchicine and paclitaxel treatment would display opposite effects on wild-type rCx36 
expressing cells. In cells treated with colchicine, an increase in the mobile fraction, indicating a 
reduction in stability, at the ‘plaque lateral’ ends was predicted. Additionally, we expected an 
impairment in lateral end replenishment, thus promoting a prolonged recovery time with colchicine 
treatment. In contrast, we predicted that treatment with paclitaxel would decrease the mobile 
fraction at the ‘plaque lateral’ ends to indicate an increase in stability. Finally, we anticipated that 
recovery would be promoted with paclitaxel treatment, leading to a reduction in recovery time 
would be observed. In addition to wild-type rCx36-EYFP, rCx36 Δ279-292-EYFP was also 
utilized since the predicted tubulin binding domain is largely deleted in this mutant. Because a 
direct interaction was not expected, it was hypothesized that no significant difference in the mobile 
fraction or recovery time would exist regardless of treatment applied.  
 
Wild-type rCx36 expressing cells treated with colchicine displayed no significant difference in the 
mobile fraction at the plasma membrane (30.48±3.93%) in comparison to the ‘plaque lateral’ ends 
(23.34±3.76%, p=0.25). Comparison of the ‘plaque lateral’ end ROIs to the untreated wild-type 
revealed that colchicine treatment significantly increases mobility (p=5.71-3). Overall, this would 
suggest that the inhibition of tubulin polymerization interferes with the stability of the gap junction 
plaque. The plasma membrane ROIs were indistinguishable between the untreated and treated 
wild-type rCx36 expressing cells, indicating that the dynamics of rCx36 at the plasma membrane 
was maintained regardless of colchicine treatment. As predicted, in cells expressing rCx36 Δ279-
292, treatment with colchicine revealed no significant difference in the mobile fraction between 
the ‘plaque lateral’ ends (30.10±4.78%) and the plasma membrane (36.25±5.92%, p=0.45). 
Similarly, comparison to the untreated rCx36 Δ279-292 expressing cells showed that the plasma 
membrane ROIs (p=0.28) and the ‘plaque lateral’ end ROIs (p=0.29) were both indistinguishable 
(Figure 26A).  
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Upon the analysis of the half-time of recovery, no significant difference was found between the 
plasma membrane (7.09±4.77s) and respective ‘plaque lateral’ ends (47.66±20.94s) of wild-type 
rCx36 expressing cells treated with colchicine. Similarly, comparison to the untreated wild-type 
revealed that the plasma membrane ROIs and the ‘plaque lateral’ end ROIs were indistinguishable. 
As such, it was suggested that colchicine treatment did not significantly impair recovery of the gap 
junction plaque. The addition of colchicine to rCx36 Δ279-292 expressing cells revealed that the 
plasma membrane region (11.88±233s) was indistinguishable from the respective ‘plaque lateral’ 
ends (28.80±8.96s, p=0.20). Likewise, comparison to the untreated rCx36 Δ279-292 showed no 
significant difference in the half-time of recovery at either the plasma membrane ROIs or the 
‘plaque lateral’ end ROIs (Figure 26B). 
 
As expected, the GJP area was significantly reduced to 1.37±0.21µm2 in wild-type expressing cells 
treated with colchicine in comparison to its untreated counterpart (2.22± 0.19µm2). In contrast, 
GJP area was unaffected in rCx36 Δ279-292 expressing cells regardless of colchicine treatment. 
As such, it was further supported that tubulin inhibition is non-effective in the absence of aa: 
Lys279-Lys292; this is due to the lack of interaction (Figure 26C).  
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Figure 26| Effect of tubulin polymerization inhibition with colchicine on rCx36 dynamics in N2a cells. 
N2a cells were transfected with pEYFP-rCx36 WT or -Δ279-292 and subsequently treated with colchicine to 
determine the function consequence of inhibition tubulin polymerization. ROIs were bleached briefly at 70% laser 
power and recorded over 200 cycles at 1.0-second intervals. Results were normalized against the extracellular space 
and averaged across each ROI, represented as the mean±SEM. (A) Mobile fraction (%) at the ‘plaque lateral’ ends 
significantly increased in wild-type N2a cells treated with colchicine in comparison to the untreated wild-type. No 
significant difference was found in rCx36 Δ279-292 treated with colchicine compared to its untreated counterpart. (B) 
Treatment with colchicine had no significant difference on the half-time of recovery at the ‘plaque lateral’ ends of 
rCx36 WT or -Δ279-292 expressing cells. (C) A reduction in the GJP area occurred in wild-type rCx36 cells treated 
with colchicine; no significant difference was found on the gap junction plaque size of treated rCx36 Δ279-292 
expressing cells. 
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The mobile fraction of wild-type rCx36 expressing cells treated with paclitaxel showed a 
significant reduction at the ‘plaque lateral’ ends (11.46±1.50%) in comparison to the respective 
plasma membrane region (21.54±.06%, p=7.22-3). When treated cells were compared to their 
untreated counterpart, no significant difference was found at either the plasma membrane ROIs 
(p=0.13) or the ‘plaque lateral’ end ROIs (p=0.83). Interestingly, a considerable reduction in the 
mobile fraction of the ‘plaque lateral’ ends (17.39±1.74%) in comparison to the respective 
membrane region (40.54±5.99%) was observed with rCx36 Δ279-292 expressing cells treated with 
paclitaxel. This result is in contrast to previous observations of the untreated rCx36 Δ279-292 
expressing cells that showed no significant difference between the plasma membrane ROI and 
respective ‘plaque lateral’ end ROI (see section 5.2.6). However, comparison of rCx36 Δ279-292 
treated with paclitaxel to the untreated counterpart showed no significant difference in the mobile 
fraction at the ‘plaque lateral’ end ROIs (p=0.012) or plasma membrane ROIs (p=0.63) (Figure 
27A). Therefore, it was confirmed that no additional effects on stability could be achieved with 
the addition of paclitaxel in rCx36 Δ279-292 expressing cells due to the lack of tubulin interaction.  
 
Analysis of the half-time of recovery revealed that the ‘plaque lateral’ ends (11.86±5.02s) were 
indistinguishable to the respective membrane region (14.58±5.75s, p=0.74). In comparison to the 
untreated wild-type, no significant difference in half-time of recovery was found at the plasma 
membrane ROIs (p=0.59) or the ‘plaque lateral’ end ROIs (p=0.65). The half-time of recovery for 
rCx36 Δ279-292 expressing cells treated with paclitaxel was found to be indistinguishable between 
the ‘plaque lateral’ ends (25.58±7.45s) and the respective membrane region (12.12±3.14s). 
Similarly, no significant difference was recorded at the plasma membrane ROIs or the ‘plaque 
lateral’ end ROIs upon cross analysis to the non-treated rCx36 Δ279-292 expressing cells (Figure 
27B).  
 
As expected, treatment with paclitaxel had no additional effects on the GJP area of rCx36 Δ279-
292 expressing cells (1.22±0.08µm2, p=0.08) further supporting that tubulin interaction was 
abolished in this mutant. However, a significant reduction was observed in wild-type rCx36 
expressing cells (1.44±0.20µm2) in comparison to the untreated counterpart (2.22± 0.19µm2) 
(Figure 27C). Therefore, it was suggested that paclitaxel did inhibit trafficking and/or stabilization 
despite MT stabilizing effects.  
   
88 
   
In summary, colchicine, which inhibits the polymerization of tubulin, reduced the stability of wild-
type rCx36 GJPs at the lateral ends but failed to have an impact on of rCx36 Δ279-292 expressing 
cells. The absence of additional effects on the CTB mutant, in comparison to the untreated 
counterpart, was likely observed due to its inability to interact with tubulin. This further supports 
the role of tubulin in the stabilization of rCx36 GJPs, specifically through interactions between aa: 
Lys279-Lys292. In contrast, paclitaxel, which stabilizes MTs and inhibits its depolymerization, 
was shown to have no additional effects on the mobility of rCx36 WT or -Δ279-292 GJPs. The 
half-time of recovery was not impacted in rCx36 WT or -Δ279-292 expressing cells with either 
paclitaxel or colchicine in comparison to the untreated counterpart. However, a significant 
reduction in the GJP area of rCx36 treated with either paclitaxel or colchicine was observed. As 
such this served as an illustration of impairments in tubulin-specific trafficking, achieved with 
pharmacological agents. 
 
 
 
 
 
 
 
 
 
 
 
.   
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Figure 27| Effects of promoting tubulin stabilization with paclitaxel on the dynamics of wild-type rCx36 in 
                   N2a cells. 
N2a cells were transfected with pEYFP-rCx36 WT or -Δ279-292 and subsequently treated with paclitaxel to determine 
the function consequence of tubulin polymerization promotion. ROIs were bleached briefly at 70% laser power and 
recorded over 200 cycles at 1.0-second intervals. Results were normalized against the extracellular space and averaged 
across each ROI, represented as the mean±SEM. (A) Mobile fraction (%) at the ‘plaque lateral’ ends showed no 
significant difference in either rCx36 WT or Δ279-292 expressing cells treated with paclitaxel in comparison to the 
respective untreated counterpart. (B) Treatment with paclitaxel had no significant difference on the half-time of 
recovery at the ‘plaque lateral’ ends of rCx36 WT or Δ279-292 expressing cells. (C) A reduction in the GJP area 
occurred in rCx36 WT cells treated with paclitaxel; no significant difference was found in the gap junction plaque 
size of treated rCx36 Δ279-292 expressing cells in comparison to the respective untreated counterpart. 
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5.3.3 Pharmacological Blocking of Actin 
Next, we further investigated the role of actin interaction with rCx36. For this study, cytochalasin 
D was chosen to inhibit polymerization of actin microfilaments. Previously, we proposed that actin 
may be involved with transport and stability of rCx36 at the GJP in addition to tubulin. Therefore, 
it was hypothesized that inhibition of actin polymerization would result in an increase of mobile 
fraction and half-time of recovery as well as a reduction in gap junction plaque size.  
 
The mobile fraction of wild-type rCx36 expressing cells treated with cytochalasin D was found to 
be 27.61±2.61% at the ‘plaque lateral’ ends; this was indistinguishable from the respective plasma 
membrane region (34.26±7.05%). Comparison to the untreated wild-type revealed a significant 
increase in mobile fraction at the ‘plaque lateral’ ends of wild-type rCx36 expressing cells treated 
with cytochalasin D. However, no significant difference was found between the membrane regions 
of the untreated WT and cytochalasin D treatment (Figure 28A). Therefore, this result indicated 
that cytochalasin D had no effect on the plasma membrane dynamics or the fluidity of rCx36 at 
the membrane. Half-time of recovery of rCx36 expressing cells treated with cytochalasin D at the 
plasma membrane ROI (10.83±4.67s) was indistinguishable to the respective ‘plaque lateral’ end 
ROI (12.87±3.78s). Similarly, no significant difference was found at the plasma membrane ROIs 
(p=0.34) or the ‘plaque lateral’ end ROIs (p=0.44) when compared to the untreated wild-type 
(Figure 28B). Additionally, blocking of actin polymerization with cytochalasin D revealed no 
significant effect on GJP area in wild-type rCx36 expressing cells (2.13±0.41µm2) in comparison 
to non-treated cells (Figure 28C). However, a considerable reduction in the CTFGJP was recorded 
at the gap junction plaque of wild-type expressing cells treated with cytochalasin D. Therefore, we 
suspect that the accumulation of connexons decreased, potentially as a result of impaired 
trafficking or stability (Table 12). 
 
These results support actin as a major contributor to rCx36 stabilization post-insertion at the gap 
junction plaque. Additionally, since the half-time of recovery and gap junction plaque area were 
minimally impacted. This result would suggest that actin’s role in trafficking of rCx36 to the lateral 
ends of the gap junction plaque is minor in comparison to tubulin.  
   
91 
   
 
 
Figure 28| Effect of inhibiting actin polymerization with cytochalasin D on the dynamics of wild-type rCx36 in    
                  N2a cells.  
N2a cells were transfected with pEYFP-Cx36 WT subsequently treated with cytochalasin D 48h post-transfection to 
determine the function consequence of the inhibition of actin polymerization. ROIs were bleached briefly at 70% laser 
power and recorded over 200 cycles at 1.0-second intervals. Results were normalized against the extracellular space 
and averaged across each ROI, represented as the mean±SEM. (A) Mobile fraction (%) of the ‘plaque lateral’ ends 
showed a significant increase when treated with cytochalasin D in comparison to the untreated cells. (B) Half-time of 
recovery of the ROIs were indistinguishable regardless of treatment with cytochalasin D. (C) No significant difference 
was found in the gap junction plaque size of treated rCx36 WT expressing cells in comparison to the untreated 
counterpart. 
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Table 12: Corrected total fluorescence of wild-type gap junction plaques under cytochalasin D treatment.* 
 WT WT+ CytoD 
CTFGJP 58335.13±8949.49 465.60±104.85 
 p-value - 7.13-5 
  *Significant values are bolded. 
 
 
 
5.4 IDENTIFICATION OF CRITICAL RESIDUES IN CX36-TUBULIN INTERACTION 
WITH SITE-DIRECTED MUTAGENESIS 
 
5.4.1 Generation and Cloning of CTB and CLB Point Mutation Constructs 
To determine the amino acid residues critical for cytoskeletal interaction with rCx36, site-directed 
mutagenesis was performed. We suspected that amino acids large in size might be significant 
contributors for interaction to occur. As such, our aim was to introduce single residue substitutions 
in rCx36 at the hypothesized binding region for actin (aa: Asp167-Ala184), and tubulin (aa: 
Lys279-Ala287). For actin specifically, since we previously predicted that residues spanning 175-
184 might be most critical for interaction, amino acids pertaining to this region were targeted; one 
amino acid outside of this range was arbitrarily chosen for preliminary studies. As such, Val171, 
His177, Ser179, Leu181 and Arg182 were selected as initial targets to study the rCx36-actin 
interaction. For the study of the rCx36-tubulin interaction, Lys279, Ile280, Lys281, Leu282, 
Val284, Arg285 and Gly286 were chosen as targets for site-directed mutagenesis. Alanine, a non-
polar amino acid, was chosen for mutation because its small size and inability to interfere with 
protein function due to the non-reactive methyl group. Primers were designed accordingly to 
introduce point mutations into the rCx36 gene, using the pEGFP-rCx36 template, so that an alanine 
residue would be encoded at the designated CLB and CTB regions of rCx36.  
 
Mutant pEGFP-rCx36 plasmids were generated using Q5® Site-Directed Mutagenesis Kit as per 
manufacturer's protocol and transformed into NEB 5-alpha competent E. coli cells. The bacteria 
were subsequently plated onto LB-AMP plates and single bacterial colonies were isolated and 
grown in LB-AMP media overnight. DNA was isolated via small-scale plasmid purification, 
sequenced and aligned with the wild-type rCx36 gene to identify mutants. By this technique, we 
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were successfully able to introduce alanine point mutations at the targeted residues in the rCx36 
CLB domain (V171A, H177A, S179A, L181A and R182A) and the CTB domain (K279A, I280A, 
K281A, L282A, V284A, R285A and G286A). 
 
5.4.2 Confirmation of Point Mutant Expression and Localization in N2a 
Upon confirmation of pEGFP-rCx36 point mutant variants, expression was verified by transfecting 
N2a cells with the respective DNA. Whole cell protein lysates were fractionated on a 10% 
SDS/PAGE gel 48h post-transfection, and transferred to a nitrocellulose membrane for western 
blotting. For the detection and validation of EGFP-tagged protein expression, the anti-GFP 
primary antibody was applied; β-actin served as a loading control. By this, rCx36-EGFP WT and 
point mutant variants of the CLB (Figure 29A) and CTB (Figure 29B) domains were successfully 
detected. All rCx36 CLB and CTB point mutant variants were capable of expression in the N2a 
cell line as confirmed by the presence of a band approximately 60kDa. However, expression of the 
rCx36 CLB and CTB mutant variants was significantly reduced in comparison to the wild-type; 
particularly with the CLB mutants: H177A, S179A, L181A and R182A and CTB mutants: K279A 
and I280A.  
 
Localization studies confirmed that rCx36-EGFP CLB (Figure 30) and CTB (Figure 31) mutant 
variants were capable of forming GJPs. However, for the remainder of this thesis, only the 
interaction between rCx36 and tubulin achieved with the CTB point mutants will be addressed.  
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Figure 29| Western blot analysis of rCx36-EGFP WT, CLB and CTB point mutations expression in N2a cells. 
Western blot of the (A) CLB point mutations and (B) CTB point mutants (denoted in red) generated using the Q5 site-
directed mutagenesis protocol. N2a cells transfected with pEGFP-rCx36 WT, CLB and CTB point mutant constructs 
were lysed 48h post-transfection. Lysates were fractionated on a 10% SDS-PAGE gel and subsequently used for 
western blot analysis with the anti-GFP and anti-β-actin primary antibodies; anti-rabbit IRDye680 and anti-mouse 
IRDye800 served as the secondary antibodies respectively. (A) Poor expression was observed in both CTB mutants 
and all CLB mutants with the exception of V171 in comparison to the wild-type. (B) Although all the mutants 
expressed poorly in comparison to the wild-type, K279A and I280A were particularly low in expression. β-actin 
labeled in green served as a loading control. Expression was confirmed by a band approximately 60 kDa. 
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Figure 30| Localization of EGFP-tagged rCx36 wild-type and various CLB point mutant variants. 
N2a cells were transfected with pEGFP-rCx36 WT, -V171A, -H177A, S179A, -L181A, or –R182A to determine localization. Confocal images 
were obtained 48h post-transfection. Localization studies have indicated that rCx36 WT and mutant variants were capable of forming gap 
junction plaques; GJPs (in green) are indicated with boxes. Staining of the nucleus was achieved with DAPI (blue). Scale bar = 10µm 
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Figure 31| Localization of EGFP-tagged rCx36 CLB point mutant variants. 
Localization studies have indicated CTB point mutants were capable of forming GJPs; GJPs (in green) are indicated with boxes. Although rCx36 K279A was able to 
form GJPs, trafficking was significantly impaired as indicated by the minimal amount of GJPs observed, low fluorescence and the presences of large intracellular 
deposits. Scale bar = 5µm 
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5.4.3 Identification of Critical Binding Residues in the rCx36-Tubulin Interaction 
Although all CTB point mutant variants generated for rCx36 were capable of forming gap junction 
plaques (Figure 31), EGFP-tagged rCx36 K279A (0.90±0.18µm²), -K281A (1.06±0.15µm²), -
L282A (1.26±0.11µm²) and -G286A (1.13±0.19µm²) displayed a significant reduction in gap 
junction plaque area in comparison to the wild-type (2.22±0.19µm²). Most notably, rCx36 K279A 
(0.90±0.18µm2) was shown to have more than a 50% reduction in GJP size in comparison to wild-
type. In addition, qualitative assessment of localization revealed that the number of observable 
plaques for rCx36 K279A significantly diminished indicating that this residue may be most critical 
in the trafficking of rCx36 to the plasma membrane. No significant difference was found in the 
plaque area of cells expressing EGFP-tagged rCx36 I280A, -V284 or -R285A with respect to the 
wild-type (Figure 32).   
 
 
 
 
Figure 32| Gap junction plaque area across N2a cells expressing EGFP-tagged rCx36 WT and CTB point 
                   mutant variants. 
N2a cells were transfected with pEGFP-tagged rCx36 WT and CTB point mutant variants for imaging 48h post 
transfection. GJPs were optimized along the axis that yielded the largest surface area and subsequently traced with 
ImageJ. Gap junction plaque area was averaged and presented as mean±SEM. A significant reduction in gap junction 
plaque was observed for G276A, K279A, K281A, L282A and G286A in comparison to WT rCx36 expressing cells.  
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Although we previously found that the mobile fraction of wild-type rCx36 expressing cells at the 
lateral ends of the GJP was significantly reduced in comparison to the respective membrane region, 
this affect was nearly abolished in the CTB rCx36 point mutant variants. Within the tubulin binding 
region, the mobile fraction at the plasma membrane of rCx36 K279A (37.84±4.84%), -I280 
(32.85±8.07%), -K281 (27.93±7.45%), -V284 (30.64±7.08%), -R285A (23.69±5.42%) and -
G286A (23.99±4.98%) were found to be indistinguishable from the respective ‘plaque lateral’ 
regions. In comparison to the wild-type, a significant increase in the mobile fraction at the ‘plaque 
lateral’ end ROIs of rCx36 K279A (p=7.0-4) and -G286A (p=8.0-3) was found. This result 
suggested that these two residues are critical for the stability of the GJP upon insertion. The mobile 
fraction at the plasma membrane ROIs of rCx36 K279A and -G286A was unaffected in 
comparison to the wild-type. Similarly, rCx36 I280A, -K281A, -V284A and -R285A were 
indistinguishable from the wild-type at both the plasma membrane ROIs and the ‘plaque lateral’ 
end ROIs suggesting that the reduction in stability was negligible. Interestingly, the rCx36 L282A 
mutant retained its stability; the mobile fraction of the ‘plaque lateral’ ends was determine to be 
13.74±2.48%, a significant reduction in comparison to the respective membrane region 
(33.02±6.85%). Comparison to the wild-type revealed no significant difference between either the 
plasma membrane ROIs or at the ‘plaque lateral’ end ROIs (Figure 33A). 
 
Half-time of recovery of the ‘plaque lateral’ ends in comparison to the respective plasma 
membrane region were indistinguishable across the CTB point mutations with the exception of 
rCx36 R285A. This mutant showed a significant increase in half-time of recovery to 25.57±4.71s 
with respect to the plasma membrane region 3.73±1.72s. A modest reduction in the half-time of 
recovery was also recorded at the ‘plaque lateral’ ends of rCx36 G286A in comparison to the 
respective plasma membrane, however, was deemed as insignificant by our statistical measures. 
Upon cross-analysis to wild-type rCx36, a significant increase in recovery time at the gap junction 
lateral ends was reported for rCx36 R285A (p=6.90-3). In turn, this suggested that the Arg285 
residue may be critical in the transport of the rCx36 to the ‘plaque lateral’ ends of the GJP. 
Similarly, a modest increase in half-time of recovery was also reported with rCx36 K279A 
(p=2.98-2). Although by our statistical standard this was deemed as insignificant, taken together 
with the reduction in gap junction plaque size, stability and observable puncta, Lys279 was 
determined to be the most critical mediator in the rCx36-tubulin interaction. Half-time of recovery 
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was reported to be indistinguishable between the plasma membrane region of rCx36 K282A 
expressing cells (4.80±2.10s) and the respective ‘plaque lateral’ ends (19.64±5.77s). In 
comparison to the wild-type, no significant difference existed between the plasma membrane ROIs 
or the ‘plaque lateral’ and ROIs (Figure 33B). 
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Figure 33| Mobile fraction and half-time of recovery at selected ROIs of wild-type rCx36 and various CTB  
                   point mutants. 
N2a cells were transfected with various pEGFP constructs to identify the residue(s) critical for interaction with tubulin 
and to determine the functional consequence of mutation. ROIs were bleached briefly at 70% laser power and recorded 
over 200 cycles at 1.0-second intervals. Results were normalized against the extracellular space. (A) Although modest 
impairments in the mobile fraction were recorded across the various CTB mutants, rCx36 K279A and G286A 
expression significantly increase the mobile fraction at the ‘plaque lateral’ ends in comparison to the WT indicated 
that these two results may be critical mediators in rCx36 GJP stability. (B) Half-time of recovery was significantly 
impaired at the ‘plaque lateral’ ends of rCx36 R285A, suggesting that this residue may be critical in transport 
mediation.    
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5.5 INVESTIGATING CYTOSKELETAL DEPENDENCY DURING THE CX36 RUN-UP 
PHENOMENON OF PLASTICITY 
 
Previously, del Corsso et al. (2012) have shown that rCx36 is capable of exhibiting LTP-like 
behavior in a phenomenon known as the run-up. Similar to LTP at chemical synapses, during this 
phenomenon, gap junction conductance increases 10-fold in a CaMKII-dependent manner (Del 
Corsso et al., 2012). However, what remains unclear is the means by which the run-up 
phenomenon is achieved. Two possibilities are that (I) more channels are being recruited into the 
GJP or (II) the already existing channels in the GJP open to allow for a greater exchange of 
signaling molecules. A third potential possibility would involve a combination of increased Cx36 
hemichannel recruitment and opening of channels at the gap junction plaque. As such, we sought 
to investigate whether the cytoskeletal-dependent transport was likely involved in the run-up 
phenomenon by assessing dynamics under conditions similar to the run-up. 
 
5.5.1 Influences of Double Transfection on rCx36 in N2a 
Prior to our investigations, the impact of double transfection on rCx36 behavior in N2a cells was 
assessed to confirm consistency in the chosen cell model. As such, localization, mobile fraction, 
half-time of recovery and gap junction plaque area was compared between pEGFP-rCx36 single 
transfected cells and cells double transfected with pDsRed-CaM. For rCx36 behavior to be 
considered consistent across the transfection conditions, we expected that the parameters, as 
mentioned above, would be indistinguishable. 
 
As a qualitative measurement, localization studies revealed that double transfected cells were 
capable of forming gap junction plaques at the plasma membrane of two adjoining cells. Although 
CaM expression was observed widely throughout N2a cells, CaM was shown to co-localize 
heavily at regions rCx36 was highly concentrated (i.e. intracellular deposits, gap junction plaques) 
(Figure 34A). Moreover, no observable differences in gap junction formation (i.e. observable 
puncta, intracellular deposits) was noted. In support of this, quantitatively it was found that the 
gap junction plaque area of double transfected cells (1.72±0.20µm²) was indistinguishable from 
the wild-type (2.22± 0.19µm2) (Figure 34B).  
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Upon review of FRAP analyzes, the mobile fraction of the ‘plaque lateral’ end (22.58±4.19%) was 
determined to be indistinguishable from the respective membrane region (24.86±4.54%). 
Comparison to the single transfection condition revealed no significant difference at the plasma 
membrane ROIs (p=0.31) or the ‘plaque lateral’ end ROIs (p=0.02) (Figure 34C). Therefore, the 
stability of the GJP was comparable between single and double transfection conditions. 
Additionally, no significant difference in the half-time of recovery was reported between the 
‘plaque lateral’ ends (12.10±2.67s) and the respective membrane region (7.35±2.41s) of double 
transfection cells. Similarly, half-time of recovery was indistinguishable at the plasma membrane 
ROIs and ‘plaque lateral’ end ROIs upon cross comparison to the single transfection condition 
(Figure 34D). This result indicated that double transfected cells behaved similarly to their single 
transfection counterpart. Therefore, we were successful in confirming that behavior of rCx36 
remained consistent across transfection conditions in the N2a cell model.  
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Figure 34| Effects of double transfection with calmodulin on rCx36 dynamics in N2a cells. 
Qualitative and quantitative assessments were carried out to determine if double transfection introduced impairments 
in the ability of rCx36 to function. N2a cells were transfected with either pEGFP-rCx36 WT (as the single transfection 
condition) or a combination of pEGFP-rCx36 WT and pDsRed-CaM WT (as the double transfection condition) 
constructs. ROIs were bleached briefly at 70% laser power and recorded over 200 cycles at 1.0-second intervals. 
Results were normalized against the extracellular space, represented as the mean±SEM. (A) Localization studies 
confirmed that double transfected cells were capable of gap junction plaque formation. CaM was found to co-localize 
heavily at areas highly concentrated in rCx36. Scale bar = 5µm. (B) Although mild impairments in the mobility were 
observed in double transfected cells, no significant difference was found when compared to the wild-type. (C) Half-
time of recovery was found to be indistinguishable at the selected ROIs. (D) No significant difference was observed 
in the gap junction plaque area suggesting that double transfected cells were indistinguishable from the single 
transfected counterpart. 
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5.5.2 Stability and Transport of rCx36 Under Run-Up-Like Conditions 
Finally, to assess whether cytoskeletal-dependent transport was a regulator in the run-up 
phenomenon, double transfected cells were treated with ionomycin. Calcium-dependent effects on 
mobility, half-time of recovery and gap junction plaque formation were recorded relative to the 
untreated counterpart. Ionomycin, a selective calcium ionophore agent, stimulates Ca2+ entry 
across the cell membrane. In doing so, intracellular calcium levels increase and allows for CaM 
activation; once CaM is activated, this in turn activates CaMKII. In this way, CaMKII was 
indirectly activated, and cells were primed to maximally simulate run-up-like conditions for 
assessment. Once active, CaMKII is known to be involved in a number of processes, including the 
enhancement of tubulin polymerization through MAP2 association upon phosphorylation (Khan 
& Ludueña, 1996) and activation of rCx36 run-up. Since our group has shown that run-up is 
inhibited in the presence of colchicine (unpublished), we speculated that cytoskeletal-dependent 
trafficking of rCx36 to the GJP may be a requirement of the run-up phenomenon. Therefore it was 
hypothesized that an increase in mobile fraction, relative to the increase in activity at the ‘plaque 
lateral’ ends, would be observed with ionomycin treatment. Additionally, we predicted a decrease 
in recovery time and increase in gap junction plaque area would be observed in parallel to the 
increase in rCx36 channel recruitment. 
 
In cells treated with ionomycin, a significant reduction in the mobile fraction was recorded at the 
‘plaque lateral’ ends (7.30±1.14%) in comparison to the respective membrane region 
(39.91±7.94%, p=6.50-6). Further, the ‘plaque lateral’ end ROI of treated cells was significantly 
reduced compared to its untreated equivalent (p=1.27-3) suggesting that the stability of rCx36 gap 
junction plaques was promoted upon Ca2+ stimulation. The mobile fraction of the plasma 
membrane ROIs was determined to be indistinguishable from the treated and untreated conditions 
(Figure 35A). No significant difference in the half-time of recovery was found between the plasma 
membrane region of double transfected cells treated with ionomycin in comparison to the 
respective ‘plaque lateral; end. Similarly, both the plasma membrane ROI and ‘plaque lateral’ end 
ROI of wild-type rCx36-EGFP/CaM-dsRed treated with ionomycin were indistinguishable from 
the untreated double transfected cells (Figure 35B). This result indicated that transport was neither 
impaired nor promoted. In support of this, the GJP area in cells treated with ionomycin 
(0.74±0.20µm²) was found to be indistinguishable from its untreated counterpart (Figure 35C). 
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Additionally, no significant difference in the CTFGJP of stimulated cells (293.77±43.64 RFU) was 
found in comparison to the unstimulated counterpart (188.87±30.12 RFU) (Figure 35D). 
Therefore, it is likely that cytoskeletal-dependent trafficking to the existing gap junction plaques 
does not serve as a prerequisite to the run-up phenomenon.   
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Figure 35| Modulation of rCx36 in the presence of Ca2+/ionomycin in N2a cells double transfected with CaM. 
Quantitative and qualitative assessments were carried out to determine if cytoskeletal-dependent trafficking was a 
mediator in the conditions similar to the run-up phenomenon. N2a cells were transfected with a combination of wild-
type pEGFP-Cx36 WT and pDsRed-CaM (as the double transfection condition) constructs and treated with ionomycin. 
ROIs were bleached briefly at 70% laser power and recorded over 200 cycles at 1.0-second intervals. Results were 
normalized against the extracellular space, represented as the mean±SEM. (A) The mobile fraction of the ‘plaque 
lateral’ ends in cells treated with ionomycin displayed a significant reduction in comparison to the untreated cells 
suggesting the stabilization of the GJP is calcium mediated. (B) Half-time of recovery was found to be 
indistinguishable at the selected ROIs despite ionomycin treatment. (C) No significant difference was observed in the 
gap junction plaque area between stimulated and unstimulated double transfected cells. (D) CTFGJP was not impacted 
upon calcium stimulation. Overall these results suggest that tubulin-dependent trafficking to existing gap junction 
plaques is not a prerequisite for the run-up phenomenon. 
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6 DISCUSSION 
6.1 SUMMARY OF RESULTS 
 
This thesis addressed the interaction between rCx36 and the cytoskeletal proteins tubulin and actin, 
in N2a cells. It was hypothesized that interaction with the cytoskeleton is critical for the transport 
of rCx36 hemichannels into the GJP, particularly during the run-up. This thesis demonstrates the 
following: 
I. rCx36 interacts with tubulin-beta 3 in vivo as confirmed by BioID. 
II. rCx36 hemichannels are delivered to the lateral ends of the GJP and removed from the 
center. 
III. Deletion mutants altering the CLB and CTB domains are less stable than wild-type rCx36. 
IV. Disruption of tubulin interaction with rCx36 impairs trafficking and aggregation of 
hemichannels as determined by TAT peptides, colchicine and paclitaxel interference. 
V. Disruption of actin interaction with rCx36 reduces GJ stability and has minor effects on 
hemichannel transport. 
VI. Lys279 was determined to be the most critical residue supporting tubulin interaction with 
rCx36. 
VII. Intracellular calcium elevation stabilizes rCx36 GJPs and hemichannel recruitment ceases.  
 
6.2 BIOID CONFIRMS IN VIVO INTERACTION BETWEEN RCX36 AND TUBULIN 
 
6.2.1 Tubulin-Beta III and rCx36 Interact In Vivo 
The first aim of this thesis was to confirm the interaction between rCx36 and tubulin in vivo while 
simultaneously assessing the efficiency of the newly developed BioID methodology (see section 
5.1). A fusion protein with BirA* and rCx36 wild-type and mutant variants (Δ175-196 and Δ279-
292) were successfully generated and expressed in the N2a cell model (see section 5.1). Initial 
pull-down of biotinylated proteins captured with wild-type rCx36-BirA* revealed tubulin as a 
potential interacting candidate via mass spectrometry (See Appendix D) and western blotting with 
the β-tubulin antibody (Figure 15). Specifically the tubulin-beta 3 (βIII-tubulin) isotype was 
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identified as being unique to rCx36-BirA* with respect to the negative control BirA*. While biotin 
affinity capture of tubulin was also achieved with BirA* alone, only the βIII-tubulin monomer and 
isotype could be exclusively identified as an interacting candidate of rCx36. This is in contrast to 
reports on Cx43 confirming interaction with both α- and β-tubulin monomers (Giepmans, Verlaan, 
Hengeveld, et al., 2001). Data interpretation needs to be cautious since tubulin is present in the 
cytoplasm in high concentrations. Therefore, it can’t be excluded that interaction between BirA* 
and tubulin is due to the high abundance of the target protein and the overlapping distribution in 
the cytoplasm. However, we are the first to describe and confirm βIII-tubulin as an interacting 
candidate of rCx36. In mammalian cell lines, tubulin isoforms are differentially expressed 
depending on tissue and stage of development. In the mammalian brain specifically, presence of 
tubulin isoforms is most prominent; the tubulin-beta 3 isotype is known to be exclusively 
expressed in neuronal cells and unique in that a Ser444 phosphorylation site is present and used 
(Ferreira & Caceres, 1992; Khan & Ludueña, 1996; Ludueña, Zimmermann, & Little, 1988). Thus, 
interaction between rCx36 and βIII-tubulin may be critical in mediation of transport and additional 
cellular functions in neurons with the potential of the tubulin Ser444 phosphorylation site being of 
significance for this process.  
 
In our experiments, the amount of biotinylated proteins captured with BirA* was significantly 
reduced in comparison to the rCx36-BirA* (Figure 16). Although the mechanism for targeting 
remains unclear in mammals, acetyl-CoA carboxylases such as BirA* are located in the cytosol 
(Robinson, Oei, Saunders, & Gravel, 1983; Shi & Chang, 2007). As such, protein interaction 
achieved with BirA* fused to the rCx36 protein should allow a greater range of specific 
interactions since the fusion protein is bound to membranes; not surprisingly, additional rCx36 
interacting proteins were identifiable via mass spectrometry, particularly those associated with the 
golgi apparatus and mitochondria (See Appendix D). However, an increase in biotinylated tubulin 
captured with BirA* was observed in comparison to wild-type rCx36-BirA* (Figure 16), 
suggesting that fusion of BirA to rCx36 limits the amount of interaction with cytosolic tubulin. 
This result is likely caused by spatial restrictions due to the membrane localization of rCx36. 
As expected, a reduction in the fluorescence signal detected on the western blot was observed for 
the CTB mutant (rCx36 Δ279-292) (Figure 17B, D, F), which indicated that the deletion of the 
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proposed tubulin binding site reduces interaction with βIII-tubulin (and potentially other isoforms 
common to both rCx36 and BirA*). As such, the remaining signal detected for tubulin is likely 
attributable to an unspecific interaction with BirA*. Unexpectedly, a reduction in the fluorescence 
signal in the CLB mutant (rCx36 Δ175-196) was also observed (Figure 17A, C, E), which 
suggests that an indirect interaction specific to tubulin exists between the CLB and CTB domains. 
This result may be attributed to additional interacting partner capable of mediating interactions 
with tubulin through the CLB either directly or indirectly.  
 
6.2.2 Efficiency and Limitation of BioID 
The original authors of the BioID methodology used this technique to identify a novel interacting 
partner of LaA. Limitations addressed in the publication were pertaining to solubility of the bait 
proteins (where conditions required to solubilize the protein may bias interaction with candidates) 
and low abundance of interaction proteins (resulting in false-negative results) (Roux et al., 2012b). 
However, here we propose an additional limitation to the methodology: highly abundant proteins, 
such as tubulin, may lead to both false-negative results and false-positive results. False-negative 
results may become evident in the comparison of identified protein candidates between the bait 
and the BirA* control, where proteins capable of interaction with both may be disregarded as non-
specific to the bait. Similarly, false-positive results may arise due to spatial constraints, where 
proteins are biotinylated due to close proximity rather than true interaction. In such cases, users 
interested in confirming interaction with highly abundant proteins must design control experiments 
strategically to eliminate a BirA*-specific bias; we found that the authors failed to address BirA* 
specific interactions as a control. In this thesis, we demonstrated that BirA* was able to interact 
with tubulin (Figure 16), but only one isotype; βIII-tubulin showed specific interaction with rCx36. 
This method wasn’t able to clarify whether the α-tubulin monomer is capable of interacting at the 
CTB in a similar fashion to what has been shown for Cx43 (Giepmans, Verlaan, Hengeveld, et al., 
2001). Although the region of interaction could be predicted, we could not determine beyond doubt 
whether amino acids Lys279-Ala287 are the tubulin binding region under the BioID methodology, 
thus limiting the effectiveness of studying protein-protein interactions with this technique. 
However, since interaction between tubulin and rCx36 was successfully identified in vivo, we 
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propose that BioID can serve as an initial screening method to identify potential interacting 
candidates, in combination with additional in vivo studies optimized for specificity. 
 
6.3 DYNAMICS OF THE CX36 GAP JUNCTION PLAQUE 
 
6.3.1 Transport of rCx36 is Consistent with Literature 
Previous studies have indicated that Cx43 hemichannels are delivered to the lateral ends of the gap 
junction plaque whereas the removal of hemichannels occurs from the center (Lauf et al., 2002a). 
This mechanism for transport is supported for Cx35, the fish ortholog of Cx36, at the mixed 
synapses of the goldfish Mauthner cells (Flores et al., 2012). Here we report that the dynamic 
delivery of rCx36 to the gap junction plaque coincides with the reports of Lauf et al. (2002) and 
Flores et al. (2012). Through time lapsed imaging observations, rCx36 connexons were reported 
to be delivered in small groups, in multiple instances; no observation of single channel delivery 
was recorded. We also have reported removal of rCx36 at the center of the nexus. As a precursor 
to removal, we recorded an invagination event and subsequent division of the gap junction plaque. 
Early literature reports that internalization of connexons is preceded by the invagination, restriction, 
and pinching off of both junction membranes into one of the adjoining cells (Larsen, Tung, Murray, 
& Swenson, 1979). As such, both the delivery and removal of rCx36 from the nexus was 
successfully recorded and shown to be consistent with previous reports on Cx43 and Cx35.  
 
6.3.2 Characteristics of the rCx36 Gap Junction Nexus 
Relative to the plasma membrane and intracellular space, wild-type rCx36 at the lateral ends of 
the gap junction plaque was determined to be stable in nature as indicated by the measurement of 
the mobile fraction. At the center of the gap junction plaque, mobility was more stable in 
comparison to the plasma membrane, yet dynamics were comparable to the intracellular space. 
Most likely this reflects an equilibrium between dynamic insertion and removal of Cx36 from the 
plaque (Figure 23A). Although integration and removal of connexons is a continual and dynamic 
process, gap junctions are known to typically be stable in nature for hours while embedded in the 
plasma membrane for the duration of its lifetime. Gap junctions can be stabilized by direct and 
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indirect interactions with proteins such as actin and ZO-1, and may potentially serve as anchoring 
junctions for microtubules as suggested for Cx43 (Giepmans, Verlaan, & Moolenaar, 2001; 
Giepmans, Verlaan, Hengeveld, et al., 2001; Li, Olson, Lu, Kamasawa, et al., 2004). Lauf et al. 
(2002) has found that upon reaching the plasma membrane, Cx43 hemichannels can move freely, 
where the mobile fraction was determined to be approximately 70% (Lauf et al., 2002a). This in 
turn correlated to the rapid repopulation of the gap junction plaque upon bleaching (Shaw et al., 
2007). The mobile fraction of rCx36 was found to be much less motile at the plasma membrane 
relative to Cx43, suggesting that rCx36 dynamics are uniquely controlled and regulated. This novel 
finding may be indicative of rCx36 modulation through cytoskeletal interactions, and differences 
thereof, in terms of regulatory proteins. 
 
We expected to see a reduction in the half-time of recovery at the gap junction plaque, particularly 
at the lateral ends, relative to the intracellular space. We also predicted that the recovery of the 
GJP would comparable to the recovery at the plasma membrane as an indication of trafficking 
dynamics. However, this was not the case as all ROIs analyzed were indistinguishable from each 
other (Figure 23B). Two plausible, and potentially related, explanations could account for this 
result. Firstly, since recordings were taken noninvasively in vivo, lack of observable difference 
could be a true reflection of the dynamic trafficking of rCx36 throughout the cell. In this case, the 
required transition through cytosolic and membrane stages prior to docking at the gap junction 
plaque would be accounted for. As connexons are continuously transported throughout these 
regions, indistinguishable recovery times seems plausible as it not an indication of single protein 
velocity. Secondly, this also may indicate a lack in sensitivity in the method dependent upon ROI 
selection. Since FRAP is a live cell imaging technique, it is sensitive to fluctuations in cellular 
movements, which are more prominent at the plasma membrane and intracellular space ROIs. 
Consequently, the shuffling of rCx36 in and out of these ROIs produces a large degree of 
variability, which in turn makes it more difficult to detect minor changes in half-time of recovery.  
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To date, few reports have addressed gap junction area as a characteristic of connexin isoforms. 
Here we reported the mean gap junction plaque area of EYFP-tagged rCx36 to be 2.22± 0.19µm2 
(Figure 19F). More precisely, since we didn’t aim at 3D reconstructions of the entire plaque area, 
this value represents a tangential cut through the widest section of this plaque, thus reflecting its 
extension in the plasma membrane. Further, it is important to take into consideration that 
measurements were obtained based on fluorescence, which radiates outward of the GJP, decaying 
with distance from its origin, and creating an image that is larger than the actual plaque size. 
Comparative to the reported value mean gap junction plaque area of Cx43 (0.26 μm2, SD ± 0.145) 
(Jones et al., 1993), the rCx36 gap junction plaque therefore appears relatively large. Although 
this would still fall between typical values reported for gap junction plaques, which ranges from 
0.3 µm² to ≥ 5 µm² depending on isoform expressed and tissue type, further confirmation via 
electron microscopy would be required.  However, it is interesting to note that typically, gap 
junctions with larger surface areas display a reduction gap junctional conductance per µm² 
(Jongsma & Wilders, 2000). Therefore, a relatively large GJP area for rCx36 would complement 
earlier reports of low single channel conductance for Cx36 (Srinivas et al., 1999), although the 
number of open/closed channels might equally well explain this observation.  
 
6.4 THE CYTOSKELETON IS CRITICAL FOR CX36 INTEGRATION AT THE GJP 
 
6.4.1 Interactions with the Actin Cytoskeleton  
6.4.1.1 Mutant variant rCx36-Δ175-196 reveals potential actin binding domain  
In this thesis, we have proposed that an actin binding site is present within the cytoplasmic loop 
of the rCx36 protein. As predicted by ELM we investigated a region encompassing amino acid 
residues Asp167-Ala184 as potential actin binding site (See Appendix E). Although Cx36 has 
been shown to interact directly with Zonula occludens (ZO) proteins, known interactors of actin 
(Li, Olson, Lu, & Nagy, 2004; Li, Olson, Lu, Kamasawa, et al., 2004), it has yet to be shown that 
a direct relationship between actin and Cx36 exists. Therefore, we are the first to propose actin 
and an interacting partner of Cx36. The hypothesized actin binding domain was found to be highly 
conserved across species yet less conserved across connexin isoforms (Figure 20). Sequence 
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alignment against the glial connexins rCx43 and rCx30 revealed the presence of spacer sequences 
between conserved residues not present in rCx36 or respective orthologs. As such, we speculate 
that the Cx36 actin binding region may be unique to this neuronal isoform. Although the functional 
significance of these spacer residues is currently unknown, one can speculate that in similar notion 
to that of actin cross-linking proteins, these spacer sequences may act to provide variability in actin 
bundling and/or actin-specific plasma membrane association (Matsudaira, 1991) directly or 
indirectly. The proposed actin binding domain of rCx36 is rich in non-polar (hydrophobic) amino 
acids, particularly leucine, alanine and proline. The presence of hydrophobic amino acids is 
characteristic of most actin binding domains such as the WASP homolog 2 (WH2) domain, 
gelsolin and the thymosin-β domain, which have been shown to associate with the cleft of 
hydrophobic amino acids in actin (Chereau et al., 2005; Hertzog et al., 2004; Irobi et al., 2004; 
Quinlan, Heuser, Kerkhoff, & Mullins, 2005; Schutt, Myslik, Rozycki, Goonesekere, & Lindberg, 
1993; Yarmola, Parikh, & Bubb, 2001). Additionally, a number of electrically charged amino acids, 
particularly glutamic acid, were present in the proposed rCx36 actin binding domain. It is worth 
mentioning that of the electrically charged amino acids, 50% were basic residues which have been 
shown to facilitate actin binding in the cytoskeletal binding protein coronin (Gatfield, Albrecht, 
Zanolari, Steinmetz, & Pieters, 2005). Taken together, this provides strong evidence that actin 
interaction with rCx36 and orthologs may be direct rather than indirect, however, this still remains 
to be proven experimentally. 
 
At the cellular level, actin is known to maintain and regulate vesicular pools by acting as a scaffold 
to restrict mobility thus creating a barrier preventing fusion or by serving as a transport pathway, 
guiding vesicles for docking. In this scenario, the functional role of actin is dependent on synaptic 
type, state and organism. Additionally, actin has been shown to anchor receptors through the 
interaction with scaffolding proteins (Kuriu, Inoue, Bito, Sobue, & Okabe, 2006). Thus, we 
hypothesized that interference of actin-dependent interaction with rCx36 may influence both 
vesicular and docked connexons at the gap junction plaque, particularly at the lateral ends. As such, 
our analyses were focused at this region. We aimed to characterize the functional significance of 
actin interaction with a two-step approach of (1) understanding interaction at the level of gap 
junction plaque and (2) understanding the interaction with respect to the whole cell. Initially, 
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localization studies revealed that expression of the CLB mutant rCx36 Δ175-196 resulted in a 
reduction in observable puncta and gap junction plaque area, in comparison to the wild-type 
(Figure 19), without impairments to total cell protein production (Table 11) (see section 5.2.2). 
As a result, an increase in intracellular vesicles of rCx36 Δ175-196 was observable suggesting that 
the lack of actin interaction impairs trafficking and/or promotes removal of connexons from the 
gap junction plaque. In this way, actin may be functionally linked to transport and/or anchoring of 
the rCx36 connexons respectively. Quantitatively, the mobile fraction of rCx36 Δ175-196 gap 
junction plaques was significantly higher than the wild-type at the lateral ends, yet 
indistinguishable from the respective plasma membrane region (Figure 24A). Here, we suggest 
that an increase in mobility is a direct reflection of the reduction in anchoring ability rather than 
enhanced transport as determined by the reduction in gap junction plaque area. Since no significant 
difference in half-time of recovery was observed (Figure 24B), it is likely that actin-dependent 
trafficking of rCx36 connexons is minor and an additional mechanism for transport is involved. 
We find that our proposal is in agreement with the proposal of  Qu, Gardner, & Schrijver (2009) 
suggesting the implication of actin in connexon anchoring and short distance transport. 
 
6.4.1.2 Actin interference with Cytochalasin D reduces stability 
To determine the effects of actin inhibition on rCx36, pharmacological blocking of actin was 
achieved with cytochalasin D. In this way, the effects of actin impairment on the whole cell level 
was assessed. Previously, it was demonstrated that cytochalasin B treatment of Cx26-YFP and 
Cx43-GFP inhibited connexon recruitment and assembly at the GJP (Thomas et al., 2005). Upon 
treatment of wild-type rCx36 expressing cells with cytochalasin D, mobility at the gap junction 
‘plaque lateral’ ends significantly increased, in comparison to the untreated counterpart, such that 
mobility was indistinguishable from the respective plasma membrane region (see section 5.3.3). 
This observed increase in mobility could be attributed to more movement at the lateral ends, as a 
result of anchoring impairment of docked connexons, or an increase in activity specific to an 
increase in vesicular recruitment. For the latter to hold true, this would imply that an actin 
meshwork near the GJP could act as a barrier to limit the amount of vesicular fusion of 
hemichannels under basal conditions. In this case, cytochalasin D treatment would disrupt the actin 
barrier, allowing for an increase in vesicular fusion and hemichannel insertion. However, this 
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theory would require further investigation. Within the scope of this thesis, since gap junction 
plaque area with cytochalasin D treatment was indistinguishable from the untreated counterpart, 
we cannot confidently conclude that actin possesses barrier capabilities at the rCx36 nexus in the 
N2a cell model. Since we found a reduction in CTFGJP in cells treated with cytochalasin D 
suggesting a reduction in connexons at the GJP, our findings are parallel to the reports of Thomas 
et al. (2005) on Cx26 and Cx43. However, our results suggest that the primary role of actin 
interaction is the anchoring of rCx36 hemichannels, particularly at the lateral ends; we deemed 
actin’s role in trafficking as secondary. Again, this supports the work of Qu, Gardner and Schrijver 
(2009) providing evidence to suggest that actin anchors and supports Cx30 GJPs at the plasma 
membrane, with minor roles in short distance trafficking (Qu et al., 2009). Since we are the first 
to describe such relationship with rCx36, one can speculate then that such interaction improves 
efficiency of connexon integration upon docking at the gap junction plaque.  
 
 
6.4.2 Interactions with the Tubulin Cytoskeleton 
6.4.2.1 Deletion of the tubulin binding domain reduces trafficking and aggregation 
Previous studies have shown that connexon delivery, in some instances, is tubulin-dependent and 
relative dependency is determined by connexon isoform. Therefore, it has been speculated that 
tubulin enhances transport (Laird, 2010). We hypothesized that interference of tubulin interaction 
would negatively impact rCx36 transport such that gap junction plaque size and recovery time 
would be impaired if trafficking was indeed tubulin-dependent. Our research initiative was again 
designed in a two-step approach of understanding effects of tubulin interference at the (1) gap 
junction plaque (2) whole cell levels. Although localization studies confirmed the presence of 
rCx36 Δ279-292 gap junction plaques, unexpectedly, the gap junction plaque size (Figure 19), 
and half-time of recovery (Figure 24B) was found to be indistinguishable from the wild-type. As 
such we propose that a tubulin-independent transport mechanism is involved in the delivery of 
rCx36 hemichannels, with actin as a potential candidate. However, we found that the gap junction 
fluorescence of rCx36 Δ279-292 expressing cells was significantly reduced in comparison to the 
wild-type (Table 11). In combination with the maintained gap junction plaque size, this would 
suggest that less rCx36 Δ279-292 connexons are participating at the gap junction plaque and thus 
are likely less densely packed. Therefore, it is probable that in the absence of amino acid residues 
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spanning from Lys279-Lys292, trafficking was impaired. By this we suggest that tubulin aids in 
mediation of trafficking in addition to the aggregation and tight clustering of hemichannels at the 
gap junction plaque. In support of the latter, the mobile fraction at the ‘plaque lateral’ ends was 
found to increase considerably in comparison to wild-type (Figure 24). Overall, this indicated a 
greater exchange in bleached connexons for the unbleached, which we attribute to the loss in 
aggregation ability. Therefore, this resulted in more mobility and exchange of connexons at the 
GJP.  
 
6.4.2.2 Tubulin interference reduces trafficking and stability of the rCx36 GJP 
Several pharmacological targets of tubulin were used in this study to confirm the role of tubulin-
rCx36 interaction. Firstly, competitive blocking of the tubulin binding domain was achieved with 
the cell penetrating TAT peptide. In this way, tubulin interference was specific to the gap junction 
plaque. Wild-type rCx36 expressing cells treated with TAT CT-ON showed a significant increase 
in the half-time of recovery at the ‘plaque lateral’ ends, in comparison to the untreated wild-type, 
indicating that there was an impairment in trafficking at the ‘plaque lateral’ ends (Figure 25B). 
We attribute this impairment to the inhibition of tubulin interaction at the cytoplasmic binding 
domain of rCx36. Similar to the expression of the rCx36 Δ279-292 mutant variant, gap junction 
plaque size was maintained upon tubulin interference at the gap junction plaque (Figure 25C). 
Therefore, some functionality with respect to transport is maintained when alteration occurs at the 
level of the gap junction. It is important to note that TAT, within the boundaries of this thesis, 
served as competitive blocker and therefore not all functionality is completely abolished with 
treatment. Nevertheless, this does suggest that a tubulin-independent mechanism for transport 
exists and can be used as an alternative. However, it is likely less efficient at doing so as indicated 
by the increase in half-time of recovery. We speculate that this transport mechanism involves actin, 
and may be dependent temporally and spatially on connexon reserves near the plaque. Further, 
wild-type rCx36 cells treated with TAT CT-ON showed a significant increase in the mobile 
fraction in comparison to the untreated wild-type (Figure 25A), rendering mobility 
indistinguishable from the respective plasma membrane region. This result may be a reflection of 
the inability of tubulin to aggregate connexons, thus allowing for more mobility and exchange of 
hemichannels within the gap junction plaque. To date, there are no reports outlining the effects of 
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TAT-peptide blocking of the tubulin binding region specific to connexins as a reference. As such, 
our results are the first of its kind to be described, specifically at the Cx36 nexus.  
Interestingly, treatment of wild-type rCx36 expressing cells with TAT CT-OFF revealed a 
significant reduction in gap junction plaque size (Figure 25C). Therefore, it was suggested that 
another interacting partner important in trafficking and/or anchoring of connexons at the GJP is 
housed within the CLP. Outside of the scope of this project, a number of C-terminal interacting 
partners have been identified as connexin stabilizers. In particular, ZO-1 has been shown to interact 
with the C-terminal domain of Cx36 and is speculated to be involved in formation, distribution, 
turnover and the indirect regulation of communication (J.-C. Hervé, Derangeon, Sarrouilhe, 
Giepmans, & Bourmeyster, 2012). These interactions are likely impaired with CT TAT-OFF 
treatment, promoting removal and recycling of rCx36 connexons and thus resulting in a reduction 
in gap junction plaque size without impairments in mobile fraction at the ‘plaque lateral’ ends.  
 
6.4.2.3 Total cell tubulin interference causes trafficking impairments 
On the whole cell level, the effects of tubulin alteration on rCx36 in vivo was characterized 
pharmacologically with the tubulin polymerization inhibitor, colchicine, and promoter, paclitaxel. 
In Novikoff hepatoma cells, inhibition of MTs with 100 µM colchicine showed no impairments 
on the initiation of gap junction assembly or hemichannel aggregation under basal conditions 
(Johnson et al., 2002). Unlike Cx43, Colchicine treatment of wild-type rCx36 expressing cells 
resulted in a decrease in gap junction plaque area in comparison to the untreated cells, yet no 
change in the half time of recovery (Figure 26B-C). As such, a reduction in the gap junction 
plaque size could be attributed to either an increase in pre-mature removal and/or decrease in 
trafficking. However, since half-time of recovery was not largely impacted, in combination with 
our building evidence, it is likely that the decrease in gap junction plaque size is a reflection of a 
trafficking impairment. In such case, a compensatory mechanism allows for recovery to be 
relatively maintained. We find that these results further support the potential of actin-dependent 
trafficking as a compensatory mechanism, most likely over a short distance. Additionally, a 
significant increase in the mobile fraction is likely attributable to a reduction in clustering ability 
as previously detailed (Figure 26A). Therefore, these results are not in conjunction with the reports 
of Cx43 by Johnson et al. (2002) and are seemingly unique to rCx36. 
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Previous studies have demonstrated that paclitaxel treatment was sufficient to impair recovery of 
Cx43 hemichannels at the GJP, thus disrupting the fast repopulation, post-bleach (Shaw et al., 
2007). Paclitaxel treatments on wild-type rCx36 expressing cells had no adverse effects on the 
mobile fraction or half-time of recovery, but did reveal an impairment in gap junction plaque area 
(Figure 26). Although paclitaxel is known to promote the polymerization of microtubules, it has 
also been shown to promote MT bundling which negatively affects anterograde transport (i.e. 
forward trafficking) (Theiss & Meller, 2000). Therefore, we suspect that the reduction in gap 
junction plaque size is a reflection of the adverse effects of paclitaxel on trafficking. In comparison 
to Cx43, no change in half-time of recovery under paclitaxel treatment demonstrates that fast-
repopulation is not a characteristic of Cx36. Instead, this suggests that trafficking of Cx36 to the 
GJP is distinguishable from Cx43, likely due to difference in interaction candidates.  
 
Neither colchicine nor paclitaxel treatment had additional effects on rCx36 Δ279-286 expressing 
cells (Figure 26-27). Therefore, it was reaffirmed that rCx36 interacts with tubulin in vivo and the 
binding domain is located within this region. Interestingly, paclitaxel did seem to have some 
stabilizing effects on the rCx36 Δ279-286 mutant, however this was found to be insignificant in 
comparison to the untreated counterpart (Figure 27).  
 
6.4.2.4 Point Mutations Disrupt rCx36-tubulin interaction 
The tubulin binding region of rCx43 was previously determined to be conserved at the cytoplasmic 
terminal of rCx36 (Figure 6). The participating residues spanning from Lys279-Ala287 are a 
combination of non-polar and electrically charged (basic) amino acids, typical of microtubule 
binding regions. In the third aim of this thesis, the critical binding residues involved in tubulin-
specific interaction was determined via site-directed mutagenesis (see section 5.4). Of the mutated 
amino acids, replacement of alanine at Ile280 and Val284 was minimally impacted and thus were 
not deemed as critical residues in the tubulin-rCx36 interaction. However, Lys279, Lys281, 
Leu282, Arg285, Gly286 were confirmed as residues of importance (Figure 32-33). In particular, 
we are the first to report Lys279 as the most critical residue in the interaction between rCx36 and 
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tubulin. The rCx36 K279A mutation resulted in a significant reduction in observable puncta, gap 
junction plaque area well as an increase in mobile fraction and moderate impairments in the half-
time of recovery (Figure 31-33). Although it is unclear why the effects of rCx36 K279A mutation 
was more pronounced than that of rCx36 Δ279-292, one can only speculate that the size of the 
replacement amino acid at this position may be of functional significance. In such case, large 
amino acids may enhance the ability to access tubulin-rCx36 interaction. For our purpose, a polar 
serine residue replaced lysine at position 279 with the rCx36 Δ279-292 mutant variant. Earlier 
reports on Cx43 have identified a short region in the CT juxtamembrane (Glu227-Val231) as 
critical for facilitating tubulin interaction. In contrast to Lys279, these residues (ELFYV) are 
mainly non-polar. As such, our reports supporting Lys279 as critical for tubulin interaction is 
unique to rCx36.   
 
6.4.3 Additional Cytoskeletal Interactions at the rCx36 Nexus  
Throughout this thesis, several lines of evidence let us conclude that rCx36 is modulated at the 
nexus by proteins that may work in conjunction with cytoskeletal proteins. The biotin pull-down 
achieved with rCx36 Δ175-196 revealed a reduction in biotinylated tubulin (Figure 17). As such, 
we inferred that a non-direct interaction specific to tubulin exists between the CLB and CTB 
domains. Therefore it is undoubtedly possible that through a mediating candidate and/or post-
translational modification providing structurally favorable conditions, interaction between tubulin 
and rCx36 can be facilitated. In support of this, it was found that β-tubulin is capable of binding 
to the CL domain of Cx43. However, the affinity of this interaction was reduced by 80% (Kang et 
al., 2009). Therefore it is plausible that a third interaction candidate is involved. An already known 
interaction partner known to be involved in dual domain interaction of Cx36 is CaMKII (Alev et 
al., 2008). Although it is not yet conclusive, we speculate that CaMKII might be involved in the 
mediation of tubulin and actin interaction at the Cx36 nexus to influence synaptic strength. It is 
worth mentioning that in support of this, half-time of recovery was impaired when cells were 
treated with TAT-CT ON, which also reduces CaMKII interaction at rCx36. Therefore, it is likely 
that an interplay between rCx36 and CaMKII, along with additional protein candidates at the nexus, 
may be intricately related. In turn, we suspect that the delay in tubulin-specific trafficking may be 
in partner with CaMKII.  
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The expression of rCx36 Δ182-198 revealed an increase in the mobile fraction, yet reduction in 
connexons participating at the gap junction plaque (Figure 24, Table 11). Therefore, this implied 
that transport and/or stabilization (through aggregation ability) of connexons could still be 
modulated outside of direct tubulin- and actin-dependency. This would be of significance in 
neurons where tubulin is restricted by the dendritic spine. Interestingly, rCx36 Δ182-198, 279-292 
behaved similarly to rCx36 Δ279-292 with respect to fluorescence, half-time of recovery and gap 
junction plaque size (Table 11, Figure 19F, and 24B). However, no significant difference in the 
mobile fraction was found between the wild-type and rCx36 Δ182-198, 279-292 (Figure 24). 
Although it is unclear why these gap junction plaques appeared to be as stable as the wild-type, 
alteration of protein structure and/or net charge may be of influence. 
 
It should not go unsaid, however, that half-time of recovery was seldom affected throughout this 
thesis, particularly in comparison to the plasma membrane ROIs. Therefore, we propose that rCx36 
can be transported to the plasma membrane in tubulin- and/or actin-dependent manners. However, 
upon reaching the plasma membrane, lateral movement towards the gap junction plaque may occur 
independently of actin and tubulin interactions. Our findings thus coincides with reports of Lauf 
et al. (2002) stating that Cx43 is able to move freely in the plasma membrane (Lauf et al., 2002a). 
Connexons near to- or already docked at the GJP may participate in cytoskeletal interactions where 
we suggest that actin facilitates anchoring and tubulin subsequently facilitates aggregation in the 
N2a cell model. Our findings are the first to describe the influence of cytoskeletal interactions on 
Cx36. Since the potential of gap junction plaques serving as tubulin anchors still exists, tubulin 
may potentially regulate the degree of third party interactions. In such case, this would be achieved 
by regulating the degree of clustering (i.e. amount of channels participating at the gap junction 
plaque); however, this may be dependent on the cell model. Since it was previously shown that 
inhibition of tubulin was sufficient to abolish the run-up phenomenon (unpublished), in which gap 
junctional conductance increases 10-fold, this stands as a strong possibility.  
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6.5 ASSESSMENT OF CYTOSKELETAL INVOLVEMENT IN THE RUN-UP 
 
6.5.1 Double Transfected Cells Behave Similar to Single Transfected Cells 
The LTP-like "run-up" phenomenon has been exclusively described at the Cx36 nexus and was 
found to be CaMKII dependent (Alev et al., 2008; Del Corsso et al., 2012). This phenomenon 
resembles the phosphorylation of NMDARs by CaMKII to further evoke an influx of Ca2+, a 
critical mediating step in LTP-based plasticity at chemical synapses. In our efforts to design a 
model to maximally simulate conditions similar to run-up, we double transfected N2a cells with 
wild-type rCx36 and calmodulin (CaM). CaM, a precursor to CaMKII activation, is a key 
component in the run-up phenomenon and acts in a calcium-dependent manner. Prior to our 
analysis of cytoskeletal involvement in the run-up phenomenon, we confirmed that double 
transfected cells were indistinguishable from single transfected cells in the recovery, mobility and 
size of rCx36 gap junction plaques (Figure 34). To our knowledge, such comparison has not been 
addressed in previous literature reports, yet is crucial to ensure validity and reliability of results.  
 
6.5.2 Studying Cytoskeletal Involvement in the Run-Up Phenomenon 
As previously mentioned, this research project was based on results confirming rCx36-tubulin 
interaction in vitro and determining that tubulin interference was sufficient to abolish the run-up 
phenomenon. As such, we predicted that tubulin might be a critical mediator in the run-up 
phenomenon, primarily by recruiting more channels to the gap junction plaque. Unexpectedly, 
double transfected cells stimulated with ionomycin had a significantly reduced mobile fraction at 
the ‘plaque lateral’ ends in comparison to the untreated counterpart, yet half-time of recovery and 
gap junction area were unaffected. Furthermore, CTFGJP was indistinguishable between the 
stimulated and unstimulated conditions (Figure 35). Overall, this suggested that upon the indirect 
activation of CaMKII via calcium stimulation of CaM, the gap junction plaque stabilizes and 
further recruitment to the existing GJP ceases.  
 
Our initial hypothesis proposed that cytoskeletal-dependent trafficking of rCx36 to the GJP may 
be a requirement of the run-up phenomenon and would be reflected by an increase in hemichannel 
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activity during calcium stimulation. Although our results rejected this hypothesis, we have gained 
new insight into the dynamics of rCx36 under stimulated conditions. This in turn will help us to 
understand, in full, the involvement of cytoskeletal proteins in mediating run-up. In part, our 
understanding of such interaction would need to be in conjunction with understanding the 
relationship between CaMKII and the cytoskeleton. Firstly, activated CaMKII is known to bind 
and bundle F-actin (Okamoto, Narayanan, Lee, Murata, & Hayashi, 2007). Alternatively, CaMKII 
also phosphorylates actin, through a β-PIX mediated pathway, thus increasing polymerization 
(Meng et al., 2002; Park et al., 2003; Xie et al., 2007) which may serve as an inhibitory barrier to 
vesicular fusion at existing gap junction plaques. However, this too would require further 
investigation. In contrast, effects of CaMKII phosphorylation on tubulin is dependent on its state; 
in the case of unpolymerized tubulin, it has been shown that phosphorylation inhibits subsequent 
polymerization (Wandosell, Serrano, Hernandez, & Avila, 1986) whereas phosphorylation of 
polymerized tubulin promotes MT polymerization through association with MAPs, particularly 
MAP2. Specifically, CaMKII mediated phosphorylation of the βIII-tubuin Ser444 residue is 
crucial for MAP2 mediated polymerization (Khan & Ludueña, 1996). Interestingly, Bricki-
Nigassa et al. (2012) showed that Cx43-tubulin interaction can be inhibited by phosphorylation of 
a residue down-stream of the tubulin binding domain (Saidi Brikci-Nigassa et al., 2012). Although 
this interaction however was not CaMKII-mediated, it reflects the significance in the mediation of 
connexin-tubulin interaction via phosphorylation. As such, defining and refining the exact 
mechanism for cytoskeletal contribution to the run-up will be a new and upcoming challenge ahead.  
 
6.6 CONCLUSION AND OUTLOOK 
In conclusion, we have successfully confirmed the interaction between rCx36 and tubulin in vivo 
through both BioID and FRAP methodologies in combination with mutant variant expression and 
pharmacological blockers. We propose that rCx36 interacts primarily with the βIII-tubulin isotype 
to regulate the trafficking of connexons to the plasma membrane and connexon aggregation at the 
gap junction plaque. Furthermore, we report that Lys279 is most critical in the tubulin-specific 
interaction with rCx36. Our studies have also lead to the identification of a potential actin binding 
site within the CLB domain of rCx36, which appears to be unique to this isoform. Partial deletion 
of this site in combination with pharmacological blocking suggest that actin is an interacting 
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partner of rCx36, and mediates stabilization of the gap junction plaque with minor roles in 
trafficking. However, whether rCx36-actin interaction is direct or indirect has yet to be shown. We 
propose that trafficking of rCx36 connexons requires a tubulin/actin-dependent stage prior to 
delivery at the plasma membrane. At the plasma membrane, the lateral movements of rCx36 occur 
independently of actin or tubulin. Subsequent docking at the gap junction plaque requires both 
actin and tubulin interaction for anchoring and aggregation respectively. Although the exact 
contribution of the cytoskeleton to the run-up is still inconclusive, we reject the proposal of 
enhanced trafficking to existing gap junction plaques.  
 
To further characterize cytoskeletal involvement at the Cx36 nexus, additional studies directed at 
actin involvement would be required. Confirmation of actin interaction would strongly be 
supported with complementary in vitro studies, such as GST-pull down or co-immunoprecipitation, 
in addition to in vivo studies such as FRET or bi-molecular fluorescence complementation assays. 
We are currently in the stages of pursuing these. In such ways, whether actin interaction is direct 
or indirect can be deciphered. Additionally, critical binding residues involved in actin interaction 
needs to be identified; this process has already been initiated using site-directed mutagenesis as 
outlined in this thesis.  
 
On a structural level, exact binding mechanics of cytoskeletal interactions with Cx36 are, as of yet, 
undefined but may aid in our understanding of association ability. In efforts to define such 
mechanics, we have generated potential models of the rCx36 protein (See Appendix F). Previously, 
Bricki-Nigassa et al. (2012) found that upon the binding of tubulin, the tubulin binding region and 
subset of down-stream residues take on a helical structure (Saidi Brikci-Nigassa et al., 2012). It is 
interesting to note that in these proposed models, the tubulin binding domain takes a helical 
structure, which coincides with the reports of Bricki-Nigassa et al. (2012). Using the generated 
models of Cx43-tubulin interaction as a comparative reference will be of great advantage in the 
future to determine Cx36-specific interactions with tubulin, and additional target proteins once the 
Cx36 structure is solved. 
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There seems to be an intricate relationship between Cx36, CaMKII and the cytoskeleton which 
likely influences properties of the run-up phenomenon. Our future focus aims at defining this 
relationship. Since binding of the βIII-tubulin isotype was identified as being unique to rCx36, 
exploring whether the Ser444 phosphorylation site is critical for interaction is of interest. Since 
this residue is a target of CaMKII, such studies may solidify evidence supporting an interaction 
between rCx36, tubulin and CaMKII. As a start, whether Cx36 interaction with tubulin is a 
CaMKII-mediated process will be assessed with the use of the CaMKII blocker KN-93 in addition 
to site-directed mutagenesis of the Ser444 residue of βIII-tubulin. 
 
Finally, we aim to continue identifying additional candidates of rCx36 as contributors of synaptic 
plasticity at the nexus. In doing so, we anticipate that results from this continuing research project 
will contribute to our understanding electrical synapse-specific plasticity as a mediator to learning, 
memory, vision and behavior in conjunction with chemical synapse-mediated pathways. Our hope 
is that from this understanding, new insight into neurological disorders affecting learning and 
memory can be gained. 
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8 APPENDIX 
APPENDIX A: EUKARYOTIC EXPRESSION VECTORS 
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APPENDIX B: DRUGS 
 
Colchicine 
Product Description 
Molecular Formula: C22H25NO6 
Molecular Weight: 399.4 
Melting Point: 142-150ºC, 155-157ºC 
Solubility: Water; Chloroform; Benzene 
 
 
Cytochalasin D 
 
Product Description 
Molecular Formula: C30H37NO6 
Molecular Weight: 507.62 
Melting Point: 268-271ºC 
Solubility: Chloroform; DMSO 
 
 
Paclitaxel 
 
Product Description 
Molecular Formula: C47H51NO14 
Molecular Weight: 853.91 
Melting Point: 213ºC 
Solubility: Methanol; DMSO; Ethanol; 
Acetonitrile 
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APPENDIX C: MEAN, SEM AND SAMPLE SIZE OF FRAP AND GJP STUDIES 
 
Table A1.1: The mobile fraction (%) and half-time of recovery (s) at the selected ROIs of wild-
type rCx36 expressing N2a cells (n=8) represented as the mean ± SEM.   
 Mobile Fraction (%) Half-Time of Recovery (s) 
Intracellular 37.02±10.20 11.85±6.00 
Membrane 33.77±7.50 20.33±9.69 
Plaque Lateral 11.02±1.25 8.67±3.52 
Plaque Center 10.46±1.32 1.68±0.58 
 
Table A1.2: The p-values corresponding to the mobile fraction and half time of recovery 
analyses of wild-type rCx36 expressing N2a cells (n=8). 
 Mobile Fraction Significance Half-Time of Recovery Significance 
Plaque Center to Membrane 0.008 ** 0.075 ns 
Plaque Center to Intracellular 0.022 * 0.114 ns 
Membrane to Intracellular 0.801 ns 0.469 ns 
Plaque Lateral to Membrane 0.000 *** 0.178 ns 
Plaque Lateral to Intracellular 0.002 ** 0.631 ns 
Plaque Lateral to Plaque Center 0.783 ns 0.181 ns 
 
Table A2.1: The mobile fraction (%) and half-time of recovery (s) at the selected ROIs of wild-
type and (deletion) mutant rCx36 expressing N2a cells represented as the mean ± SEM.   
 n 
Mobile Fraction (%) Half-Time of Recovery (s) 
Membrane Plaque Lateral Membrane Plaque Lateral 
WT 8 33.77±7.50 11.02±1.25 11.85±6.00 1.68±0.58 
Δ182-198, 279-
292 6 27.72±7.89 18.41±3.60 17.68±8.79 5.82±1.56 
Δ182-198 5 27.33±16.37 35.47±4.98 11.11±5.77 13.97±5.21 
Δ279-292 13 28.61±5.23 23.27±5.08 17.65±5.89 8.51±3.49 
Δ175-196 11 34.48±6.71 25.68±3.26 4.66±2.53 20.02±3.33 
 
Table A2.2: The p-values corresponding to the mobile fraction and half time of recovery 
analyses of (deletion) mutant rCx36 expressing N2a cells. 
  
Mobile 
Fraction Significance 
Half-Time of 
Recovery Significance 
Δ182-198, 279-
292 
Plaque Lateral to 
Membrane 0.231434 ns 0.083352 ns 
Membrane 0.593804 ns 0.848208 ns 
Plaque Lateral 0.039772 ns 0.514054 ns 
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Δ182-198 
Plaque Lateral to 
Membrane 0.54965 ns 0.740678 ns 
Membrane 0.692689 ns 0.500021 ns 
Plaque Lateral 5.34E-06 **** 0.390009 ns 
Δ279-292 
Plaque Lateral to 
Membrane 0.582355 ns 0.607338 ns 
Membrane 0.490012 ns 0.660993 ns 
Plaque Lateral 7.43E-05 **** 0.417485 ns 
Δ175-196 
Plaque Lateral to 
Membrane 0.190702 ns 0.004911 ** 
Membrane 0.94482 ns 0.089288 ns 
Plaque Lateral 0.000745 **** 0.027354 ns 
*Shaded areas represent the cross comparisons to the WT rCx36 ROIs (refer to Table A1.1). 
 
Table A2.3: Gap junction plaque area represented as the mean ± SEM, and corresponding p-
values, of wild-type and (deletion) mutant rCx36 expressing N2a cells. 
 
GJP area 
(µm²) 
n p-value Significance 
WT 2.22±0.19 28   
Δ182-198, 279-292 2.33±0.37 24 0.020 ns 
Δ182-198 1.38±0.23 19 0.000 *** 
Δ279-292 1.75±0.19 26 0.009 ** 
Δ175-196 1.25±0.21 24 0.000 **** 
*p-value is based on comparisons to WT rCx36. 
Table A3.1: The mobile fraction (%) and half-time of recovery (s) at the selected ROIs of wild-
type rCx36 expressing N2a cells treated with various TAT-peptides represented as the mean ± 
SEM.   
  Mobile Fraction (%) Half-Time of Recovery (s) 
 n Membrane Plaque Lateral Membrane Plaque Lateral 
WT 8 33.77±7.50 11.02±1.25 11.85±6.00 1.68±0.58 
 
WT + TAT CT-ON 11 37.53±5.25 32.81±3.31 4.92±1.23 8.67±4.63 
 
WT + TAT CT-OFF 15 36.23±55.5 10.32±1.84 16.32±3.94 26.17±8.85 
 
WT + TAT CT ON 
(Scrambled) 11 37.12±5.07 15.44±2.53 15.91±5.52 20.91±5.84 
 
WT + TAT CT-OFF 
(Scrambled) 9 36.22±4.89 18.86±2.82 21.78±8.83 34.31±12.97 
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Table A3.2: The p-values corresponding to the mobile fraction and half time of recovery 
analyses of WT rCx36 expressing N2a cells treated with various TAT-peptides. 
  
Mobile 
Fraction Significance 
Half-Time 
of Recovery Significance 
TAT CT-ON 
Plaque Lateral to 
Membrane 0.434544 ns 0.003212 ** 
Membrane 0.676485 ns 0.080721 ns 
Plaque Lateral 4.4E-06 **** 0.007818 ** 
TAT CT-OFF 
Plaque Lateral to 
Membrane 0.001983 ** 0.522863 ns 
Membrane 0.779183 ns 0.919091 ns 
Plaque Lateral 0.055176 ns 0.16222 ns 
TAT CT-ON 
(Scrambled) 
Plaque Lateral to 
Membrane 0.00016 *** 0.5897 ns 
Membrane 0.705413 ns 0.677491 ns 
Plaque Lateral 0.170784 ns 0.111406 ns 
TAT CT-OFF 
(Scrambled) 
Plaque Lateral to 
Membrane 2.46E-05 **** 0.24901 ns 
Membrane 0.79184 ns 0.648514 ns 
Plaque Lateral 0.76415 ns 0.047373 ns 
*Shaded areas represent the cross comparisons to the WT rCx36 ROIs (refer to Table A3.1). 
 
Table A3.3: Gap junction plaque area represented as the mean ± SEM, and corresponding p-
values, of wild-type rCx36 expressing N2a cells treated with various TAT-peptides.  
 GJP area (µm²) n p-value significance 
TAT CT-ON 1.71±0.14 17 0.058637 ns 
TAT CT-OFF 1.43±0.21 26 0.006483 ** 
TAT CT-ON (Scrambled) 1.50±0.18 13 0.022841 ns 
TAT CT-OFF (Scrambled) 2.34±0.51 14 0.792181 ns 
*p-value is based on comparisons to WT rCx36 (refer to Table A2.3). 
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Table A4.1: The mobile fraction (%) and half-time of recovery (s) at the selected ROIs of wild-
type (and Δ279-292 where specified) rCx36 expressing N2a cells treated with colchicine, 
paclitaxel, or cytochalasin D, represented as the mean ± SEM.   
  Mobile Fraction (%) Half-Time of Recovery (s) 
 n Membrane Plaque Lateral Membrane Plaque Lateral 
WT 8 33.77±7.50 11.02±1.25 11.85±6.00 1.68±0.58 
 
Δ279-292 13 28.61±5.23 23.27±5.08 17.65±5.89 8.51±3.49 
 
WT +  
Colchicine 9 30.48±3.93 23.34±3.76 7.09±4.77 47.66±20.94 
 
Δ279-292 + 
Colchicine 10 36.25±5.92 30.10±4.78 11.88±2.33 28.80±8.96 
 
WT + 
Paclitaxel 13 21.54±4.06 11.46±1.50 14.58±5.75 11.86±5.02 
 
Δ279-292 + 
Paclitaxel 15 40.54±5.99 17.39±1.74 12.12±3.14 25.58±7.45 
 
WT + 
Cytochalasin D 12 34.26±7.05 22.50±1.73 10.83±4.67 12.87±3.78 
 
 
Table A4.2: The p-values corresponding to the mobile fraction and half time of recovery 
analyses of WT (and Δ279-292 where specified) rCx36 expressing N2a cells treated with 
colchicine, paclitaxel or cytochalasin D. 
  
Mobile 
Fraction Significance 
Half-Time of 
Recovery Significance 
WT + Colchicine 
Plaque Lateral 
to Membrane 0.247 ns 0.190 ns 
Membrane 0.694 ns 0.223 ns 
Plaque Lateral 0.006 ** 0.093 ns 
Δ279-292 + 
Colchicine 
Plaque Lateral 
to Membrane 0.447 ns 0.200 ns 
Membrane 0.282 ns 0.565 ns 
Plaque Lateral 0.290 ns 0.068 ns 
WT + Paclitaxel 
Plaque Lateral 
to Membrane 0.007 ** 0.742 ns 
Membrane 0.133 ns 0.591 ns 
Plaque Lateral 0.839 ns 0.650 ns 
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Δ279-292 + 
Paclitaxel 
Plaque Lateral 
to Membrane 0.000 **** 0.221 ns 
Membrane 0.119 ns 0.558 ns 
Plaque Lateral 0.012 ns 0.137 ns 
WT + Cytochalasin 
D 
Plaque Lateral 
to Membrane 0.000 *** 0.178 ns 
Membrane 0.964 ns 0.340 ns 
Plaque Lateral 0.000 **** 0.438 ns 
*Shaded areas represent the cross comparisons to the ROIs of the untreated counterpart (refer to 
Table A4.1). 
 
Table A4.3: Gap junction plaque area represented as the mean ± SEM, and corresponding p-
values, of wild-type (and Δ279-292 where specified) rCx36 expressing N2a cells treated with 
colchicine, paclitaxel or cytochalasin D. 
 GJP area (µm²) n p-value Significance 
WT + Colchicine 1.37±0.21 15 0.006986669 ** 
Δ279-292 + Colchicine 1.32±0.18 13 0.335340799 ns 
WT + Paclitaxel 1.44±0.20 17 0.009155905 ** 
Δ279-292 + Paclitaxel 1.22±0.08 19 0.081437 ns 
WT + Cytochalasin D 2.13±0.41 14 0.806818105 ns 
*p-values is based on comparisons to the untreated counterpart (refer to Table A2.3). 
 
Table A5.1: The mobile fraction (%) and half-time of recovery (s) at the selected ROIs of wild-
type and (point) mutant rCx36 expressing N2a cells represented as the mean ± SEM.   
  Mobile Fraction (%) Half-Time of Recovery (s) 
 n Membrane Plaque Lateral Membrane Plaque Lateral 
WT 8 33.77±7.50 11.02±1.25 11.85±6.00 1.68±0.58 
K279A 5 37.38±4.84 25.08±0.30 17.05±12.67 33.73±3.35 
I280A 10 32.85±8.07 22.88±4.92 4.46±2.53 28.47±8.66 
K281A 8 27.93±7.45 16.27±4.03 7.15±2.09 14.09±2.17 
L282A 9 33.02±6.85 13.73±2.48 4.80±2.10 19.64±5.77 
V284A 11 30.63±7.08 17.16±3.12 10.94±5.55 18.12±9.82 
R285A 7 23.69±5.42 14.92±2.73 3.78±1.81 25.57±4.71 
G286A 9 23.99±4.98 21.44±3.29 3.73±1.72 14.30±2.84 
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Table A5.2: The p-values corresponding to the mobile fraction and half time of recovery 
analyses of point mutant rCx36 expressing N2a cells. 
  Mobile Fraction Significance 
Half-Time of 
Recovery Significance 
K279A 
Plaque Lateral 
to Membrane 0.097 ns 0.423 ns 
Membrane 0.733 ns 0.839 ns 
Plaque Lateral 0.001 *** 0.030 ns 
I280A 
Plaque Lateral 
to Membrane 0.276 ns 0.065 ns 
Membrane 0.936 ns 0.099 ns 
Plaque Lateral 0.042 ns 0.061 ns 
K281A 
Plaque Lateral 
to Membrane 0.146 ns 0.160 ns 
Membrane 0.589 ns 0.205 ns 
Plaque Lateral 0.223 ns 0.262 ns 
L282A 
Plaque Lateral 
to Membrane 0.003 ** 0.088 ns 
Membrane 0.942 ns 0.118 ns 
Plaque Lateral 0.352 ns 0.126 ns 
V284A 
Plaque Lateral 
to Membrane 0.051 ns 0.504 ns 
Membrane 0.769 ns 0.383 ns 
Plaque Lateral 0.117 ns 0.284 ns 
R285A 
Plaque Lateral 
to Membrane 0.121 ns 0.005 ** 
Membrane 0.308 ns 0.140 ns 
Plaque Lateral 0.185 ns 0.007 ** 
G286A 
Plaque Lateral 
to Membrane 0.664 ns 0.019 ns 
Membrane 0.285 ns 0.094 ns 
Plaque Lateral 0.008 ** 0.219 ns 
*Shaded areas represent the cross comparisons to the WT rCx36 ROIs (refer to Table A5.1). 
 
Table A5.3: Gap junction plaque area represented as the mean ± SEM, and corresponding p-
values, of point mutant rCx36 expressing N2a cells. 
 
GJP area 
(µm²) 
n p-value Significance 
K279A 0.90±0.18 7 0.001822 ** 
I280A 1.67±0.26 19 0.079548 ns 
K281A 1.06±0.15 9 0.00176 ** 
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L282A 1.26±0.11 16 0.000668 *** 
V284A 1.38±0.26 14 0.012561 ns 
R285A 1.60±0.30 12 0.079888 ns 
G286A 1.13±0.19 10 0.00255 ** 
*p-value is based on comparisons to WT rCx36 (refer to Table A2.3). 
 
Table A6.1: The mobile fraction (%) and half-time of recovery (s) at the selected ROIs of N2a 
cells expressing CaM and wild-type rCx36 with ionomycin application (where specified) 
represented as the mean ± SEM.   
 
 Mobile Fraction (%) Half-Time of Recovery (s) 
 n Membrane Plaque Lateral Membrane Plaque Lateral 
WT 8 33.77±7.50 11.02±1.25 11.85±6.00 1.68±0.58 
WT+CaM 9 24.86±4.54 22.58±4.19 7.35±2.41 12.10±2.67 
WT+CaM+Iono 9 39.91±7.94 7.31±1.14 10.49±3.09 3.09±2.22 
 
 
Table A6.2: The p-values corresponding to the mobile fraction and half time of recovery 
analyses of N2a cells expressing CaM and wild-type rCx36 with ionomycin application (where 
specified). 
  Mobile Fraction Significance 
Half-Time of 
Recovery Significance 
Cx36 + 
CaM 
Plaque Lateral 
to Membrane 0.739075 ns 0.264598 ns 
Membrane 0.313134 ns 0.189661 ns 
Plaque Lateral 0.017337 ns 0.436955 ns 
Cx36 + 
CaM + 
Ionomycin 
Plaque Lateral 
to Membrane 6.46E-06 **** 0.736209 ns 
Membrane 0.119227 ns 0.43527 ns 
Plaque Lateral 0.001272 ** 0.928627 ns 
* Text in red denotes the cross comparisons to the rCx36 (wild-type) ROIs whereas the text in 
blue denotes cross comparisons to the rCx36 (wild-type) + CaM ROIs (refer to Table A6.1). 
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Table A6.3: Gap junction plaque area represented as the mean ± SEM, and corresponding p-
values, of point mutant rCx36 expressing N2a cells. 
  
GJP area 
(µm²) 
n p-value Significance 
WT+CaM 1.72±0.20 35 0.075103 ns 
WT+CaM+Ionomycin 0.74±0.20 14 0.609691 ns 
* Text in red denotes the cross comparisons to the rCx36 (wild-type) ROIs whereas the text in 
blue denotes cross comparisons to the rCx36 (wild-type) + CaM ROIs (refer to Table A2.3 for 
WT).  
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APPENDIX D: PREDICTED PROTEIN CANDIDATES OF RCX36  
 
The potential interaction candidates identified for rCx36 in N2a cells via mass-spectrometry of BioID elution 
fraction. 
 
Partner Protein ID 
  
Membrane-associated progesterone receptor component 2 [PGRC2_MOUSE] 
60S ribosomal protein L17  [RL17_MOUSE] 
60S ribosomal protein L29  [RL29_MOUSE] 
ATP synthase subunit alpha, mitochondrial  [ATPA_MOUSE] 
Alpha-enolase  [ENOA_MOUSE] 
cAMP-dependent protein kinase type I-alpha regulatory subunit  [KAP0_MOUSE] 
Lamina-associated polypeptide 2, isoforms 
beta/delta/epsilon/gamma  
[LAP2B_MOUSE] 
Mitochondrial ribonuclease P protein 1 [MRRP1_MOUSE] 
Tubulin beta-3 chain  [TBB3_MOUSE] 
T-complex protein 1 subunit beta  [TCPB_MOUSE] 
WW domain-containing oxidoreductase [WWOX_MOUSE] 
Neutral amino acid transporter B(0)  [AAAT_MOUSE] 
Cytoskeleton-associated protein 4  [CKAP4_MOUSE] 
Importin subunit alpha-1  [IMA1_MOUSE] 
Sequestosome-1  [SQSTM_MOUSE] 
T-complex protein 1 subunit alpha  [TCPA_MOUSE] 
Netrin receptor UNC5B  [UNC5B_MOUSE] 
Calnexin  [CALX_MOUSE] 
Putative pre-mRNA-splicing factor ATP-dependent RNA 
helicase DHX15  
[DHX15_MOUSE] 
Elongation factor 2  [EF2_MOUSE] 
Golgi resident protein GCP60  [GCP60_MOUSE] 
Heterogeneous nuclear ribonucleoprotein M  [HNRPM_MOUSE] 
Heat shock protein HSP 90-beta  [HS90B_MOUSE] 
Ribosomal RNA processing protein 1 homolog B [RRP1B_MOUSE] 
AP-3 complex subunit delta-1  [AP3D1_MOUSE] 
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2  [AT2A2_MOUSE] 
Lysine-rich nucleolar protein 1  [KNOP1_MOUSE] 
ATP-dependent RNA helicase DDX24  [DDX24_MOUSE] 
G-protein coupled receptor-associated sorting protein 1  [GASP1_MOUSE] 
E3 SUMO-protein ligase RanBP2  [RBP2_MOUSE] 
Ribosome-binding protein 1  [RRBP1_MOUSE] 
RRP12-like protein [RRP12_MOUSE] 
Bifunctional glutamate/proline--tRNA ligase  [SYEP_MOUSE] 
Small subunit processome component 20 homolog  [UTP20_MOUSE] 
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APPENDIX E: PREDICTED SHORT LINEAR MOTIFS OF THE RCX36 PROTEIN 
 
A Eukaryotic Linear Motif (ELM) search was conducted on the full length rCx36 protein sequence to identify possible 
binding motifs within all cell compartments. Output generated indicated a possible actin binding domain within the 
cytoplasmic loop (aa: 167-184), denoted as the protein sequence "DCLEVKELAPHPSGLRTA." 
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